,Open,High,Low,Close,Adjusted Close,Volume,Dividend Amount,Split Coefficient,Symbol,AssetType,Name,Description,CIK,Exchange,Currency,Country,Sector,Industry,Address,OfficialSite,FiscalYearEnd,LatestQuarter,MarketCapitalization,EBITDA,PERatio,PEGRatio,BookValue,DividendPerShare,DividendYield,EPS,RevenuePerShareTTM,ProfitMargin,OperatingMarginTTM,ReturnOnAssetsTTM,ReturnOnEquityTTM,RevenueTTM,GrossProfitTTM,DilutedEPSTTM,QuarterlyEarningsGrowthYOY,QuarterlyRevenueGrowthYOY,AnalystTargetPrice,AnalystRatingStrongBuy,AnalystRatingBuy,AnalystRatingHold,AnalystRatingSell,AnalystRatingStrongSell,TrailingPE,ForwardPE,PriceToSalesRatioTTM,PriceToBookRatio,EVToRevenue,EVToEBITDA,Beta,52WeekHigh,52WeekLow,50DayMovingAverage,200DayMovingAverage,SharesOutstanding,SharesFloat,PercentInsiders,PercentInstitutions,DividendDate,ExDividendDate
2010-01-04,17.840000,18.290000,17.690000,18.140000,18.140000,163200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-05,18.170000,18.330000,17.790000,18.010000,18.010000,146100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-06,18.040000,18.580000,18.040000,18.350000,18.350000,162400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-07,18.390000,18.750000,18.050000,18.610000,18.610000,140100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-08,18.600000,19.290000,18.600000,18.680000,18.680000,212300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-11,18.750000,18.990000,18.665000,18.720000,18.720000,133400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-12,18.670000,18.670000,17.950000,18.000000,18.000000,216300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-13,18.140000,18.540000,17.870000,18.500000,18.500000,162500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-14,18.400000,18.820000,18.360000,18.400000,18.400000,104400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-15,18.480000,18.630000,17.510000,17.600000,17.600000,270900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-19,17.510000,18.160000,17.500000,18.160000,18.160000,176100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-20,18.110000,18.250000,17.340000,17.850000,17.850000,208600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-21,17.930000,17.940000,17.150000,17.210000,17.210000,156300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-22,17.240000,17.665000,17.130000,17.280000,17.280000,204500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-25,17.440000,17.440000,16.900000,17.040000,17.040000,150200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-26,16.930000,17.230000,16.900000,16.930000,16.930000,129200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-27,16.830000,17.370000,16.830000,17.360000,17.360000,154400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-28,17.400000,17.400000,16.810000,16.840000,16.840000,186600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-01-29,16.950000,17.210000,16.810000,16.900000,16.900000,120100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-01,16.950000,17.210000,16.754000,17.110000,17.110000,163700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-02,17.080000,17.430000,16.880000,17.360000,17.360000,142000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-03,17.250000,17.890000,17.150000,17.780000,17.780000,265900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-04,17.630000,17.730000,16.550000,16.570000,16.570000,271700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-05,16.650000,16.800000,16.410000,16.670000,16.670000,178500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-08,16.740000,17.100000,16.640000,16.910000,16.910000,109900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-09,17.050000,17.360000,16.880000,16.930000,16.930000,140400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-10,16.820000,17.200000,16.710000,16.750000,16.750000,193900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-11,16.750000,17.236000,16.610000,17.150000,17.150000,128900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-12,16.950000,17.480000,16.950000,17.480000,17.480000,122400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-16,17.520000,17.590000,17.230000,17.400000,17.400000,100500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-17,17.500000,17.540000,17.230000,17.490000,17.490000,107400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-18,17.430000,17.530000,17.270700,17.430000,17.430000,51600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-19,17.430000,17.480000,17.240000,17.390000,17.390000,101500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-22,17.400000,17.470000,16.970000,17.010000,17.010000,85100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-23,17.030000,17.910000,16.960000,17.790000,17.790000,269100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-24,17.890000,18.180000,17.700000,17.940000,17.940000,157600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-25,17.720000,17.970000,17.550000,17.970000,17.970000,133400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-02-26,17.950000,18.120000,17.200000,17.420000,17.420000,218200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-01,17.460000,17.840000,17.320000,17.480000,17.480000,174300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-02,17.560000,17.895000,17.490000,17.730000,17.730000,148800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-03,17.810000,18.390000,17.810000,17.890000,17.890000,129300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-04,17.950000,18.030000,17.520000,18.010000,18.010000,151900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-05,18.050000,18.410000,17.480000,18.240000,18.240000,163700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-08,18.270000,18.440000,18.030000,18.170000,18.170000,153200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-09,18.060000,18.430000,18.060000,18.160000,18.160000,95200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-10,18.220000,18.740000,18.180000,18.320000,18.320000,145100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-11,18.180000,18.770000,18.180000,18.700000,18.700000,99800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-12,18.690000,18.690000,18.160000,18.280000,18.280000,118000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-15,18.310000,18.370000,18.110000,18.150000,18.150000,74500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-16,18.260000,18.370000,18.060000,18.160000,18.160000,181900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-17,18.170000,18.200000,17.910000,17.920000,17.920000,129600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-18,17.900000,17.932000,17.600400,17.790000,17.790000,104100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-19,17.890000,17.930000,17.580000,17.680000,17.680000,144500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-22,17.660000,18.140000,17.500000,17.990000,17.990000,158300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-23,18.050000,18.720000,17.800000,18.700000,18.700000,219200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-24,18.780000,18.850000,18.010000,18.070000,18.070000,206000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-25,18.269000,18.450000,17.890000,17.930000,17.930000,136000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-26,17.950000,18.110000,17.200000,17.410000,17.410000,180600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-29,17.500000,17.510000,17.030000,17.170000,17.170000,195400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-30,17.240000,17.360000,17.010000,17.080000,17.080000,172700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-03-31,17.090000,17.370000,17.000000,17.020000,17.020000,199800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-01,17.170000,17.260000,16.900000,17.010000,17.010000,154600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-05,17.120000,17.200000,16.950000,17.060000,17.060000,146900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-06,17.010000,17.079400,16.930000,17.000000,17.000000,83600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-07,17.090000,17.120000,16.930000,16.980000,16.980000,198200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-08,16.900000,17.220000,16.830000,17.110000,17.110000,151000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-09,17.160000,17.200000,16.820000,17.170000,17.170000,169300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-12,17.180000,17.180000,16.890000,16.960000,16.960000,116700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-13,17.000000,17.100000,16.832000,16.910000,16.910000,171400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-14,17.050000,17.050000,16.870000,16.960000,16.960000,213200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-15,16.890000,17.050000,16.870000,17.050000,17.050000,178600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-16,17.050000,17.100000,16.830000,17.040000,17.040000,153300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-19,16.960000,17.100000,16.850000,16.990000,16.990000,142000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-20,17.040000,17.070000,16.910000,17.070000,17.070000,84600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-21,17.100000,17.100000,16.920000,17.000000,17.000000,129400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-22,16.910000,17.030000,16.800000,16.910000,16.910000,107700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-23,16.880000,17.050000,16.800000,16.920000,16.920000,101300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-26,16.820000,17.049900,16.803600,16.930000,16.930000,144100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-27,16.890000,17.150000,16.800000,17.010000,17.010000,179400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-28,17.050000,17.100000,16.910000,17.070000,17.070000,188000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-29,17.110000,17.590000,17.000000,17.580000,17.580000,307500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-04-30,17.560000,17.560000,16.960000,16.960000,16.960000,245100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-03,17.090000,17.165000,16.970000,17.090000,17.090000,204600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-04,17.030000,17.360000,16.900000,17.230000,17.230000,353300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-05,17.130000,17.130000,16.880000,16.900000,16.900000,307200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-06,16.850000,17.010000,15.200000,16.240000,16.240000,487400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-07,16.290000,16.960000,15.845000,16.000000,16.000000,421900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-10,16.780000,16.987500,16.480000,16.680000,16.680000,291800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-11,16.550000,16.990000,16.115000,16.710000,16.710000,142300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-12,16.670000,17.050000,16.620000,17.030000,17.030000,139500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-13,16.880000,17.070000,16.800000,16.830000,16.830000,116800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-14,16.660000,16.770000,16.080000,16.360000,16.360000,189400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-17,16.510000,16.610000,16.230000,16.450000,16.450000,152200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-18,16.600000,16.698400,16.350000,16.350000,16.350000,88100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-19,16.330000,16.590000,16.170000,16.370000,16.370000,125100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-20,16.060000,16.350000,15.690000,15.900000,15.900000,327700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-21,15.630000,15.850000,15.300000,15.550000,15.550000,278100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-24,15.490000,15.880000,15.270000,15.440000,15.440000,127500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-25,15.190000,15.460000,14.880000,15.350000,15.350000,282100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-26,15.400000,15.760000,15.070000,15.150000,15.150000,330800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-27,15.430000,15.680000,15.180000,15.670000,15.670000,273500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-05-28,15.580000,16.050000,15.510000,15.800000,15.800000,207000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-01,15.610000,15.680000,15.290000,15.400000,15.400000,296200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-02,15.400000,15.820000,15.400000,15.820000,15.820000,241200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-03,15.750000,16.150000,15.730000,16.090000,16.090000,175400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-04,15.740000,16.020000,15.620500,16.000000,16.000000,402500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-07,16.040000,16.050000,15.590000,15.750000,15.750000,237400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-08,15.750000,15.800000,15.177500,15.270000,15.270000,492800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-09,15.360000,15.380000,15.080000,15.230000,15.230000,276800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-10,15.470000,15.610000,15.140000,15.570000,15.570000,175700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-11,15.430000,15.990000,15.300000,15.990000,15.990000,230500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-14,16.140000,16.330000,15.720000,15.780000,15.780000,125200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-15,15.890000,16.070000,15.740000,15.980000,15.980000,327000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-16,15.850000,15.970000,15.651000,15.690000,15.690000,170900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-17,15.740000,15.885000,15.520000,15.610000,15.610000,187200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-18,15.610000,15.705000,14.910000,14.920000,14.920000,453700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-21,15.140000,15.500000,15.000000,15.120000,15.120000,284000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-22,15.230000,15.580000,15.210000,15.250000,15.250000,362500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-23,15.250000,15.520000,15.170000,15.340000,15.340000,133100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-24,15.310000,15.610000,15.180000,15.450000,15.450000,165100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-25,15.530000,15.670000,15.350000,15.600000,15.600000,414900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-28,15.500000,15.940000,15.210000,15.760000,15.760000,404700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-29,15.500000,15.750000,15.130000,15.250000,15.250000,386600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-06-30,15.180000,15.350000,15.010000,15.020000,15.020000,207700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-01,15.030000,15.100000,14.760100,15.040000,15.040000,236600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-02,15.170000,15.330000,15.120000,15.170000,15.170000,105600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-06,15.350000,15.600000,15.000000,15.060000,15.060000,264500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-07,15.150000,15.440000,14.970000,15.420000,15.420000,139800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-08,15.570000,15.890000,15.330000,15.650000,15.650000,126100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-09,15.670000,15.980000,15.540000,15.960000,15.960000,91000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-12,15.980000,16.360000,15.570000,15.580000,15.580000,109600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-13,15.730000,16.140000,15.560000,16.090000,16.090000,133900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-14,15.990000,16.160000,15.500000,16.040000,16.040000,74900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-15,16.010000,16.048000,15.640000,15.770000,15.770000,65100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-16,15.630000,15.680000,14.920000,15.000000,15.000000,230100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-19,14.990000,15.110000,14.800000,14.950000,14.950000,101300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-20,14.770000,15.240000,14.770000,15.200000,15.200000,119200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-21,15.260000,15.270000,14.860000,14.960000,14.960000,103100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-22,15.160000,15.480000,14.990000,15.350000,15.350000,147200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-23,15.340000,15.590000,14.930000,15.340000,15.340000,181600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-26,15.370000,16.130000,15.280000,15.810000,15.810000,184800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-27,15.950000,16.020000,15.650000,15.700000,15.700000,125300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-28,15.650000,15.780000,15.183000,15.230000,15.230000,86900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-29,15.340000,15.550000,15.110000,15.190000,15.190000,148100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-07-30,15.000000,15.640000,15.000000,15.350000,15.350000,93200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-02,15.590000,15.740000,15.380000,15.450000,15.450000,173300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-03,15.350000,15.625000,15.070000,15.190000,15.190000,142000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-04,15.250000,15.560000,15.010000,15.050000,15.050000,139000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-05,14.980000,15.195000,14.910000,14.950000,14.950000,341100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-06,14.810000,15.100000,14.705000,14.910000,14.910000,902000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-09,15.040000,15.090000,14.950000,14.990000,14.990000,187300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-10,14.810000,14.980000,14.640000,14.640000,14.640000,143800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-11,14.500000,14.510000,14.030000,14.060000,14.060000,287700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-12,13.930000,14.140000,13.750000,13.960000,13.960000,177600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-13,13.900000,14.025000,13.690000,13.770000,13.770000,300600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-16,13.670000,14.190000,13.580000,13.970000,13.970000,245300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-17,14.160000,14.190000,13.908300,14.090000,14.090000,160600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-18,14.130000,14.290000,13.910000,14.020000,14.020000,89300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-19,14.030000,14.120000,13.660000,13.680000,13.680000,259000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-20,13.590000,13.760000,13.530000,13.730000,13.730000,139500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-23,13.840000,14.050000,13.670000,13.750000,13.750000,162300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-24,13.630000,13.820000,13.570000,13.590000,13.590000,145400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-25,13.510000,14.180000,13.510000,14.160000,14.160000,166700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-26,14.230000,14.230000,13.910000,13.940000,13.940000,120100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-27,14.110000,14.750000,13.900000,14.710000,14.710000,208800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-30,14.720000,14.860000,14.140000,14.140000,14.140000,136300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-08-31,14.140000,14.363000,13.650000,13.670000,13.670000,139800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-01,13.900000,14.550000,13.860000,14.510000,14.510000,171500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-02,14.420000,14.860000,14.180000,14.810000,14.810000,115300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-03,14.980000,14.980000,14.650100,14.810000,14.810000,110500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-07,14.810000,14.810000,14.230000,14.260000,14.260000,110200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-08,14.310000,14.530000,14.190000,14.330000,14.330000,60100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-09,14.490000,14.520000,14.070000,14.180000,14.180000,104800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-10,14.260000,14.420000,14.100000,14.290000,14.290000,259600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-13,14.330000,14.430000,14.090000,14.260000,14.260000,169500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-14,14.180000,14.310000,14.050000,14.090000,14.090000,166000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-15,14.040000,14.310000,14.010000,14.270000,14.270000,288800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-16,14.210000,14.240000,13.890000,14.180000,14.180000,231600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-17,14.320000,14.570000,14.020000,14.480000,14.480000,211600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-20,14.500000,15.020000,14.400000,15.020000,15.020000,173700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-21,15.010000,15.190000,14.790000,14.790000,14.790000,117400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-22,14.740000,14.874000,14.520000,14.670000,14.670000,87000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-23,14.540000,14.700000,14.210000,14.220000,14.220000,121800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-24,13.830000,13.980000,13.150000,13.270000,13.270000,592600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-27,13.210000,13.210000,12.460000,12.470000,12.470000,637600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-28,12.500000,12.740000,12.330000,12.360000,12.360000,471400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-29,12.370000,12.540000,12.350000,12.410000,12.410000,398300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-09-30,12.500000,12.590000,12.240000,12.270000,12.270000,486700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-01,12.280000,12.410000,12.080000,12.150000,12.150000,581400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-04,12.070000,12.350000,12.070000,12.110000,12.110000,217800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-05,12.240000,12.280000,12.150000,12.230000,12.230000,361300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-06,12.230000,12.340000,12.170000,12.310000,12.310000,164300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-07,12.410000,12.640000,12.293000,12.340000,12.340000,170400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-08,12.380000,12.810000,12.380000,12.730000,12.730000,229000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-11,12.690000,12.900000,12.650000,12.810000,12.810000,161400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-12,12.740000,12.840000,12.510000,12.630000,12.630000,262900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-13,12.640000,13.040000,12.580000,12.980000,12.980000,201800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-14,13.020000,13.410000,13.020000,13.390000,13.390000,172000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-15,13.560000,13.815000,13.410000,13.680000,13.680000,301400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-18,13.680000,13.850000,13.550000,13.670000,13.670000,190100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-19,13.480000,13.770000,13.280000,13.510000,13.510000,174100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-20,13.610000,13.810000,13.450000,13.670000,13.670000,71700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-21,13.750000,13.850000,13.230000,13.380000,13.380000,100100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-22,13.400000,13.890000,13.180000,13.800000,13.800000,158200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-25,13.890000,13.980000,13.620000,13.680000,13.680000,75300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-26,13.580000,13.920000,13.430000,13.740000,13.740000,159000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-27,13.680000,13.760000,13.270000,13.520000,13.520000,154200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-28,13.630000,13.630000,13.250000,13.290000,13.290000,92100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-10-29,13.250000,13.410000,13.080000,13.140000,13.140000,104000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-01,13.160000,13.370000,12.590000,12.590000,12.590000,183400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-02,12.680000,12.789900,12.500000,12.570000,12.570000,354500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-03,12.600000,12.660000,12.410000,12.600000,12.600000,217000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-04,12.800000,13.500000,12.800000,13.200000,13.200000,386600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-05,13.530000,13.640000,12.640000,12.900000,12.900000,270500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-08,12.780000,12.850000,12.410000,12.550000,12.550000,186600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-09,12.600000,12.730000,12.270000,12.290000,12.290000,174000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-10,12.370000,12.480000,12.150000,12.390000,12.390000,149700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-11,12.240000,12.370000,12.210000,12.260000,12.260000,105200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-12,12.190000,12.270000,12.100000,12.140000,12.140000,128700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-15,12.150000,12.190000,11.800000,11.850000,11.850000,354000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-16,11.800000,11.829400,11.330000,11.550000,11.550000,296200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-17,11.330000,11.490000,10.900000,10.940000,10.940000,361500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-18,10.940000,10.990000,9.730000,10.170000,10.170000,1302400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-19,10.140000,10.420000,9.860000,9.880000,9.880000,555800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-22,9.900000,10.060000,9.402500,9.460000,9.460000,543000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-23,9.440000,9.960000,9.345000,9.950000,9.950000,408100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-24,10.040000,10.070000,9.760000,9.770000,9.770000,251100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-26,9.760000,9.829400,9.639000,9.770000,9.770000,97600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-29,9.750000,9.750000,9.250000,9.350000,9.350000,462900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-11-30,9.290000,9.410000,9.100000,9.150000,9.150000,380400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-01,9.240000,9.490000,9.210000,9.390000,9.390000,333100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-02,9.680000,9.680000,9.370000,9.450000,9.450000,447800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-03,9.370000,9.490000,9.210000,9.240000,9.240000,471000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-06,9.250000,9.520000,9.210000,9.440000,9.440000,406400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-07,9.570000,9.800000,9.550000,9.610000,9.610000,237300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-08,9.630000,9.720000,9.110000,9.140000,9.140000,578000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-09,9.200000,9.330000,8.950000,8.960000,8.960000,485700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-10,8.980000,9.490000,8.790000,9.470000,9.470000,467100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-13,9.500000,9.700000,9.400000,9.500000,9.500000,275100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-14,9.550000,9.700000,9.540000,9.650000,9.650000,219100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-15,9.700000,9.940000,9.650000,9.810000,9.810000,331400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-16,9.840000,10.130000,9.730000,9.980000,9.980000,750600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-17,9.990000,10.530000,9.980100,10.140000,10.140000,483700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-20,10.230000,10.290000,9.920000,9.930000,9.930000,327900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-21,9.930000,10.020000,9.910000,9.950000,9.950000,379400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-22,10.000000,10.170000,9.690000,9.690000,9.690000,391100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-23,9.680000,9.860000,9.580000,9.790000,9.790000,417100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-27,9.790000,10.070000,9.550000,10.070000,10.070000,342400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-28,10.060000,10.070000,9.810000,9.860000,9.860000,221600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-29,9.860000,9.980000,9.840000,9.860000,9.860000,151000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-30,9.870000,9.920000,9.750000,9.880000,9.880000,215400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2010-12-31,9.830000,9.940000,9.700000,9.860000,9.860000,389000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-03,9.910000,10.160000,9.820000,10.010000,10.010000,233100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-04,10.360000,10.390000,10.060000,10.160000,10.160000,242100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-05,10.150000,10.490000,10.030000,10.450000,10.450000,252400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-06,10.500000,10.570000,10.240000,10.280000,10.280000,505900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-07,10.290000,10.370000,10.040000,10.060000,10.060000,351200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-10,10.010000,10.075000,9.860000,10.020000,10.020000,364800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-11,10.040000,10.260000,9.940000,10.110000,10.110000,218700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-12,10.180000,10.330000,10.040000,10.330000,10.330000,195700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-13,10.340000,10.420000,10.250000,10.330000,10.330000,148000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-14,10.380000,10.620000,10.250000,10.620000,10.620000,290200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-18,10.690000,10.810000,10.550000,10.672500,10.672500,226600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-19,10.690000,10.730000,10.310000,10.310000,10.310000,269200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-20,10.250000,10.430000,10.185000,10.340000,10.340000,233400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-21,10.360000,10.620000,10.330000,10.600000,10.600000,330400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-24,10.570000,10.644500,10.440000,10.580000,10.580000,170900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-25,10.550000,11.160000,10.550000,10.965000,10.965000,363300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-26,10.980000,11.110000,10.900000,10.950000,10.950000,385600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-27,10.920000,10.920000,10.590000,10.620000,10.620000,322700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-28,10.590000,10.620000,10.290000,10.290000,10.290000,356400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-01-31,10.340000,10.470000,10.150000,10.325000,10.325000,220100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-01,10.340000,10.470000,10.200000,10.260000,10.260000,234400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-02,10.230000,10.480000,10.200000,10.320000,10.320000,160100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-03,10.280000,10.360000,9.960000,9.960000,9.960000,256300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-04,9.960000,10.070000,9.880000,10.040000,10.040000,228200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-07,10.100000,10.260000,9.970000,10.000000,10.000000,97200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-08,10.000000,10.010000,9.756400,9.870000,9.870000,128200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-09,9.820000,9.940000,9.720000,9.920000,9.920000,131000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-10,9.840000,9.900000,9.650000,9.760000,9.760000,148400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-11,9.730000,10.060000,9.680000,10.000000,10.000000,177700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-14,9.940000,10.170000,9.870000,10.110000,10.110000,125500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-15,10.050000,10.150100,9.960000,10.010000,10.010000,125900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-16,10.050000,10.110000,9.885000,10.080000,10.080000,139300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-17,10.030000,10.210000,9.749500,9.870000,9.870000,231500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-18,10.670000,11.920000,10.670000,11.370000,11.370000,1562900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-22,11.130000,11.580000,10.930000,11.170000,11.170000,601400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-23,11.670000,12.340000,11.330000,11.360000,11.360000,493800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-24,11.360000,11.650000,10.960000,11.100000,11.100000,326000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-25,11.090000,11.450000,10.980000,11.360000,11.360000,259000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-02-28,11.400000,11.510000,10.920000,10.980000,10.980000,256900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-01,11.000000,11.090000,10.650000,10.710000,10.710000,189500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-02,10.750000,10.790000,10.450000,10.600000,10.600000,199300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-03,10.690000,10.690000,10.500000,10.570000,10.570000,150400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-04,10.600000,10.740000,10.500000,10.520000,10.520000,110900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-07,10.570000,10.580000,9.930000,10.180000,10.180000,344100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-08,10.160000,10.320000,10.080000,10.302500,10.302500,144700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-09,10.320000,10.610000,10.260000,10.410000,10.410000,124900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-10,10.280000,10.330000,9.930000,10.160000,10.160000,203200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-11,10.130000,10.150000,9.550000,9.780000,9.780000,503300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-14,9.670000,10.200000,9.670000,10.140000,10.140000,299200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-15,9.800000,10.020000,9.691000,9.800000,9.800000,290900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-16,9.800000,10.210000,9.720000,10.150000,10.150000,384300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-17,10.240000,10.320000,9.860000,9.860000,9.860000,244300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-18,9.910000,10.110000,9.770000,9.820000,9.820000,1238200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-21,9.920000,9.979500,9.518600,9.640000,9.640000,269000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-22,9.660000,9.880000,9.550000,9.820000,9.820000,134300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-23,9.830000,9.860000,9.440000,9.520000,9.520000,185500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-24,9.530000,9.670000,9.450000,9.580000,9.580000,161500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-25,9.580000,9.700000,9.250000,9.390000,9.390000,252200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-28,9.380000,9.380000,9.030000,9.220000,9.220000,417000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-29,9.240000,9.450000,9.220000,9.450000,9.450000,277400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-30,9.590000,9.980000,9.520000,9.830000,9.830000,232500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-03-31,9.800000,9.930000,9.430000,9.562500,9.562500,205600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-01,9.650000,9.760000,9.540000,9.720000,9.720000,201700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-04,9.760000,9.760000,9.510000,9.590000,9.590000,198000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-05,9.570000,9.805000,9.511000,9.640000,9.640000,112600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-06,9.700000,9.970000,9.640000,9.960000,9.960000,206800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-07,9.950000,10.010000,9.805000,9.970000,9.970000,229600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-08,10.020000,10.060000,9.830000,9.830000,9.830000,162900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-11,9.790000,9.860000,9.640000,9.735000,9.735000,227900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-12,9.650000,9.730000,9.520000,9.580000,9.580000,169700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-13,9.590000,9.590000,9.340000,9.430000,9.430000,158700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-14,9.350000,9.590000,9.250000,9.560000,9.560000,151600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-15,9.510000,9.630000,9.400000,9.620000,9.620000,128400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-18,9.520000,9.560000,9.420000,9.510000,9.510000,99900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-19,9.550000,9.680000,9.400000,9.490000,9.490000,154800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-20,9.600000,9.730000,9.450000,9.570000,9.570000,156800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-21,9.630000,9.630000,9.320000,9.460000,9.460000,125300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-25,9.440000,9.639000,9.360000,9.560000,9.560000,142000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-26,9.560000,9.760000,9.390000,9.660000,9.660000,273300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-27,9.640000,9.910000,9.570000,9.900000,9.900000,171600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-28,9.940000,10.020000,9.700000,10.010000,10.010000,171900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-04-29,10.040000,10.580000,9.930000,10.260000,10.260000,311000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-02,10.310000,10.480000,9.950000,10.000000,10.000000,253400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-03,9.930000,10.060000,9.620000,9.860000,9.860000,626700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-04,9.830000,9.890000,9.600000,9.700000,9.700000,400600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-05,9.610000,9.710000,9.380000,9.560000,9.560000,381000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-06,9.660000,10.090000,9.610000,9.920000,9.920000,272000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-09,9.940000,9.970000,9.760000,9.780000,9.780000,151400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-10,9.790000,10.000000,9.740000,10.000000,10.000000,229000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-11,9.950000,10.130000,9.780000,9.850000,9.850000,176500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-12,9.800000,10.240000,9.730000,10.190000,10.190000,199800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-13,10.200000,10.570000,10.090000,10.230000,10.230000,216000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-16,10.200000,10.400000,9.880000,9.920000,9.920000,244000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-17,9.850000,10.010000,9.720000,9.950000,9.950000,185300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-18,9.970000,10.030000,9.860000,9.950000,9.950000,68500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-19,10.020000,10.020000,9.820000,9.980000,9.980000,148300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-20,9.920000,10.090000,9.800000,9.950000,9.950000,180500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-23,9.900000,9.900000,9.550000,9.600000,9.600000,408300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-24,9.600000,9.660000,9.540000,9.550000,9.550000,209000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-25,9.520000,9.870000,9.520000,9.680000,9.680000,262300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-26,9.680000,9.950000,9.600000,9.930000,9.930000,112900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-27,9.990000,10.300000,9.990000,10.300000,10.300000,111200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-05-31,10.320000,10.510000,10.140000,10.470000,10.470000,319300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-01,10.430000,10.590000,10.200000,10.200000,10.200000,209900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-02,10.190000,10.360000,9.950000,10.110000,10.110000,156200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-03,9.960000,10.079600,9.810000,9.820000,9.820000,205100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-06,9.650000,9.970000,9.550000,9.630000,9.630000,233800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-07,9.720000,9.760000,9.536000,9.670000,9.670000,118300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-08,9.590000,9.710000,9.420000,9.590000,9.590000,236700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-09,9.600000,9.600000,9.200000,9.300000,9.300000,163600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-10,9.250000,9.300000,9.000000,9.000000,9.000000,214400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-13,9.020000,9.340000,9.020000,9.310000,9.310000,208900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-14,9.380000,9.390000,9.200000,9.270000,9.270000,156300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-15,9.170000,9.230000,9.120000,9.150000,9.150000,128900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-16,9.140000,9.400000,9.110000,9.400000,9.400000,151400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-17,9.420000,9.450000,9.000000,9.030000,9.030000,680500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-20,9.030000,9.090000,8.860000,8.980000,8.980000,273000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-21,9.000000,9.111000,8.941000,9.060000,9.060000,181500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-22,9.030000,9.200000,8.950000,9.085000,9.085000,126900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-23,9.020000,9.110000,8.880000,9.070000,9.070000,103800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-24,9.070000,9.100000,8.920000,8.980000,8.980000,322400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-27,8.970000,9.240000,8.800000,9.190000,9.190000,94000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-28,9.240000,9.360000,9.100000,9.310000,9.310000,125200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-29,9.310000,9.379900,9.140000,9.250000,9.250000,91500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-06-30,9.280000,9.390000,9.280000,9.370000,9.370000,132000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-01,9.390000,9.400000,9.210000,9.400000,9.400000,142600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-05,9.340000,9.370000,9.280000,9.350000,9.350000,112400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-06,9.320000,9.400000,9.270000,9.400000,9.400000,84700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-07,9.440000,9.450000,9.400000,9.450000,9.450000,131300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-08,9.390000,9.470000,9.390000,9.440000,9.440000,117500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-11,9.340000,9.460000,9.330000,9.440000,9.440000,105900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-12,9.500000,9.780000,9.430000,9.750000,9.750000,259900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-13,9.770000,10.090000,9.750000,9.990000,9.990000,178900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-14,10.000000,10.210000,9.920000,10.150000,10.150000,165500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-15,10.160000,10.370000,10.120000,10.260000,10.260000,344100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-18,10.210000,10.210000,9.800000,9.870000,9.870000,138100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-19,9.890000,9.953400,9.720000,9.760000,9.760000,245600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-20,9.760000,9.870000,9.660000,9.810000,9.810000,79700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-21,9.840000,10.200000,9.760000,10.120000,10.120000,126200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-22,10.150000,10.250000,9.880000,9.890000,9.890000,128100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-25,9.780000,9.830000,9.650000,9.700000,9.700000,126700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-26,9.690000,9.730000,9.543500,9.560000,9.560000,96500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-27,9.500000,9.590000,9.400000,9.400000,9.400000,193600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-28,9.400000,9.545000,9.340000,9.440000,9.440000,121100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-07-29,9.390000,9.480000,9.280000,9.380000,9.380000,162700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-01,9.480000,9.780000,9.281000,9.400000,9.400000,199700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-02,9.390000,9.840000,9.020000,9.040000,9.040000,245400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-03,9.020000,9.080000,8.395000,8.440000,8.440000,324100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-04,8.360000,8.487100,7.670000,7.690000,7.690000,260600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-05,7.740000,7.880000,6.990000,7.560000,7.560000,457200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-08,7.350000,7.500000,6.910000,6.910000,6.910000,353000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-09,7.080000,7.330000,6.540000,7.150000,7.150000,370000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-10,7.030000,7.230000,6.340000,6.370000,6.370000,392800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-11,6.410000,7.110000,6.320000,7.000000,7.000000,345600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-12,7.070000,7.280000,6.870000,6.900000,6.900000,257000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-15,6.980000,7.370000,6.980000,7.340000,7.340000,175100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-16,7.710000,7.750000,7.160000,7.190000,7.190000,319600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-17,7.200000,7.410000,7.040000,7.170000,7.170000,168000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-18,6.970000,7.020000,6.650000,6.650000,6.650000,271700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-19,6.550000,6.856700,6.550000,6.620000,6.620000,149800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-22,6.770000,6.930000,6.410000,6.470000,6.470000,183800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-23,6.520000,6.860000,6.420000,6.850000,6.850000,240300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-24,6.810000,7.180000,6.680000,6.900000,6.900000,152200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-25,6.950000,7.050000,6.610000,6.680000,6.680000,169900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-26,6.630000,6.880000,6.520000,6.760000,6.760000,101800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-29,6.850000,7.210000,6.790000,7.190000,7.190000,123300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-30,7.150000,7.220000,6.965000,7.170000,7.170000,149400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-08-31,7.190000,7.310000,6.910000,6.980000,6.980000,219500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-01,7.000000,7.000000,6.720000,6.800000,6.800000,253000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-02,6.680000,6.800000,6.490000,6.520000,6.520000,310800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-06,6.320000,6.630000,6.320000,6.450000,6.450000,268100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-07,6.580000,6.870000,6.510000,6.810000,6.810000,203500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-08,6.760000,6.930000,6.610000,6.660000,6.660000,172900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-09,6.580000,6.620000,6.310000,6.380000,6.380000,288600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-12,6.480000,6.760000,6.280000,6.580000,6.580000,307600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-13,6.760000,7.290000,6.610000,7.250000,7.250000,419700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-14,7.290000,7.500000,7.000000,7.360000,7.360000,326600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-15,7.440000,7.480000,7.320000,7.430000,7.430000,166600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-16,7.480000,7.500000,7.190000,7.480000,7.480000,849500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-19,7.320000,7.460000,6.900000,6.970000,6.970000,188600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-20,7.030000,7.230000,6.920000,6.930000,6.930000,296000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-21,6.940000,7.100000,6.910000,6.920000,6.920000,220200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-22,6.710000,6.920000,6.620000,6.720000,6.720000,327600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-23,6.680000,6.960000,6.609000,6.800000,6.800000,279500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-26,6.870000,6.870000,6.600000,6.700000,6.700000,142100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-27,6.850000,6.980000,6.760000,6.850000,6.850000,608200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-28,6.870000,6.900000,6.610000,6.650000,6.650000,379000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-29,6.770000,6.820000,6.500000,6.700000,6.700000,171700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-09-30,6.580000,6.770000,6.530000,6.570000,6.570000,262600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-03,6.500000,6.700000,6.000000,6.000000,6.000000,356900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-04,5.930000,6.500000,5.879000,6.460000,6.460000,427800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-05,6.480000,6.700000,6.380000,6.610000,6.610000,271400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-06,6.580000,6.580000,6.330000,6.540000,6.540000,287500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-07,6.560000,6.590000,6.390000,6.430000,6.430000,197300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-10,6.550000,6.700000,6.410000,6.690000,6.690000,161400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-11,6.650000,6.850000,6.600000,6.780000,6.780000,227100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-12,6.850000,7.050000,6.740000,7.020000,7.020000,192900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-13,6.950000,7.150000,6.940000,7.130000,7.130000,158000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-14,7.250000,7.530000,7.170000,7.510000,7.510000,300300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-17,7.470000,7.470000,7.060000,7.090000,7.090000,229400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-18,7.110000,7.590000,7.030000,7.540000,7.540000,206000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-19,7.570000,7.650000,7.270000,7.320000,7.320000,126200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-20,7.320000,7.420000,7.110000,7.360000,7.360000,140100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-21,7.510000,7.680000,7.390000,7.540000,7.540000,241600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-24,7.580000,7.840000,7.511100,7.830000,7.830000,338700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-25,7.800000,7.900000,7.470000,7.510000,7.510000,314700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-26,7.650000,7.880000,7.481400,7.830000,7.830000,250100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-27,8.080000,8.520000,7.950000,8.510000,8.510000,403400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-28,8.460000,8.620000,8.410100,8.540000,8.540000,271100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-10-31,8.380000,8.380000,8.112600,8.120000,8.120000,258800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-01,7.930000,8.040000,7.610000,7.730000,7.730000,407500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-02,7.950000,8.280000,7.600000,7.780000,7.780000,263800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-03,7.910000,8.160000,7.690000,8.110000,8.110000,279900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-04,7.990000,8.000000,7.800000,7.900000,7.900000,225400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-07,7.900000,7.980000,7.551000,7.840000,7.840000,292600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-08,7.910000,7.970000,7.660000,7.680000,7.680000,329000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-09,7.450000,7.700000,7.330000,7.340000,7.340000,278400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-10,7.440000,7.440000,7.020000,7.160000,7.160000,410000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-11,7.230000,7.430000,7.150000,7.260000,7.260000,163700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-14,7.250000,7.250000,7.000000,7.050000,7.050000,345600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-15,7.010000,7.130000,6.900000,6.930000,6.930000,308700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-16,6.850000,6.920000,6.680000,6.740000,6.740000,253000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-17,6.720000,7.000000,6.650000,6.960000,6.960000,285400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-18,7.000000,7.330000,7.000000,7.210000,7.210000,478200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-21,7.130000,7.290000,6.970000,7.060000,7.060000,165700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-22,7.070000,7.070000,6.760000,6.760000,6.760000,340700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-23,6.700000,6.700000,6.500000,6.500000,6.500000,370400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-25,6.500000,6.660000,6.500000,6.500000,6.500000,214200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-28,6.730000,6.870000,6.560000,6.770000,6.770000,375400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-29,6.770000,6.870000,6.540000,6.600000,6.600000,421800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-11-30,6.880000,7.140000,6.750000,7.100000,7.100000,469400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-01,7.060000,7.060000,6.870000,6.870000,6.870000,379500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-02,6.920000,7.000000,6.750000,6.810000,6.810000,243200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-05,6.940000,7.020000,6.820000,6.890000,6.890000,244800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-06,6.890000,7.040000,6.750000,6.970000,6.970000,169300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-07,6.930000,7.120000,6.750000,7.070000,7.070000,187700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-08,7.000000,7.190000,6.820000,6.870000,6.870000,221200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-09,6.890000,7.160000,6.875000,7.090000,7.090000,164300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-12,7.010000,7.260000,7.000000,7.240000,7.240000,260900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-13,7.290000,7.370000,7.120000,7.160000,7.160000,201900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-14,7.070000,7.370000,7.030000,7.370000,7.370000,353800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-15,7.520000,7.920000,7.500000,7.900000,7.900000,720400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-16,7.960000,8.058000,7.730000,7.760000,7.760000,511500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-19,7.800000,7.930000,7.610000,7.620000,7.620000,145800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-20,7.810000,7.930000,7.710000,7.910000,7.910000,319300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-21,7.870000,8.160000,7.690000,8.160000,8.160000,244500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-22,8.170000,8.240000,8.010000,8.040000,8.040000,242700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-23,8.070000,8.230000,7.930000,8.190000,8.190000,78300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-27,8.130000,8.250000,8.031000,8.120000,8.120000,144300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-28,8.110000,8.140000,7.880000,7.990000,7.990000,106400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-29,7.990000,8.240000,7.970000,8.220000,8.220000,153700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2011-12-30,8.200000,8.420000,8.070000,8.150000,8.150000,237700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-03,8.330000,8.750000,8.330000,8.660000,8.660000,357800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-04,8.850000,8.980000,8.620000,8.650000,8.650000,241100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-05,8.650000,8.751700,8.550000,8.650000,8.650000,230900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-06,8.650000,8.830000,8.650000,8.670000,8.670000,216600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-09,8.760000,8.920000,8.700000,8.850000,8.850000,171500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-10,9.010000,9.110000,8.904000,9.000000,9.000000,298800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-11,9.000000,9.290000,8.850000,9.260000,9.260000,404700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-12,9.280000,10.340000,9.250000,10.080000,10.080000,1061400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-13,10.010000,10.160000,9.680000,9.880000,9.880000,336800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-17,9.950000,10.570000,9.810000,10.470000,10.470000,534400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-18,10.460000,10.460000,9.790000,10.300000,10.300000,405900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-19,10.320000,10.350000,10.130000,10.260000,10.260000,296800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-20,10.150000,10.660000,10.060000,10.340000,10.340000,473300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-23,10.370000,10.660000,10.300000,10.500000,10.500000,241900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-24,10.450000,10.760000,9.820000,10.700000,10.700000,297200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-25,10.700000,10.970000,10.610000,10.890000,10.890000,207400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-26,10.900000,10.995000,10.610800,10.800000,10.800000,375100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-27,10.740000,11.170000,10.650000,10.910000,10.910000,422600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-30,10.840000,11.270000,10.810000,11.160000,11.160000,226000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-01-31,11.170000,11.695000,11.140400,11.560000,11.560000,421900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-01,11.640000,12.130000,11.550000,12.080000,12.080000,650100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-02,12.100000,12.650000,12.060000,12.600000,12.600000,635000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-03,12.870000,13.230000,12.600000,13.010000,13.010000,701500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-06,12.980000,13.250000,12.930100,13.130000,13.130000,313700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-07,13.100000,13.100000,12.740800,12.950000,12.950000,480700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-08,13.020000,13.150000,12.650000,13.050000,13.050000,569500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-09,13.060000,13.110000,12.570000,13.050000,13.050000,342600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-10,12.600000,12.790000,11.720000,12.150000,12.150000,724400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-13,12.310000,12.430000,12.170000,12.390000,12.390000,405300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-14,11.710000,11.726000,10.970000,10.980000,10.980000,1115000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-15,11.160000,12.990000,11.050000,12.550000,12.550000,3779800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-16,12.530000,12.870000,12.430000,12.610000,12.610000,622000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-17,12.670000,12.670000,12.080000,12.200000,12.200000,420900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-21,12.220000,12.440000,11.620000,11.980000,11.980000,709300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-22,11.920000,12.040000,11.590000,11.950000,11.950000,414800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-23,12.000000,12.820000,11.870000,12.760000,12.760000,507900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-24,12.930000,13.710000,12.540100,13.420000,13.420000,848300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-27,13.420000,13.750000,13.380000,13.580000,13.580000,573800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-28,13.590000,13.660000,13.390000,13.520000,13.520000,738500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-02-29,13.530000,13.730000,13.180000,13.340000,13.340000,1369700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-01,13.380000,13.730000,13.040000,13.640000,13.640000,467100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-02,13.580000,13.660000,12.480000,12.510000,12.510000,534500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-05,12.520000,12.670000,12.310000,12.650000,12.650000,549900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-06,12.490000,12.570000,11.600000,11.680000,11.680000,439800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-07,11.700000,12.050000,11.690000,12.020000,12.020000,486900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-08,12.150000,12.240000,11.960000,12.140000,12.140000,209600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-09,12.120000,12.350000,12.010000,12.180000,12.180000,259600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-12,12.210000,12.320000,11.820000,11.950000,11.950000,273600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-13,12.020000,12.050000,11.750000,12.000000,12.000000,240500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-14,11.960000,12.070000,11.750000,11.790000,11.790000,158100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-15,11.840000,12.162000,11.800000,12.000000,12.000000,234800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-16,12.030000,12.170000,11.540000,11.590000,11.590000,1312700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-19,11.520000,12.125000,11.510000,12.090000,12.090000,278000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-20,11.990000,11.990000,11.490000,11.580000,11.580000,241400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-21,11.610000,11.649500,11.380000,11.450000,11.450000,166200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-22,11.350000,11.350000,11.000000,11.300000,11.300000,299200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-23,11.340000,11.430000,11.100000,11.340000,11.340000,240700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-26,11.470000,11.640000,11.310000,11.390000,11.390000,520800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-27,11.410000,11.580000,11.280000,11.330000,11.330000,320900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-28,11.380000,11.640000,11.100000,11.350000,11.350000,213200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-29,11.260000,11.360000,11.010000,11.270000,11.270000,172200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-03-30,11.350000,11.548000,11.010000,11.070000,11.070000,370400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-02,11.050000,11.370000,10.950100,11.100000,11.100000,508300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-03,11.110000,11.220000,10.750000,10.820000,10.820000,209900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-04,10.680000,10.820000,10.170000,10.360000,10.360000,489400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-05,10.310000,10.720000,10.310000,10.640000,10.640000,282100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-09,10.330000,10.540000,9.960000,10.290000,10.290000,684800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-10,10.280000,10.349200,9.990000,10.000000,10.000000,553800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-11,10.140000,10.330000,10.100000,10.280000,10.280000,209500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-12,10.385000,10.500000,10.230000,10.330000,10.330000,209000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-13,10.260000,10.297100,9.910000,10.020000,10.020000,363700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-16,10.110000,10.170000,9.840000,10.010000,10.010000,505600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-17,10.110000,10.298800,9.990000,10.140000,10.140000,244900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-18,10.050000,10.150000,9.950000,10.000000,10.000000,116100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-19,10.050000,10.440000,9.970000,10.000000,10.000000,173000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-20,10.760000,10.760000,10.290000,10.620000,10.620000,347200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-23,10.510000,10.820000,10.400000,10.655000,10.655000,327600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-24,10.690000,11.260000,10.600000,11.190000,11.190000,380500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-25,11.390000,11.920000,11.310000,11.550000,11.550000,495400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-26,11.490000,11.705000,11.420000,11.630000,11.630000,394900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-27,11.690000,11.750000,11.400000,11.670000,11.670000,204000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-04-30,11.660000,11.870000,11.270000,11.390000,11.390000,283500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-01,11.340000,11.525000,11.150000,11.170000,11.170000,300000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-02,10.950000,11.060000,10.640000,10.750000,10.750000,379200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-03,10.700000,10.720000,10.190000,10.290000,10.290000,321400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-04,10.390000,10.490000,9.690000,9.780000,9.780000,366200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-07,9.750000,10.070000,9.550000,9.970000,9.970000,356700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-08,10.250000,10.720000,10.140000,10.610000,10.610000,597700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-09,10.380000,10.780000,10.200000,10.600000,10.600000,279300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-10,10.720000,10.780000,10.460000,10.700000,10.700000,337000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-11,10.590000,10.800000,10.541100,10.690000,10.690000,266200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-14,10.530000,10.700000,10.370000,10.610000,10.610000,196000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-15,10.570000,10.590000,10.360000,10.470000,10.470000,200300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-16,10.500000,10.580000,10.270000,10.290000,10.290000,213000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-17,10.270000,10.390000,9.850100,10.000000,10.000000,243000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-18,9.990000,10.050000,9.510000,9.910000,9.910000,490000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-21,9.950000,10.130000,9.800000,10.070000,10.070000,329200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-22,10.090000,10.400000,9.930000,10.060000,10.060000,311400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-23,10.000000,10.350000,9.784000,10.300000,10.300000,219000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-24,10.310000,10.470000,10.120000,10.430000,10.430000,124200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-25,10.420000,10.500000,10.250000,10.430000,10.430000,108200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-29,10.250000,10.340000,9.965000,10.130000,10.130000,329200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-30,10.010000,10.330000,9.990000,10.040000,10.040000,692500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-05-31,10.040000,10.310000,9.980000,10.240000,10.240000,389900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-01,9.990000,10.170000,9.943000,10.090000,10.090000,400000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-04,10.200000,10.460000,10.100000,10.420000,10.420000,189500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-05,10.350000,10.860000,10.310000,10.660000,10.660000,336500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-06,10.750000,11.120000,10.750000,11.050000,11.050000,240600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-07,11.230000,11.230000,10.851000,11.000000,11.000000,314000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-08,10.940000,11.445000,10.900000,11.350000,11.350000,215700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-11,11.460000,11.460000,10.990000,11.030000,11.030000,286500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-12,11.060000,11.560000,10.910000,11.540000,11.540000,357300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-13,11.460000,11.750000,11.300000,11.430000,11.430000,450100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-14,11.430000,11.660000,11.300000,11.630000,11.630000,192700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-15,11.600000,11.830000,11.380000,11.580000,11.580000,516900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-18,11.520000,11.855000,11.430000,11.750000,11.750000,305100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-19,11.790000,11.960000,11.200000,11.730000,11.730000,251000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-20,11.720000,11.770600,11.490000,11.660000,11.660000,176100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-21,11.610000,11.848100,11.280000,11.330000,11.330000,207500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-22,11.450000,11.790000,11.410000,11.760000,11.760000,374300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-25,11.520000,11.760000,11.340000,11.640000,11.640000,138200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-26,11.610000,11.950000,11.500000,11.870000,11.870000,241900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-27,11.760000,12.040000,11.640000,12.010000,12.010000,136300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-28,11.950000,12.050000,11.260000,11.490000,11.490000,201800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-06-29,11.790000,11.980000,11.590000,11.650000,11.650000,186500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-02,11.640000,12.130000,11.640000,12.130000,12.130000,250300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-03,12.090000,12.580000,12.070000,12.570000,12.570000,124100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-05,12.480000,12.830000,12.450000,12.810000,12.810000,208600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-06,12.670000,12.870000,12.550000,12.870000,12.870000,120000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-09,12.860000,12.940000,12.670000,12.935000,12.935000,182000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-10,13.000000,13.210000,12.830000,13.120000,13.120000,267500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-11,13.110000,13.110000,11.780000,12.300000,12.300000,486900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-12,12.400000,12.540000,12.000000,12.430000,12.430000,312900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-13,12.470000,12.670000,12.360000,12.520000,12.520000,221400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-16,13.700000,19.260000,13.320000,19.160000,19.160000,9609400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-17,18.960000,19.970000,18.020000,18.640000,18.640000,4003600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-18,18.370000,18.970000,18.310000,18.720000,18.720000,901400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-19,18.740000,19.190000,18.650000,18.760000,18.760000,1253500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-20,18.520000,18.860000,18.450000,18.740000,18.740000,563900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-23,18.450000,18.920000,18.150000,18.660000,18.660000,363800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-24,18.550000,18.650000,18.360000,18.470000,18.470000,418600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-25,18.450000,18.900000,18.380000,18.770000,18.770000,194800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-26,18.980000,19.300000,18.750000,18.960000,18.960000,610600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-27,19.090000,20.630000,18.860000,20.220000,20.220000,515100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-30,20.170000,20.320000,19.060000,19.110000,19.110000,724500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-07-31,18.790000,19.210000,17.920000,18.690000,18.690000,873100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-01,18.810000,19.110000,17.970000,18.100000,18.100000,446200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-02,18.010000,18.010000,17.220000,17.400000,17.400000,734700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-03,17.810000,18.220000,17.690000,18.030000,18.030000,575100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-06,18.350000,18.820000,18.252000,18.440000,18.440000,442700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-07,17.390000,18.210000,16.950200,18.180000,18.180000,954800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-08,18.140000,18.419900,17.600000,17.870000,17.870000,448900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-09,17.810000,18.010000,17.500000,17.910000,17.910000,306700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-10,17.880000,18.000000,17.230000,17.260000,17.260000,590400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-13,17.250000,17.320000,16.920000,17.140000,17.140000,527900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-14,17.210000,17.286600,16.800000,17.000000,17.000000,279500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-15,16.990000,17.880000,16.920000,17.670000,17.670000,321900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-16,17.610000,17.960000,17.350000,17.750000,17.750000,241700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-17,17.710000,17.810000,17.390000,17.550000,17.550000,293800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-20,17.550000,17.830000,17.330000,17.600000,17.600000,269000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-21,17.730000,18.130000,17.612200,17.940000,17.940000,244800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-22,17.829000,18.110000,17.530000,17.850000,17.850000,259500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-23,17.800000,17.847700,17.450000,17.560000,17.560000,154900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-24,17.500000,17.940000,17.300000,17.740000,17.740000,140800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-27,17.790000,17.940000,17.500000,17.740000,17.740000,84300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-28,17.740000,18.600000,17.740000,18.180000,18.180000,460500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-29,18.240000,18.740000,18.240000,18.450000,18.450000,324000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-30,18.390000,18.600000,18.300000,18.440000,18.440000,345100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-08-31,18.600000,18.600000,18.130000,18.290000,18.290000,173900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-04,18.320000,18.540000,17.810000,18.500000,18.500000,260200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-05,18.440000,18.670000,18.070000,18.270000,18.270000,242600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-06,18.420000,18.440000,17.680000,18.370000,18.370000,370400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-07,18.460000,18.990000,18.370000,18.930000,18.930000,443400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-10,18.850000,19.000000,18.510000,18.650000,18.650000,350200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-11,18.700000,18.930000,18.520000,18.810000,18.810000,387400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-12,18.800000,19.930000,18.770000,19.750000,19.750000,642400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-13,19.690000,20.230000,19.490000,20.190000,20.190000,627400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-14,20.210000,20.950000,20.210000,20.870000,20.870000,427600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-17,20.740000,21.380000,20.480000,20.990000,20.990000,594200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-18,20.900000,21.000000,20.500000,20.700000,20.700000,175400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-19,20.700000,20.737400,19.360000,19.820000,19.820000,680300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-20,19.710000,20.250000,19.710000,20.230000,20.230000,302900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-21,19.890000,20.048000,19.471000,19.610000,19.610000,1092700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-24,19.480000,19.850000,19.470000,19.640000,19.640000,228100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-25,19.730000,19.840000,19.290000,19.380000,19.380000,311400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-26,19.400000,19.664500,18.790000,18.950000,18.950000,408400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-27,18.998500,19.500000,18.860000,19.200000,19.200000,217200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-09-28,19.070000,19.336600,18.780000,18.790000,18.790000,192800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-01,18.810000,19.320000,18.450000,18.850000,18.850000,241800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-02,18.980000,18.980000,18.440000,18.870000,18.870000,161200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-03,18.960000,19.208400,18.800000,18.910000,18.910000,155200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-04,19.020000,19.149900,18.500000,18.770000,18.770000,121800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-05,18.840000,19.270000,18.810000,19.040000,19.040000,117600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-08,18.930000,19.110000,18.685000,18.940000,18.940000,134400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-09,18.620000,18.960000,17.891000,17.940000,17.940000,175900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-10,17.980000,18.030000,17.490000,17.700000,17.700000,204500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-11,17.870000,18.740000,17.870000,18.730000,18.730000,221100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-12,18.750000,18.920000,18.200000,18.410000,18.410000,231500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-15,18.430000,18.740000,18.250000,18.470000,18.470000,123100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-16,18.500000,18.648700,18.000000,18.070000,18.070000,180700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-17,18.090000,18.580000,18.090000,18.490000,18.490000,134400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-18,18.430000,18.430000,17.790000,17.830000,17.830000,108100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-19,17.630000,17.670000,17.160000,17.320000,17.320000,300300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-22,17.430000,17.480000,16.720000,17.060000,17.060000,263900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-23,16.810000,17.190000,16.660000,17.100000,17.100000,180100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-24,17.240000,17.410000,16.990000,17.070000,17.070000,242000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-25,17.290000,17.290000,16.690000,16.820000,16.820000,262500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-26,16.770000,16.900000,16.080000,16.390000,16.390000,141100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-10-31,16.350000,16.620000,15.930000,16.170000,16.170000,154200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-01,16.130000,16.990000,16.130000,16.950000,16.950000,219600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-02,16.780000,16.950000,15.900000,16.090000,16.090000,280400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-05,16.050000,16.790000,16.010000,16.730000,16.730000,153200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-06,16.730000,16.980000,15.940000,16.210000,16.210000,272700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-07,16.030000,16.430000,15.960000,16.180000,16.180000,190000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-08,16.160000,16.240000,15.210000,15.220000,15.220000,479300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-09,15.090000,15.870000,14.900000,15.420000,15.420000,487300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-12,15.520000,16.240000,15.520000,16.120000,16.120000,213800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-13,16.170000,17.230000,16.170000,16.940000,16.940000,595300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-14,17.030000,17.300000,15.580000,15.800000,15.800000,502200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-15,15.590000,15.590000,14.880000,15.300000,15.300000,647700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-16,15.250000,16.080000,15.010000,16.000000,16.000000,350300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-19,16.160000,16.448500,15.610000,16.110000,16.110000,368600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-20,16.100000,16.920000,15.892900,16.630000,16.630000,288800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-21,16.630000,16.640000,16.240000,16.420000,16.420000,130200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-23,16.500000,16.550000,16.310000,16.470000,16.470000,60000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-26,16.480000,16.480000,15.895000,16.250000,16.250000,159100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-27,16.280000,16.600000,15.915000,15.930000,15.930000,122100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-28,15.890000,16.440000,15.560000,16.400000,16.400000,144700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-29,16.530000,17.120000,16.345000,17.100000,17.100000,153000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-11-30,17.190000,17.248500,16.790000,16.970000,16.970000,204500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-03,17.040000,17.040000,16.380000,16.510000,16.510000,216700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-04,16.550000,16.760000,16.140000,16.430000,16.430000,120000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-05,16.490000,16.720000,16.210000,16.350000,16.350000,169400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-06,16.380000,16.670000,16.260000,16.620000,16.620000,87100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-07,16.750000,16.830000,16.460000,16.650000,16.650000,92000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-10,16.690000,17.990000,16.541900,17.599100,17.599100,248600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-11,17.770000,18.130000,17.490000,17.990000,17.990000,266200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-12,18.480000,19.480000,18.210000,18.600000,18.600000,648600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-13,18.680000,18.860000,18.390000,18.440000,18.440000,223600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-14,18.400000,18.710000,18.190000,18.540000,18.540000,159000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-17,18.610000,18.650000,18.290000,18.560000,18.560000,181900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-18,18.600000,18.600000,18.340000,18.400000,18.400000,324200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-19,18.370000,18.500000,18.120000,18.340000,18.340000,208000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-20,18.350000,18.770000,18.300000,18.660000,18.660000,235400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-21,18.400000,18.400000,17.810000,18.070000,18.070000,755400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-24,18.090000,18.400000,17.790000,18.400000,18.400000,70800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-26,18.400000,18.400000,17.630000,17.680000,17.680000,119200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-27,17.750000,18.230000,17.310000,17.740000,17.740000,160000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-28,17.610000,17.985600,17.610000,17.660000,17.660000,84700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2012-12-31,17.730000,18.300000,17.510000,18.250000,18.250000,199200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-02,18.950000,19.450000,18.710100,19.170000,19.170000,340100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-03,19.140000,19.340000,18.660000,18.730000,18.730000,118700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-04,18.840000,19.500000,18.610000,19.040000,19.040000,142400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-07,18.950000,19.880000,18.910000,19.760000,19.760000,298900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-08,19.680000,19.767500,19.160000,19.530000,19.530000,220500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-09,19.520000,20.320000,19.460000,20.200000,20.200000,269100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-10,20.270000,20.740000,19.930000,20.250000,20.250000,316000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-11,20.290000,20.300000,19.770000,20.160000,20.160000,123700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-14,20.120000,20.580000,20.010000,20.550000,20.550000,270900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-15,20.090000,20.250000,19.230000,20.130000,20.130000,729200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-16,20.780000,22.260000,20.700000,22.140000,22.140000,4451000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-17,22.110000,22.110000,21.730000,21.850000,21.850000,455400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-18,21.890000,22.720000,21.700000,22.650000,22.650000,600500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-22,22.720000,23.450000,22.550000,23.400000,23.400000,672800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-23,23.380000,24.400000,23.080000,23.660000,23.660000,713500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-24,23.620000,24.505000,23.120000,23.810000,23.810000,702600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-25,24.000000,24.780000,23.880000,24.770000,24.770000,650200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-28,24.600000,25.005000,24.560000,25.000000,25.000000,1000500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-29,24.960000,25.000000,24.081000,24.630000,24.630000,638500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-30,24.510000,24.510000,23.760000,23.810000,23.810000,662700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-01-31,23.480000,24.235000,22.640100,24.130000,24.130000,1921400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-01,24.260000,24.500000,23.433300,24.240000,24.240000,508600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-04,24.240000,24.370000,23.530000,23.670000,23.670000,527500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-05,23.860000,24.590000,23.510100,24.540000,24.540000,421400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-06,24.470000,24.590000,24.020000,24.400000,24.400000,249700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-07,24.380000,24.400000,23.680000,23.840000,23.840000,274000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-08,24.450000,25.770000,24.430000,24.820000,24.820000,1183900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-11,24.250000,24.540000,23.450000,24.540000,24.540000,447600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-12,24.580000,24.630000,24.160000,24.310000,24.310000,281500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-13,24.280000,24.430000,24.000000,24.220000,24.220000,279500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-14,24.220000,24.830000,24.010000,24.110000,24.110000,579000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-15,24.320000,24.320000,23.941000,24.090000,24.090000,420300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-19,24.090000,25.250000,24.090000,24.700000,24.700000,491400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-20,24.690000,24.690000,23.820000,23.920000,23.920000,518800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-21,23.910000,24.640000,22.760000,23.420000,23.420000,691900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-22,23.630000,23.980000,23.260000,23.440000,23.440000,521100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-25,23.610000,23.650000,22.760000,23.010000,23.010000,844400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-26,23.190000,24.140000,23.100000,23.590000,23.590000,965700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-27,23.490000,23.700000,23.260000,23.530000,23.530000,485900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-02-28,23.490000,23.760000,23.220000,23.690000,23.690000,546300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-01,23.520000,23.790000,22.990000,23.740000,23.740000,568400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-04,23.590000,24.420000,23.548000,24.040000,24.040000,347200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-05,24.170000,25.400000,24.128000,25.380000,25.380000,657000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-06,25.560000,25.800000,25.120000,25.390000,25.390000,508000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-07,25.330000,25.565000,24.460000,24.710000,24.710000,424100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-08,24.970000,24.970000,24.116000,24.580000,24.580000,503100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-11,24.560000,24.830000,24.390000,24.510000,24.510000,304100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-12,24.460000,24.820000,23.820000,24.760000,24.760000,245900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-13,24.800000,24.800000,24.150000,24.470000,24.470000,231700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-14,24.510000,25.040000,24.390000,24.990000,24.990000,418600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-15,25.020000,25.150000,24.767500,25.000000,25.000000,1225100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-18,24.590000,24.990000,23.980000,24.710000,24.710000,248800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-19,24.750000,24.940000,23.750000,23.970000,23.970000,496700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-20,24.130000,24.710400,23.912000,24.260000,24.260000,247400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-21,23.760000,24.200000,23.370000,23.700000,23.700000,453100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-22,23.740000,23.860000,23.460000,23.830000,23.830000,237100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-25,23.880000,23.880000,23.270000,23.570000,23.570000,286000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-26,23.660000,23.840000,23.130000,23.400000,23.400000,311500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-27,23.210000,23.820000,23.000000,23.780000,23.780000,357300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-03-28,23.820000,24.560000,23.602200,24.370000,24.370000,366300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-01,24.250000,24.420000,23.250000,23.530000,23.530000,278400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-02,23.750000,23.880000,23.340000,23.440000,23.440000,226800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-03,23.450000,23.450000,22.130000,22.660000,22.660000,406900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-04,22.970000,23.100000,22.400500,22.920000,22.920000,293400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-05,22.410000,23.030000,22.290000,22.970000,22.970000,232800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-08,23.070000,23.205000,22.570000,23.190000,23.190000,200600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-09,23.330000,23.330000,22.680000,22.740000,22.740000,242000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-10,22.770000,23.360000,22.520000,23.150000,23.150000,370800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-11,23.160000,23.380000,23.000000,23.150000,23.150000,416900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-12,23.000000,23.270000,22.853000,22.950000,22.950000,228700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-15,22.830000,22.830000,21.850000,21.880000,21.880000,466300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-16,22.150000,22.500000,21.840000,22.490000,22.490000,227700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-17,22.270000,22.629000,21.970000,22.340000,22.340000,227000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-18,22.360000,22.610000,21.600000,21.890000,21.890000,331000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-19,21.970000,23.520000,21.970000,23.410000,23.410000,518000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-22,23.480000,23.820000,23.280000,23.670000,23.670000,489400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-23,23.850000,24.149000,23.750000,24.010000,24.010000,375300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-24,24.050000,24.050000,23.220000,23.550000,23.550000,331400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-25,23.750000,24.440000,23.700000,24.050000,24.050000,320200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-26,24.000000,24.130000,23.390000,24.040000,24.040000,226200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-29,24.240000,24.240000,23.620000,23.720000,23.720000,162000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-04-30,23.730000,24.010000,23.420000,23.950000,23.950000,360400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-01,23.840000,23.856000,22.540000,22.820000,22.820000,561300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-02,23.020000,24.000000,23.020000,23.430000,23.430000,439000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-03,23.880000,24.020000,23.510000,23.590000,23.590000,397700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-06,23.640000,23.870000,23.260000,23.700000,23.700000,641000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-07,24.310000,25.880000,24.252000,24.420000,24.420000,964500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-08,24.400000,24.740000,24.120000,24.580000,24.580000,684700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-09,24.560000,25.180000,24.560000,24.760000,24.760000,362200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-10,24.880000,25.665000,24.745000,25.610000,25.610000,383800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-13,25.600000,28.330000,25.570000,27.570000,27.570000,933700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-14,27.750000,28.680000,27.390000,27.990000,27.990000,672800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-15,27.800000,28.450000,27.800000,28.170000,28.170000,419400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-16,28.120000,28.170000,27.069600,27.210000,27.210000,413200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-17,27.240000,27.890000,27.040000,27.440000,27.440000,520100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-20,27.240000,27.750000,27.240000,27.560000,27.560000,259400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-21,27.560000,28.230000,27.380000,28.030000,28.030000,211600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-22,28.160000,29.000000,27.490000,27.840000,27.840000,456400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-23,27.460000,28.116000,26.570000,28.060000,28.060000,191100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-24,28.840000,29.070000,28.470000,28.980000,28.980000,384100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-28,29.000000,30.000000,28.820000,29.820000,29.820000,617400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-29,29.760000,29.990000,29.070000,29.820000,29.820000,324400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-30,29.910000,30.440000,29.770000,30.140000,30.140000,419800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-05-31,29.820000,30.980000,29.810000,30.630000,30.630000,617200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-03,30.630000,30.732000,29.576000,30.250000,30.250000,854600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-04,30.380000,30.760000,29.840000,30.020000,30.020000,381300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-05,29.890000,30.180000,29.530000,29.710000,29.710000,323700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-06,29.700000,30.090000,29.300000,30.090000,30.090000,407900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-07,30.390000,31.000000,30.330000,30.920000,30.920000,361700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-10,31.000000,31.000000,30.380000,30.750000,30.750000,400500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-11,30.620000,31.790000,30.570000,30.590000,30.590000,760900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-12,30.970000,31.010000,30.010000,30.110000,30.110000,296500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-13,30.010000,30.380000,29.490000,30.360000,30.360000,219900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-14,30.470000,31.100000,30.100000,30.110000,30.110000,377500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-17,30.410000,30.410000,29.620000,29.690000,29.690000,375800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-18,29.730000,30.191000,29.590000,29.990000,29.990000,242500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-19,29.900000,30.839500,29.700000,30.250000,30.250000,663700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-20,29.850000,30.000000,28.050000,28.400000,28.400000,664300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-21,28.480000,29.190000,27.980000,29.010000,29.010000,961500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-24,28.570000,29.670000,28.000000,29.400000,29.400000,497400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-25,29.700000,29.700000,28.750000,29.400000,29.400000,604400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-26,29.690000,30.400000,29.510000,30.240000,30.240000,573900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-27,30.580000,30.900000,30.180000,30.840000,30.840000,231100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-06-28,30.810000,31.160000,30.650000,31.000000,31.000000,553600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-01,32.000000,33.050000,31.750000,32.990000,32.990000,1227700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-02,33.000000,35.970000,32.900000,35.840000,35.840000,1039900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-03,35.570000,36.700000,35.280000,36.660000,36.660000,326400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-05,36.830000,37.930000,36.530000,37.820000,37.820000,458800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-08,38.090000,39.420000,36.770000,37.380000,37.380000,865500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-09,37.420000,37.897500,36.601600,37.180000,37.180000,499700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-10,37.280000,37.709000,36.810000,37.600000,37.600000,296700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-11,42.730000,44.650000,41.840000,43.525000,43.525000,2683100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-12,45.365000,51.000000,45.365000,50.040000,50.040000,3233600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-15,49.030000,50.560000,47.530000,50.370000,50.370000,1814300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-16,49.980000,51.000000,46.530000,46.620000,46.620000,1239900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-17,46.600000,47.479900,45.450000,46.000000,46.000000,746400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-18,46.120000,46.276200,42.730000,42.870000,42.870000,1155800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-19,42.630000,44.700000,42.190000,44.340000,44.340000,984200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-22,43.250000,44.590000,43.230000,44.510000,44.510000,570900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-23,44.600000,45.660000,43.920000,45.310000,45.310000,588400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-24,44.750000,45.480000,44.300000,44.950000,44.950000,728400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-25,45.070000,46.000000,44.410000,45.000000,45.000000,573200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-26,44.520000,45.880000,43.980000,45.760000,45.760000,499700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-29,45.760000,45.980000,44.500000,44.720000,44.720000,383600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-30,45.020000,45.920000,44.760000,45.740000,45.740000,423700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-07-31,45.850000,46.630000,45.520000,46.170000,46.170000,424100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-01,46.640000,47.580000,46.220000,47.520000,47.520000,629800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-02,47.770000,49.730000,47.600000,48.830000,48.830000,886200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-05,48.930000,49.050000,48.030000,48.670000,48.670000,617400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-06,48.500000,48.660000,46.500000,46.840000,46.840000,636100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-07,46.800000,47.463000,45.800000,46.520000,46.520000,618000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-08,47.680000,48.210000,47.016000,47.360000,47.360000,890500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-09,48.260000,50.000000,47.500000,48.220000,48.220000,634900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-12,47.960000,48.860000,47.028500,48.610000,48.610000,510300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-13,48.710000,49.120000,47.990000,48.560000,48.560000,458200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-14,47.950000,49.890000,47.950000,48.760000,48.760000,524600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-15,47.960000,48.720000,47.960000,48.430000,48.430000,524600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-16,48.160000,49.149000,47.590000,48.260000,48.260000,249700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-19,48.160000,48.280000,46.720000,48.030000,48.030000,547900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-20,48.270000,49.560000,47.570000,49.260000,49.260000,284900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-21,49.220000,50.769900,48.550000,50.070000,50.070000,410700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-22,50.090000,51.840000,49.750000,51.600000,51.600000,298200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-23,51.720000,51.980000,51.020000,51.930000,51.930000,300900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-26,52.000000,55.320000,51.710000,54.620000,54.620000,525600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-27,54.080000,54.970000,50.920000,51.240000,51.240000,761600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-28,51.070000,51.500000,49.420000,51.000000,51.000000,702500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-29,51.000000,53.640000,50.800100,52.310000,52.310000,330600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-08-30,52.250000,52.820000,51.250000,51.800000,51.800000,350900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-03,52.740000,52.830000,51.700000,52.420000,52.420000,292700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-04,52.310000,54.920000,52.310000,54.610000,54.610000,615900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-05,54.530000,56.440000,54.150000,55.050000,55.050000,494900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-06,55.530000,56.298000,53.270000,55.900000,55.900000,387800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-09,56.000000,57.550000,55.010000,57.500000,57.500000,373900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-10,58.000000,58.340000,56.900000,57.200000,57.200000,475600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-11,56.910000,57.330000,54.860000,55.960000,55.960000,544500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-12,56.160000,57.880000,55.240000,55.520000,55.520000,565700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-13,55.820000,56.070000,54.390000,55.130000,55.130000,601800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-16,55.890000,56.100000,54.042000,54.510000,54.510000,354300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-17,54.350000,55.239900,53.730000,54.500000,54.500000,315400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-18,54.350000,56.170000,54.170000,55.700000,55.700000,472000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-19,55.940000,57.980000,55.870000,57.610000,57.610000,492800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-20,57.740000,58.550000,56.630000,57.225000,57.225000,1384000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-23,57.280000,63.840000,56.720100,63.050000,63.050000,1493100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-24,64.010000,64.900000,62.050000,63.600000,63.600000,884300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-25,63.830000,64.420000,62.830000,62.910000,62.910000,595500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-26,62.680000,64.050000,62.660000,63.780000,63.780000,476800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-27,63.080000,65.830000,62.350000,64.070000,64.070000,565000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-09-30,63.290000,65.080000,62.881000,64.010000,64.010000,566300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-01,64.030000,65.850000,64.010000,65.800000,65.800000,557500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-02,64.880000,66.170000,64.550000,66.140000,66.140000,1251700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-03,66.150000,66.150000,63.660000,64.450000,64.450000,820300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-04,64.290000,65.400000,64.100000,64.630000,64.630000,474100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-07,63.970000,64.330000,60.860000,61.030000,61.030000,901900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-08,60.910000,61.380000,56.720000,57.000000,57.000000,1330900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-09,57.090000,57.150000,52.570000,53.350000,53.350000,2049700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-10,54.560000,59.480000,54.140000,59.000000,59.000000,1038800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-11,59.020000,59.830000,56.410000,59.200000,59.200000,892000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-14,58.100000,59.710000,57.510000,59.430000,59.430000,846400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-15,59.140000,59.939900,58.691000,59.260000,59.260000,681700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-16,59.900000,62.250000,59.301000,62.071000,62.071000,1018200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-17,61.810000,62.100000,59.700000,60.240000,60.240000,1372700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-18,61.010000,61.300000,58.310000,59.750000,59.750000,1020900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-21,58.000800,59.770000,58.000800,59.310000,59.310000,816700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-22,59.700000,61.090000,57.730000,59.480000,59.480000,960900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-23,58.960000,59.930000,58.580000,59.770000,59.770000,864500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-24,60.070000,61.680000,59.695000,60.730000,60.730000,595100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-25,61.020000,61.500000,60.060000,60.740000,60.740000,456100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-28,60.970000,61.230000,58.560100,59.700000,59.700000,605300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-29,59.810000,61.530000,59.150000,61.490000,61.490000,425100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-30,61.690000,62.150000,57.860100,58.570000,58.570000,634700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-10-31,58.460000,59.180000,55.831000,57.610000,57.610000,840400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-01,57.510000,57.890000,55.660000,57.060000,57.060000,932000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-04,57.440000,58.480000,56.000000,56.130000,56.130000,537400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-05,55.440000,58.120000,54.580000,57.320000,57.320000,715300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-06,57.960000,58.162500,54.230000,54.970000,54.970000,1261500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-07,54.930000,54.990000,49.020000,50.920000,50.920000,2272200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-08,50.990000,54.120000,50.990000,52.980000,52.980000,671000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-11,54.090000,55.010000,52.680000,54.980000,54.980000,752600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-12,55.050000,55.250000,53.835800,54.190000,54.190000,867600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-13,53.590000,53.770000,52.980000,53.170000,53.170000,583300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-14,52.920000,52.970000,48.161000,50.790000,50.790000,1227300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-15,51.080000,54.070000,50.750000,53.950000,53.950000,858600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-18,54.210000,54.439900,52.150000,53.050000,53.050000,1063400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-19,53.140000,53.830000,52.270000,53.310000,53.310000,533200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-20,53.460000,54.490000,52.480000,53.560000,53.560000,398000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-21,53.880000,56.370000,53.600000,56.278000,56.278000,421900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-22,56.850000,58.640000,56.790000,58.330000,58.330000,600000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-25,58.500000,61.620000,58.190000,59.970000,59.970000,963400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-26,60.000000,62.230000,59.841000,61.020000,61.020000,696000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-27,61.310000,61.719000,60.090000,61.460000,61.460000,386000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-11-29,61.990000,61.990000,60.860000,61.200000,61.200000,203500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-02,61.250000,62.510000,60.860000,61.930000,61.930000,420300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-03,61.870000,62.350000,59.880000,61.100000,61.100000,465900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-04,60.560000,61.999400,60.500000,61.660000,61.660000,543200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-05,61.950000,63.800000,61.430000,62.980000,62.980000,790600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-06,63.860000,63.880000,61.820100,62.980000,62.980000,595300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-09,63.250000,63.880000,60.320100,61.260000,61.260000,475100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-10,61.190000,61.190000,58.390000,60.030000,60.030000,669000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-11,59.990000,60.000000,56.650000,57.130000,57.130000,841100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-12,57.460000,60.600000,57.460000,59.790000,59.790000,609000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-13,60.200000,60.590000,58.790000,59.420000,59.420000,518100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-16,59.690000,61.380000,59.460000,60.920000,60.920000,401200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-17,60.850000,62.000000,59.880000,61.060000,61.060000,645200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-18,61.100000,63.550000,60.590000,63.000000,63.000000,594300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-19,62.750000,63.870000,61.590000,62.000000,62.000000,535200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-20,62.390000,67.450000,62.390000,66.440000,66.440000,1190400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-23,67.150000,67.970000,64.745000,65.730000,65.730000,673500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-24,65.730000,66.450000,64.930000,66.200000,66.200000,159700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-26,66.520000,67.869900,65.960100,66.910000,66.910000,365200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-27,67.130000,67.450000,64.687500,65.160000,65.160000,232800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-30,64.980000,65.150000,63.880000,64.510000,64.510000,434200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2013-12-31,64.340000,65.250000,63.530100,64.300000,64.300000,460600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-02,64.250000,64.250000,62.510000,63.860000,63.860000,265200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-03,64.100000,64.489000,62.440000,63.140000,63.140000,340300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-06,63.160000,63.570000,60.610000,61.070000,61.070000,419600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-07,61.480000,62.550000,60.238200,62.310000,62.310000,417500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-08,62.080000,63.810000,61.300000,63.680000,63.680000,261900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-09,64.260000,65.950000,63.910000,64.830000,64.830000,314600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-10,64.800000,66.340000,63.000000,66.210000,66.210000,343600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-13,85.360000,112.570000,84.760000,93.280000,93.280000,5343700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-14,91.800000,93.500000,85.000000,89.760000,89.760000,1437400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-15,88.890000,88.890000,82.910000,84.610000,84.610000,867800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-16,84.420000,88.410000,83.010000,88.230000,88.230000,560400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-17,88.000000,91.820000,87.180000,87.360000,87.360000,457900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-21,90.230000,90.972000,87.020000,90.930000,90.930000,602900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-22,90.870000,93.000000,89.140000,92.130000,92.130000,679800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-23,91.430000,92.167500,89.140000,89.490000,89.490000,539900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-24,88.940000,88.940000,83.400000,83.600000,83.600000,822200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-27,83.460000,84.000000,78.500000,81.050000,81.050000,871900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-28,81.000000,85.789900,81.000000,84.530000,84.530000,754500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-29,83.690000,85.438000,81.800000,83.370000,83.370000,414000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-30,84.560000,86.730000,84.140000,85.900000,85.900000,405200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-01-31,84.010000,86.860000,82.220000,83.660000,83.660000,461600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-03,83.670000,85.440000,76.770000,78.680000,78.680000,614600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-04,79.370000,80.830000,77.450000,77.820000,77.820000,537800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-05,77.240000,79.100000,73.010000,75.340000,75.340000,740200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-06,75.730000,77.059900,74.530000,75.720000,75.720000,502300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-07,74.960000,79.830000,74.950000,79.020000,79.020000,679500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-10,79.270000,80.960000,77.800000,80.710000,80.710000,520600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-11,80.960000,82.480000,78.440000,79.920000,79.920000,490400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-12,79.130000,81.000000,79.050000,80.440000,80.440000,470000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-13,79.080000,81.809600,79.080000,81.560000,81.560000,383600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-14,81.460000,83.630000,75.825000,78.720000,78.720000,764200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-18,79.150000,81.840000,79.150000,81.230000,81.230000,602900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-19,81.140000,81.650000,78.060000,79.140000,79.140000,606200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-20,79.200000,85.540000,78.970000,84.700000,84.700000,988100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-21,85.000000,90.700000,84.720000,90.640000,90.640000,1155900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-24,90.990000,92.450000,86.630000,87.680000,87.680000,840100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-25,87.950000,88.540000,85.310000,86.130000,86.130000,542900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-26,86.000000,86.905000,84.780000,85.790000,85.790000,599100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-27,85.720000,88.559900,84.894200,87.030000,87.030000,744100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-02-28,86.940000,87.630000,78.500100,81.240000,81.240000,966400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-03,80.110000,81.700000,78.571000,79.900000,79.900000,442500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-04,80.720000,83.690000,80.500000,81.310000,81.310000,750700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-05,81.360000,81.600000,79.670000,80.200000,80.200000,483500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-06,80.000000,80.940000,75.010000,75.200000,75.200000,803400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-07,76.220000,77.000000,70.760000,73.120000,73.120000,1184200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-10,72.580000,73.100000,70.250000,72.790000,72.790000,634200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-11,73.010000,75.300000,71.990000,72.550000,72.550000,740900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-12,72.100000,75.680000,71.830000,74.140000,74.140000,550600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-13,74.230000,75.190000,70.240000,71.980000,71.980000,601800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-14,71.440000,72.670000,70.250000,71.190000,71.190000,283000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-17,71.940000,74.740000,71.645000,72.750000,72.750000,572700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-18,73.070000,75.220000,72.010000,74.770000,74.770000,678500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-19,75.010000,75.010000,72.180000,74.040000,74.040000,382500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-20,73.570000,73.930000,71.360000,73.280000,73.280000,408100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-21,73.440000,73.440000,68.020000,69.990000,69.990000,1749700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-24,70.240000,70.838000,62.000600,66.090000,66.090000,1142700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-25,66.510000,69.260000,65.040000,66.880000,66.880000,760000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-26,68.160000,68.620000,63.760000,63.970000,63.970000,718100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-27,63.830000,65.480000,61.110000,65.130000,65.130000,852600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-28,65.490000,66.449900,60.280000,61.740000,61.740000,1562700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-03-31,61.750000,67.860000,61.750000,67.140000,67.140000,1162600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-01,66.800000,68.960000,65.560000,67.430000,67.430000,719700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-02,67.940000,68.300000,64.090000,65.620000,65.620000,628400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-03,65.840000,66.190000,60.750000,61.700000,61.700000,954900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-04,63.390000,64.380000,59.000000,60.230000,60.230000,1317800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-07,60.070000,63.300000,58.260000,62.550000,62.550000,835400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-08,62.970000,65.130000,61.320000,62.470000,62.470000,874300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-09,63.010000,66.500000,62.775000,65.900000,65.900000,995200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-10,64.370000,65.540000,56.800000,57.920000,57.920000,1118700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-11,57.130000,60.070000,54.920000,55.070000,55.070000,1505300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-14,55.670000,57.560000,52.020000,53.540000,53.540000,1246100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-15,53.700000,55.380000,49.930000,53.220000,53.220000,1118300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-16,54.000000,55.660000,53.100000,54.610000,54.610000,823800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-17,54.110000,55.585000,52.420000,53.860000,53.860000,722600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-21,54.000000,55.820000,53.290100,55.730000,55.730000,377800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-22,55.650000,59.105000,55.500000,58.340000,58.340000,900500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-23,57.910000,58.020000,54.020000,54.320000,54.320000,1057900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-24,54.880000,54.999900,50.020000,52.780000,52.780000,1000100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-25,52.310000,52.980000,49.250000,49.340000,49.340000,849000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-28,49.630000,51.740000,47.030000,48.870000,48.870000,1116600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-29,48.890000,51.620000,48.360000,50.950000,50.950000,813200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-04-30,50.380000,51.217000,48.760000,49.530000,49.530000,802200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-01,49.500000,54.480000,48.740000,54.430000,54.430000,1220700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-02,54.320000,55.590000,53.570000,54.210000,54.210000,1383300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-05,53.370000,54.790000,52.340000,54.340000,54.340000,567800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-06,53.800000,54.230000,51.690000,52.270000,52.270000,1067000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-07,51.660000,52.200000,49.530000,51.610000,51.610000,940200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-08,51.090000,52.980000,50.020000,50.260000,50.260000,799300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-09,47.680000,54.570000,47.420000,54.330000,54.330000,833300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-12,57.300000,57.740000,54.460000,57.510000,57.510000,1323800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-13,57.480000,59.660000,56.710000,57.920000,57.920000,1764700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-14,57.500000,58.716400,56.020000,56.700000,56.700000,782600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-15,56.230000,57.180000,55.500000,56.940000,56.940000,1068500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-16,57.040000,57.550000,55.760000,57.300000,57.300000,1329500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-19,56.850000,58.490000,56.430000,58.260000,58.260000,861400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-20,58.370000,58.370000,54.200000,54.790000,54.790000,1124200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-21,54.940000,56.690000,52.400000,53.170000,53.170000,1067200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-22,53.070000,56.990000,53.030000,55.540000,55.540000,718400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-23,55.770000,59.040000,55.000000,58.750000,58.750000,1011400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-27,59.110000,63.670000,58.400100,63.280000,63.280000,1267900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-28,63.130000,65.310000,61.120000,61.960000,61.960000,766900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-29,62.630000,63.810000,60.850000,61.390000,61.390000,696000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-05-30,61.570000,61.890000,58.630000,59.290000,59.290000,735300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-02,59.610000,60.450000,56.620000,57.950000,57.950000,598600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-03,57.400000,58.670000,54.480000,56.460000,56.460000,796200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-04,56.000000,57.070000,55.220000,56.370000,56.370000,544000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-05,56.660000,60.680000,56.270000,59.250000,59.250000,1016400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-06,59.830000,61.380000,58.640000,61.340000,61.340000,652300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-09,61.260000,66.855000,61.260000,65.960000,65.960000,1182500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-10,65.530000,67.070000,64.160000,66.150000,66.150000,653000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-11,65.100000,69.540000,65.100000,67.710000,67.710000,867800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-12,68.420000,68.800000,66.560000,67.740000,67.740000,617400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-13,67.820000,68.400000,66.080000,67.730000,67.730000,461900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-16,69.000000,71.400000,67.990000,69.330000,69.330000,690200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-17,68.990000,70.470000,68.410000,69.800000,69.800000,573600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-18,69.830000,71.315000,68.840000,70.760000,70.760000,532700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-19,71.270000,71.340000,69.160000,70.200000,70.200000,415600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-20,70.800000,70.890000,68.660000,70.010000,70.010000,1515400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-23,70.140000,70.820000,66.780000,67.030000,67.030000,723500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-24,66.740000,69.090000,66.010000,66.270000,66.270000,567200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-25,65.650000,67.070000,65.080000,66.680000,66.680000,599300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-26,67.020000,67.490000,64.085000,64.190000,64.190000,825100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-27,64.000000,64.000000,60.740000,62.230000,62.230000,7463100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-06-30,62.660000,65.680000,62.600000,63.170000,63.170000,773500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-01,63.180000,67.080000,63.180000,66.830000,66.830000,716000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-02,66.700000,66.980000,64.690000,64.920000,64.920000,533300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-03,65.180000,66.202000,64.087800,65.725000,65.725000,190800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-07,64.940000,65.439500,61.310000,61.470000,61.470000,618200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-08,60.970000,61.360000,57.060000,57.170000,57.170000,1049100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-09,57.310000,58.830000,56.342000,58.530000,58.530000,588800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-10,55.910000,58.680000,55.750000,57.850000,57.850000,428200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-11,57.650000,58.200000,57.050000,57.360000,57.360000,287000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-14,57.760000,58.010000,56.250000,56.420000,56.420000,416300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-15,56.040000,56.960000,53.260000,53.260000,53.260000,695200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-16,53.560000,54.220000,52.760000,53.770000,53.770000,613600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-17,53.070000,53.700000,51.930000,52.020000,52.020000,901900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-18,52.350000,54.540000,52.000000,53.820000,53.820000,493500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-21,53.340000,54.410000,52.280000,54.110000,54.110000,436600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-22,54.720000,56.110000,54.160000,55.260000,55.260000,456400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-23,55.830000,57.140000,55.010000,55.860000,55.860000,359200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-24,55.920000,56.929000,54.780000,55.760000,55.760000,399800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-25,55.250000,55.680000,53.980000,54.830000,54.830000,274600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-28,54.900000,55.480000,53.300000,53.310000,53.310000,472500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-29,53.820000,55.590000,53.040000,55.330000,55.330000,538800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-30,56.070000,57.120000,54.820000,55.540000,55.540000,391700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-07-31,54.770000,55.230000,52.430000,54.117000,54.117000,779700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-01,54.160000,55.130000,52.350000,53.710000,53.710000,680100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-04,53.950000,56.040000,53.290000,55.950000,55.950000,474300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-05,55.220000,57.810000,54.510100,56.280000,56.280000,399300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-06,55.560000,57.587000,54.110000,57.280000,57.280000,325800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-07,57.730000,58.240000,55.660000,56.110000,56.110000,521300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-08,54.450000,58.240000,53.540000,58.150000,58.150000,617300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-11,58.520000,61.470000,57.260000,61.300000,61.300000,856400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-12,61.400000,62.310000,60.400000,61.410000,61.410000,749100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-13,62.090000,65.880000,61.640000,65.340000,65.340000,845000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-14,65.630000,66.980000,65.330100,66.970000,66.970000,563300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-15,67.540000,67.940000,65.790000,67.260000,67.260000,564100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-18,68.980000,69.800000,65.900000,67.220000,67.220000,608200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-19,67.680000,68.500000,66.460000,68.050000,68.050000,392600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-20,68.000000,68.500000,66.680000,67.330000,67.330000,487600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-21,67.440000,67.770000,64.610000,65.360000,65.360000,653700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-22,65.100000,65.660000,63.816200,65.350000,65.350000,395100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-25,66.060000,68.098400,66.060000,67.650000,67.650000,455600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-26,68.340000,69.880000,68.080000,69.520000,69.520000,378300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-27,69.520000,69.920000,67.820000,68.060000,68.060000,460300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-28,67.690000,69.303000,67.010000,68.460000,68.460000,536000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-08-29,68.680000,70.080000,67.686000,69.670000,69.670000,368300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-02,69.770000,69.770000,67.580000,68.470000,68.470000,417600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-03,68.890000,69.600000,67.000000,67.430000,67.430000,329300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-04,67.730000,68.820000,65.560000,65.970000,65.970000,350600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-05,65.930000,66.380000,63.475000,65.330000,65.330000,602600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-08,65.440000,67.860000,65.432000,67.790000,67.790000,402100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-09,67.570000,67.920000,65.580000,65.850000,65.850000,546600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-10,66.090000,70.680000,65.785000,69.500000,69.500000,787900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-11,69.070000,70.520000,68.430000,70.370000,70.370000,489300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-12,70.000000,74.620000,70.000000,72.550000,72.550000,902600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-15,72.860000,73.020000,70.000000,71.950000,71.950000,856500,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-16,71.800000,73.650000,70.550000,73.460000,73.460000,717800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-17,74.080000,78.250000,74.040000,77.690000,77.690000,964600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-18,79.220000,79.745000,77.590000,78.180000,78.180000,918800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-19,78.780000,78.870000,75.910000,77.770000,77.770000,949800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-22,77.890000,78.410000,76.490000,77.400000,77.400000,695400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-23,76.520000,78.380000,76.400000,76.910000,76.910000,537600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-24,77.560000,79.880000,76.970000,79.020000,79.020000,539662,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-25,78.600000,79.680000,75.481000,77.500000,77.500000,594496,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-26,78.000000,79.005000,75.610200,78.800000,78.800000,573044,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-29,77.640000,79.700000,76.900000,78.600000,78.600000,549674,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-09-30,78.200000,79.760000,77.130000,78.100000,78.100000,666153,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-01,78.430000,78.860000,74.740000,77.020000,77.020000,892436,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-02,77.130000,78.240000,73.930000,76.080000,76.080000,852789,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-03,77.560000,78.480000,75.910000,78.240000,78.240000,709230,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-06,78.360000,80.740000,78.240000,80.500000,80.500000,963760,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-07,79.720000,79.720000,77.250000,78.870000,78.870000,1026336,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-08,78.130000,79.650000,75.770000,79.580000,79.580000,808354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-09,80.260000,80.490000,75.080000,76.580000,76.580000,561685,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-10,75.800000,77.440000,72.800000,72.850000,72.850000,687260,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-13,81.510000,89.240000,80.410000,86.680000,86.680000,3665263,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-14,86.270000,89.540000,82.580000,82.950000,82.950000,1330488,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-15,82.000000,85.960000,80.250000,84.390000,84.390000,1452950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-16,85.150000,86.980000,81.770000,84.940000,84.940000,871958,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-17,85.500000,88.000000,84.600000,86.180000,86.180000,1458014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-20,86.190000,88.390000,86.190000,87.990000,87.990000,620189,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-21,88.880000,89.900000,87.670000,88.920000,88.920000,522079,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-22,89.000000,90.630000,87.050000,88.760000,88.760000,555501,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-23,89.720000,92.290000,88.620000,91.810000,91.810000,623760,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-24,90.900000,94.990000,90.900000,93.840000,93.840000,739201,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-27,93.490000,94.360000,91.280000,92.910000,92.910000,659451,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-28,93.500000,97.370000,93.240000,94.250000,94.250000,855794,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-29,93.610000,94.140000,91.100000,91.530000,91.530000,759131,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-30,90.960000,94.920000,90.431700,94.720000,94.720000,466563,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-10-31,95.800000,99.240000,91.760000,92.740000,92.740000,913687,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-03,92.000000,94.000000,91.510000,92.560000,92.560000,559902,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-04,91.680000,93.127000,89.090000,89.990000,89.990000,800748,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-05,89.990000,91.000000,87.880000,88.010000,88.010000,539079,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-06,89.030000,93.740000,86.750000,92.910000,92.910000,933724,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-07,92.360000,97.190000,91.600000,95.840000,95.840000,847214,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-10,96.270000,99.870000,95.840000,99.180000,99.180000,714966,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-11,99.720000,100.920000,97.550000,98.470000,98.470000,465874,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-12,97.820000,100.590000,97.010000,99.850000,99.850000,386400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-13,100.380000,102.760000,99.120000,99.330000,99.330000,530036,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-14,99.540000,100.000000,89.880000,90.120000,90.120000,909290,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-17,89.980000,93.990000,88.490000,88.980000,88.980000,670312,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-18,90.500000,92.860000,89.420000,89.950000,89.950000,647719,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-19,89.450000,92.070000,88.000000,89.570000,89.570000,545939,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-20,88.780000,90.390000,87.880000,89.740000,89.740000,359480,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-21,91.310000,93.000000,90.060000,91.720000,91.720000,434542,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-24,92.170000,97.000000,92.170000,96.180000,96.180000,950123,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-25,96.180000,97.850000,94.550000,97.210000,97.210000,510586,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-26,97.550000,100.810000,97.256000,100.730000,100.730000,335072,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-11-28,101.150000,103.360000,100.250000,100.550000,100.550000,211430,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-01,100.230000,101.559800,97.620000,100.690000,100.690000,479248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-02,100.910000,103.995600,99.750000,101.570000,101.570000,490270,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-03,101.600000,101.780000,98.350000,99.920000,99.920000,480753,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-04,100.050000,102.260000,99.230000,100.070000,100.070000,425418,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-05,99.700000,101.230000,98.810000,99.240000,99.240000,494505,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-08,101.250000,111.490000,101.250000,106.420000,106.420000,918403,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-09,102.520000,108.000000,102.010000,106.590000,106.590000,750555,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-10,105.420000,106.794500,100.470000,100.740000,100.740000,427583,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-11,102.030000,107.950000,100.000000,100.220000,100.220000,513488,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-12,99.290000,103.070000,98.380400,100.450000,100.450000,477410,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-15,101.980000,104.270000,93.620000,93.950000,93.950000,838112,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-16,91.330000,95.060000,90.650100,92.080000,92.080000,741482,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-17,92.500000,96.540000,91.122000,96.450000,96.450000,573234,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-18,98.260000,99.520000,96.830000,99.410000,99.410000,520524,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-19,98.540000,101.970000,97.770000,100.730000,100.730000,1408360,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-22,98.800000,104.050000,98.490000,102.480000,102.480000,535071,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-23,101.920000,102.625000,90.300000,92.550000,92.550000,963836,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-24,93.880000,95.729900,93.315000,93.520000,93.520000,162297,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-26,93.630000,98.880000,93.630000,97.920000,97.920000,243025,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-29,97.990000,99.190000,95.500000,97.110000,97.110000,254077,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-30,97.020000,98.919300,95.000000,97.000000,97.000000,279188,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2014-12-31,96.710000,99.330000,96.400000,97.000000,97.000000,349226,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-02,97.970000,99.905000,96.310000,97.770000,97.770000,380975,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-05,96.440000,96.500000,93.810000,95.380000,95.380000,615685,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-06,95.770000,97.820000,92.400000,94.020000,94.020000,922843,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-07,94.850000,95.820000,93.880000,94.860000,94.860000,601387,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-08,97.350000,102.000000,94.590000,101.700000,101.700000,800883,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-09,102.140000,102.620000,97.999200,101.300000,101.300000,622221,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-12,103.220000,106.828800,102.580000,103.780000,103.780000,773744,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-13,105.570000,108.865000,104.350000,104.970000,104.970000,689823,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-14,102.410000,105.420000,101.301000,103.550000,103.550000,421294,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-15,103.780000,103.900000,98.225000,98.640000,98.640000,496094,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-16,98.140000,101.030000,97.190000,100.770000,100.770000,512705,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-20,100.490000,102.000000,95.890000,96.250000,96.250000,783387,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-21,92.500000,92.870000,86.580000,87.360000,87.360000,5035536,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-22,88.950000,93.560000,85.030100,93.170000,93.170000,2415870,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-23,92.660000,94.990000,91.270000,93.420000,93.420000,698689,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-26,93.410000,96.200000,93.410000,95.205000,95.205000,861859,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-27,94.250000,96.340000,94.250000,95.500000,95.500000,676086,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-28,96.800000,96.800000,90.450000,90.880000,90.880000,871211,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-29,92.570000,93.510000,90.000000,93.430000,93.430000,1008796,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-01-30,92.560000,95.360000,91.560000,93.830000,93.830000,1026073,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-02,94.750000,94.780000,90.400000,92.260000,92.260000,631680,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-03,93.180000,93.229900,86.180000,88.850000,88.850000,919599,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-04,88.400000,88.739900,82.060000,85.570000,85.570000,775743,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-05,86.160000,91.579000,85.610000,91.150000,91.150000,607772,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-06,89.860000,92.390000,88.051000,89.100000,89.100000,455849,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-09,89.110000,90.900000,87.260000,87.800000,87.800000,276368,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-10,88.660000,93.560000,88.660000,93.010000,93.010000,706341,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-11,92.120000,94.920000,91.610000,93.410000,93.410000,617693,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-12,94.950000,94.950000,91.020000,93.870000,93.870000,598310,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-13,96.000000,96.150000,93.000000,95.540000,95.540000,495618,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-17,95.170000,97.780000,93.810000,96.680000,96.680000,492308,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-18,96.850000,97.340000,93.750000,97.210000,97.210000,519311,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-19,96.810000,99.180000,96.200000,98.940000,98.940000,461045,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-20,98.670000,102.660000,98.050100,102.390000,102.390000,499626,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-23,102.850000,105.350000,100.000000,104.100000,104.100000,753039,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-24,104.140000,105.780000,102.930000,105.230000,105.230000,600976,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-25,105.100000,107.800000,104.140000,106.660000,106.660000,701236,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-26,106.360000,106.900000,102.380000,104.390000,104.390000,403086,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-02-27,104.800000,105.480000,100.030000,101.530000,101.530000,574929,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-02,102.510000,105.700000,101.790000,105.400000,105.400000,442879,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-03,105.980000,107.230000,102.900000,106.910000,106.910000,437572,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-04,106.130000,109.320000,104.510000,107.230000,107.230000,632020,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-05,108.460000,115.430000,107.300000,111.560000,111.560000,927331,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-06,112.420000,113.030000,107.050000,107.670000,107.670000,448218,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-09,107.150000,108.490000,103.580000,106.950000,106.950000,581892,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-10,106.030000,112.190000,104.530000,109.750000,109.750000,626281,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-11,110.480000,114.540000,108.710000,113.600000,113.600000,641531,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-12,114.170000,114.390000,111.120000,113.900000,113.900000,519296,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-13,114.080000,114.800000,111.710000,113.570000,113.570000,347824,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-16,114.470000,117.000000,112.410000,115.940000,115.940000,483730,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-17,116.810000,120.000000,114.710000,116.290000,116.290000,765166,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-18,115.650000,116.870000,111.340000,112.800000,112.800000,1045065,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-19,113.920000,121.930000,113.000000,119.700000,119.700000,805142,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-20,120.580000,120.772500,116.290000,117.460000,117.460000,1209751,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-23,116.410000,116.490000,110.520000,111.490000,111.490000,895307,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-24,112.360000,113.050000,107.800000,110.060000,110.060000,644878,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-25,108.970000,110.968500,101.610000,101.780000,101.780000,787734,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-26,98.640000,101.970000,97.200000,99.640000,99.640000,768495,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-27,99.750000,104.960000,99.720000,104.060000,104.060000,850161,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-30,105.000000,107.980000,101.840300,107.780000,107.780000,741496,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-03-31,107.000000,109.630000,104.320000,104.420000,104.420000,669761,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-01,103.760000,105.320000,98.630000,105.260000,105.260000,828770,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-02,105.570000,106.980000,101.990000,104.410000,104.410000,539536,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-06,103.370000,106.589900,103.200000,103.690000,103.690000,579384,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-07,103.800000,108.230000,103.800000,104.050000,104.050000,402562,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-08,104.990000,107.580000,104.360000,106.500000,106.500000,571556,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-09,106.380000,109.080000,104.650000,107.800000,107.800000,651764,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-10,108.000000,114.690000,108.000000,114.220000,114.220000,726425,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-13,114.240000,117.460000,114.120000,115.240000,115.240000,567225,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-14,115.180000,118.930000,114.000000,116.670000,116.670000,655425,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-15,117.000000,121.220000,116.820000,120.000000,120.000000,686941,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-16,120.340000,123.720000,118.500000,121.370000,121.370000,478989,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-17,120.450000,121.030000,115.970000,116.980000,116.980000,835664,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-20,118.520000,120.000000,115.940000,118.680000,118.680000,460838,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-21,130.020000,132.990000,119.010000,120.700000,120.700000,1367248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-22,121.030000,124.000000,117.910000,118.000000,118.000000,1093644,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-23,117.470000,119.670000,116.870000,118.720000,118.720000,744540,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-24,118.040000,120.280000,116.810000,119.010000,119.010000,322919,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-27,118.990000,119.630000,107.200000,108.430000,108.430000,865047,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-28,108.880000,111.340000,102.500000,104.690000,104.690000,1014331,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-29,104.010000,106.610000,101.560000,104.010000,104.010000,608246,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-04-30,105.950000,105.950000,100.000000,101.870000,101.870000,855586,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-01,101.770000,107.110000,101.520000,106.890000,106.890000,786430,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-04,107.490000,112.470000,106.590000,107.160000,107.160000,684407,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-05,106.870000,107.160000,103.450000,104.030000,104.030000,751252,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-06,105.840000,107.500000,104.300000,105.710000,105.710000,627864,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-07,105.360000,107.240000,104.383900,106.630000,106.630000,822971,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-08,105.560000,112.930000,105.010000,112.790000,112.790000,1133080,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-11,112.900000,114.280000,111.183400,113.505000,113.505000,580080,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-12,111.800000,116.120000,111.560100,113.810000,113.810000,837835,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-13,115.030000,116.418000,112.770000,114.390000,114.390000,693983,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-14,115.890000,117.100000,112.780000,115.870000,115.870000,555736,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-15,117.000000,120.130000,115.770000,119.840000,119.840000,814570,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-18,119.000000,123.690000,118.770000,121.620000,121.620000,715054,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-19,121.960000,122.756300,115.960000,117.330000,117.330000,679041,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-20,117.370000,124.330000,116.320000,123.950000,123.950000,1115638,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-21,124.800000,125.990000,123.090000,124.880000,124.880000,589139,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-22,124.540000,125.180000,122.277200,124.810000,124.810000,378167,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-26,124.030000,128.260000,123.055100,127.870000,127.870000,1363240,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-27,128.060000,131.740000,127.000100,130.620000,130.620000,829023,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-28,130.040000,131.000000,126.060000,128.500000,128.500000,725577,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-05-29,128.980000,133.960000,128.400000,131.090000,131.090000,3431344,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-01,132.350000,133.480000,129.630000,131.210000,131.210000,673779,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-02,131.220000,132.559900,128.560000,131.320000,131.320000,967407,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-03,131.090000,131.990000,127.190000,128.840000,128.840000,756556,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-04,127.870000,130.790000,127.170000,129.000000,129.000000,581208,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-05,128.580000,132.835000,127.140000,131.350000,131.350000,502249,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-08,131.180000,132.794500,127.480000,129.970000,129.970000,687152,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-09,129.660000,130.050000,123.756700,127.580000,127.580000,593161,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-10,127.570000,129.700000,124.700300,128.790000,128.790000,417531,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-11,129.980000,132.990000,127.770000,132.740000,132.740000,560220,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-12,131.780000,132.000000,127.490000,130.280000,130.280000,890394,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-15,129.640000,131.200000,127.870000,129.750000,129.750000,649420,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-16,129.930000,132.000000,127.350000,127.920000,127.920000,576188,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-17,128.000000,129.270000,126.770000,128.950000,128.950000,360688,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-18,129.040000,136.004900,128.960000,134.460000,134.460000,691418,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-19,134.050000,139.780000,131.423200,136.360000,136.360000,2309953,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-22,134.260000,139.014000,134.260000,138.730000,138.730000,564447,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-23,139.000000,140.000000,131.230000,131.430000,131.430000,1182245,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-24,130.010000,130.810000,122.440000,123.660000,123.660000,1068903,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-25,123.780000,126.480000,121.560000,123.110000,123.110000,706530,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-26,121.760000,122.920000,116.950000,117.670000,117.670000,1409015,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-29,115.640000,117.110000,113.935000,114.210000,114.210000,934715,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-06-30,116.940000,120.390000,114.630000,119.870000,119.870000,773608,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-01,121.290000,123.880000,116.530000,117.570000,117.570000,725654,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-02,117.730000,119.810000,114.790000,117.840000,117.840000,460606,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-06,116.800000,120.680000,114.730000,118.700000,118.700000,717177,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-07,119.090000,120.139900,115.060000,119.530000,119.530000,574540,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-08,116.000000,118.170000,112.560000,112.730000,112.730000,660573,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-09,114.830000,118.270000,113.815000,116.040000,116.040000,649697,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-10,119.610000,122.120000,118.155000,121.770000,121.770000,557189,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-13,123.000000,126.990000,122.860000,125.640000,125.640000,742686,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-14,125.970000,130.660000,125.900000,128.930000,128.930000,630981,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-15,130.120000,131.400000,125.460000,126.340000,126.340000,438193,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-16,126.860000,134.510000,125.130000,133.400000,133.400000,855348,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-17,133.000000,137.890000,132.530100,136.550000,136.550000,748590,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-20,136.000000,136.769900,132.530000,133.870000,133.870000,453433,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-21,134.530000,134.960000,129.570100,133.370000,133.370000,631151,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-22,132.600000,135.790000,131.480000,133.330000,133.330000,699901,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-23,134.240000,136.280000,132.131000,133.490000,133.490000,409911,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-24,132.190000,136.020000,129.260000,129.620000,129.620000,625422,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-27,129.220000,130.150000,123.330000,128.820000,128.820000,753587,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-28,130.200000,132.000000,128.430000,129.760000,129.760000,475192,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-29,130.660000,130.700000,127.650000,130.090000,130.090000,458279,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-30,129.920000,129.920000,122.590000,125.460000,125.460000,580877,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-07-31,126.550000,130.000000,124.820000,127.430000,127.430000,414275,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-03,127.500000,129.840000,124.000000,126.220000,126.220000,496569,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-04,126.730000,128.590000,123.730000,125.880000,125.880000,429993,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-05,127.750000,130.000000,126.410000,127.730000,127.730000,399142,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-06,127.660000,129.993800,119.040000,119.870000,119.870000,515128,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-07,110.000000,110.000000,97.100000,106.190000,106.190000,2889636,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-10,104.850000,109.880000,104.840500,105.670000,105.670000,1207533,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-11,107.000000,109.590000,103.850000,106.320000,106.320000,723019,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-12,105.000000,110.550000,102.170000,108.480000,108.480000,774781,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-13,108.280000,110.116800,104.561000,105.050000,105.050000,417257,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-14,104.360000,106.635000,101.250000,105.740000,105.740000,609113,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-17,105.710000,111.900000,105.495000,111.450000,111.450000,617815,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-18,110.740000,113.480000,109.210000,109.770000,109.770000,700406,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-19,108.760000,110.980000,106.250000,109.020000,109.020000,551201,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-20,108.140000,108.350000,101.780000,101.950000,101.950000,1016932,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-21,100.500000,104.050000,98.240000,99.850000,99.850000,789890,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-24,90.580000,98.960000,88.000000,92.800000,92.800000,1139795,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-25,98.000000,99.740000,95.260000,95.720000,95.720000,770954,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-26,99.000000,102.640000,95.070100,102.250000,102.250000,903610,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-27,104.740000,107.989900,102.840000,104.900000,104.900000,740447,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-28,104.590000,109.720000,104.590000,109.070000,109.070000,723192,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-08-31,116.340000,116.960000,100.220000,102.910000,102.910000,1675888,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-01,100.140000,102.489900,97.500000,97.900000,97.900000,896571,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-02,99.770000,101.810000,95.520000,101.620000,101.620000,760312,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-03,102.850000,103.460000,96.890000,97.250000,97.250000,705218,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-04,96.000000,99.410000,94.300000,97.800000,97.800000,431956,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-08,100.020000,104.920000,98.320000,104.750000,104.750000,951907,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-09,105.770000,106.750000,100.400000,100.910000,100.910000,626383,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-10,100.730000,106.170000,100.260000,105.760000,105.760000,863104,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-11,105.300000,107.810000,104.805000,107.700000,107.700000,465873,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-14,108.000000,108.000000,104.090000,107.750000,107.750000,552002,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-15,108.000000,108.840000,106.050000,107.750000,107.750000,386838,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-16,108.570000,108.970000,104.650000,106.850000,106.850000,428746,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-17,106.610000,109.850000,105.440000,108.480000,108.480000,497115,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-18,107.280000,109.840000,106.270000,107.850000,107.850000,1723314,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-21,110.000000,110.000000,97.610000,98.500000,98.500000,947378,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-22,97.720000,98.710000,93.590000,97.310000,97.310000,902855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-23,97.190000,97.550000,92.220000,93.300000,93.300000,934854,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-24,92.400000,92.576500,88.240000,90.770000,90.770000,900308,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-25,92.440000,93.145000,80.590000,83.720000,83.720000,1667870,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-28,82.530000,84.100000,76.460000,79.850000,79.850000,1815724,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-29,80.190000,83.830000,76.680000,77.400000,77.400000,1659974,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-09-30,79.150000,81.890000,78.710000,80.360000,80.360000,1702435,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-01,80.300000,81.880000,77.910000,79.650000,79.650000,1379661,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-02,77.630000,83.340000,77.240000,83.020000,83.020000,1528680,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-05,84.360000,85.470000,78.590000,80.230000,80.230000,1553604,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-06,80.020000,80.020000,72.060000,76.020000,76.020000,1618204,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-07,77.000000,83.090000,74.450000,80.710000,80.710000,1108317,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-08,80.140000,83.795000,77.355000,82.280000,82.280000,955386,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-09,82.260000,85.650000,80.750000,83.160000,83.160000,974970,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-12,83.960000,84.750000,81.430000,82.390000,82.390000,599397,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-13,82.650000,85.340000,78.730000,79.060000,79.060000,849705,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-14,80.050000,83.000000,78.018000,79.460000,79.460000,661147,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-15,79.140000,85.880000,78.506600,85.480000,85.480000,941035,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-16,85.200000,88.400000,83.310000,84.910000,84.910000,1364922,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-19,84.400000,88.170000,82.250000,84.420000,84.420000,911067,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-20,84.300000,84.324000,76.990000,77.620000,77.620000,990452,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-21,78.630000,79.010000,71.140000,75.020000,75.020000,1629658,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-22,75.490000,76.210000,72.640000,75.370000,75.370000,1079230,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-23,76.130000,79.940000,76.000000,79.710000,79.710000,1052147,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-26,79.040000,81.430000,77.860000,80.310000,80.310000,861865,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-27,80.170000,83.670000,79.700000,83.460000,83.460000,774294,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-28,83.520000,90.750000,81.560000,90.580000,90.580000,1775093,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-29,90.600000,91.970000,87.300000,88.150000,88.150000,868521,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-10-30,88.560000,90.155000,85.950000,85.950000,85.950000,646244,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-02,86.830000,93.870000,86.767700,93.070000,93.070000,1074902,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-03,86.340000,96.120000,82.330000,93.480000,93.480000,1330535,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-04,91.860000,99.920000,91.860000,98.080000,98.080000,1154405,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-05,97.080000,99.410000,96.200000,98.770000,98.770000,906287,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-06,98.950000,102.970000,96.090100,101.530000,101.530000,859832,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-09,99.950000,109.800000,98.470000,108.840000,108.840000,1287585,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-10,108.920000,110.750000,106.690000,107.240000,107.240000,952566,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-11,107.350000,109.980000,104.100000,104.290000,104.290000,755174,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-12,103.440000,103.440000,98.500000,98.940000,98.940000,945226,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-13,98.830000,104.270000,97.020000,102.570000,102.570000,756473,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-16,102.080000,103.750000,98.820000,101.360000,101.360000,716105,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-17,101.350000,106.000000,99.630000,103.840000,103.840000,651897,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-18,104.230000,107.660000,102.330000,107.000000,107.000000,668526,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-19,105.880000,106.880000,101.400000,102.860000,102.860000,525019,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-20,103.370000,104.750000,101.690000,102.610000,102.610000,516973,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-23,102.390000,105.380000,101.530000,104.530000,104.530000,434554,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-24,103.570000,104.890000,102.223000,104.760000,104.760000,317817,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-25,104.780000,106.710000,104.500000,105.250000,105.250000,356738,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-27,105.810000,108.420000,104.880000,107.380000,107.380000,177969,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-11-30,107.720000,108.820000,101.675000,104.060000,104.060000,665097,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-01,105.110000,106.790000,101.820000,105.980000,105.980000,601918,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-02,106.120000,106.720000,102.460000,103.610000,103.610000,504380,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-03,104.840000,108.500000,103.810000,105.920000,105.920000,815182,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-04,107.960000,109.100000,104.080000,108.960000,108.960000,666456,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-07,105.840000,105.840000,97.570000,97.720000,97.720000,2180422,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-08,96.460000,102.510000,94.020000,101.030000,101.030000,735698,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-09,100.320000,101.810000,99.675000,100.580000,100.580000,1014105,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-10,100.510000,101.298800,94.250000,96.200000,96.200000,2507266,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-11,94.590000,96.990000,88.740000,89.680000,89.680000,1273434,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-14,89.650000,91.610000,87.410000,88.330000,88.330000,1162112,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-15,89.300000,90.850000,86.850000,88.500000,88.500000,645102,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-16,89.670000,92.500000,88.360000,91.970000,91.970000,483600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-17,92.190000,93.990000,87.110000,88.180000,88.180000,577402,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-18,88.220000,91.275000,87.560000,88.950000,88.950000,1491855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-21,90.280000,90.736200,86.510000,88.010000,88.010000,482824,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-22,88.270000,88.370000,84.690000,86.520000,86.520000,496488,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-23,87.240000,92.910000,86.570000,91.340000,91.340000,567853,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-24,91.290000,91.610000,90.070000,90.680000,90.680000,163775,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-28,90.160000,92.240000,89.570000,91.680000,91.680000,404436,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-29,92.490000,94.580000,92.490000,93.980000,93.980000,310391,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-30,93.480000,96.000000,93.480000,94.510000,94.510000,387677,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2015-12-31,94.180000,95.890000,93.250000,94.140000,94.140000,289810,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-04,92.180000,93.325000,90.800000,93.030000,93.030000,706350,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-05,93.490000,98.000000,92.870000,94.770000,94.770000,706099,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-06,92.760000,93.080000,88.020000,90.280000,90.280000,879628,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-07,87.390000,89.930000,84.820000,87.640000,87.640000,1064936,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-08,87.760000,88.110000,81.840000,84.610000,84.610000,1241648,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-11,84.150000,85.330000,78.000000,79.680000,79.680000,1492251,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-12,81.330000,85.990000,77.740000,81.830000,81.830000,1033922,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-13,82.430000,83.420000,74.470000,75.240000,75.240000,1115287,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-14,75.500000,80.680000,68.880000,78.820000,78.820000,1197185,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-15,75.300000,76.420000,72.080000,75.980000,75.980000,1193813,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-19,77.520000,78.819900,70.200000,72.410000,72.410000,1147528,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-20,71.500000,76.450000,65.540000,74.800000,74.800000,1352713,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-21,74.870000,77.030000,70.440000,71.140000,71.140000,941007,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-22,73.260000,76.425000,71.610000,76.120000,76.120000,823798,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-25,75.580000,80.195000,75.005000,75.520000,75.520000,897618,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-26,76.000000,76.770000,72.000000,75.170000,75.170000,697524,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-27,75.360000,76.680000,68.933300,69.680000,69.680000,845905,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-28,70.220000,70.930000,63.630000,65.180000,65.180000,1193876,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-01-29,65.440000,69.030000,64.670000,68.940000,68.940000,1293825,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-01,68.040000,70.640000,64.300000,69.750000,69.750000,1344029,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-02,68.710000,68.710000,64.600000,64.910000,64.910000,1135559,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-03,65.660000,67.335000,61.090000,66.130000,66.130000,1428128,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-04,65.720000,72.380000,65.000000,67.510000,67.510000,1458748,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-05,67.220000,68.010000,63.700000,65.590000,65.590000,1326204,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-08,64.140000,64.930000,59.420000,60.610000,60.610000,1175571,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-09,58.830000,61.980000,56.430000,59.220000,59.220000,1644858,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-10,59.220000,60.750000,56.530000,57.000000,57.000000,1383804,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-11,55.600000,58.330000,53.255000,56.960000,56.960000,1402045,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-12,52.380000,61.750000,51.510000,59.550000,59.550000,1920760,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-16,62.000000,65.830000,60.240000,63.900000,63.900000,1495857,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-17,64.730000,66.330000,62.630000,65.700000,65.700000,1141729,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-18,65.700000,66.250000,61.870000,62.490000,62.490000,1010199,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-19,62.440000,64.730000,60.740000,63.520000,63.520000,1342904,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-22,64.520000,65.100000,62.000000,62.680000,62.680000,834036,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-23,62.050000,62.840000,59.260000,59.450000,59.450000,651624,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-24,58.740000,59.697500,56.430000,58.020000,58.020000,1061527,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-25,58.960000,60.230000,55.940000,56.860000,56.860000,882734,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-26,57.720000,59.180000,56.650000,58.000000,58.000000,847125,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-02-29,58.000000,61.640000,57.720000,58.570000,58.570000,1763012,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-01,59.490000,60.050000,57.000000,59.830000,59.830000,1846350,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-02,59.920000,62.730000,58.090000,62.630000,62.630000,1334052,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-03,62.330000,63.580000,59.810000,59.980000,59.980000,1060594,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-04,60.660000,60.850000,59.120000,59.180000,59.180000,1010084,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-07,58.990000,60.774600,57.900000,60.090000,60.090000,1055217,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-08,59.710000,60.427500,57.340000,57.530000,57.530000,790144,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-09,58.360000,60.890000,56.140000,60.120000,60.120000,1276694,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-10,60.650000,60.861300,56.000000,58.090000,58.090000,1039923,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-11,61.000000,62.510000,59.470000,62.150000,62.150000,1931842,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-14,62.040000,66.620000,62.040000,65.770000,65.770000,1659334,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-15,64.900000,64.965000,61.560000,61.700000,61.700000,1065244,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-16,61.040000,63.360000,58.500000,60.390000,60.390000,875426,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-17,60.230000,60.690000,56.440000,57.840000,57.840000,988471,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-18,58.090000,60.190000,56.600000,59.800000,59.800000,1334790,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-21,59.570000,62.990000,58.555000,61.310000,61.310000,794390,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-22,60.690000,62.740000,59.900000,62.220000,62.220000,1193390,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-23,62.240000,63.870000,58.850000,59.060000,59.060000,709118,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-24,58.200000,60.660000,56.510000,60.280000,60.280000,700363,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-28,60.490000,61.650000,58.280000,58.780000,58.780000,701685,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-29,58.870000,60.000000,56.600000,59.840000,59.840000,912523,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-30,60.500000,62.360000,58.380000,59.080000,59.080000,675370,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-03-31,59.380000,64.940000,59.380000,62.770000,62.770000,986983,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-01,62.290000,65.600000,61.180000,64.790000,64.790000,758556,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-04,64.770000,70.075000,64.615400,67.540000,67.540000,1240796,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-05,67.690000,69.650000,65.830000,68.330000,68.330000,1306731,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-06,68.050000,73.115000,68.050000,73.000000,73.000000,977933,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-07,74.300000,75.077500,68.810000,71.740000,71.740000,1767528,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-08,73.260000,73.415800,66.900000,69.150000,69.150000,1098776,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-11,69.390000,70.000000,66.500000,66.770000,66.770000,1061498,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-12,66.800000,67.610000,65.520000,67.430000,67.430000,800942,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-13,67.890000,69.589900,66.700000,69.390000,69.390000,528173,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-14,69.390000,69.390000,67.290000,67.790000,67.790000,597740,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-15,67.910000,68.900000,66.840000,68.790000,68.790000,705918,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-18,68.210000,70.580000,67.690000,69.160000,69.160000,571507,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-19,69.050000,69.340000,66.500000,66.810000,66.810000,1090684,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-20,67.890000,69.000000,66.850000,67.250000,67.250000,600874,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-21,67.030000,71.790000,66.760000,71.630000,71.630000,709579,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-22,71.670000,72.830000,69.950000,71.860000,71.860000,518360,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-25,71.500000,72.720000,71.260000,71.950000,71.950000,433145,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-26,72.030000,72.250000,69.210000,70.370000,70.370000,592380,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-27,70.430000,70.765000,68.370000,68.630000,68.630000,446854,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-28,68.380000,70.390000,67.000000,67.880000,67.880000,474202,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-04-29,67.680000,68.230000,66.400000,67.040000,67.040000,426201,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-02,67.470000,69.030000,65.870000,68.790000,68.790000,512704,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-03,66.800000,66.990000,60.070100,60.810000,60.810000,1827811,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-04,60.130000,60.630000,57.160000,57.450000,57.450000,1375474,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-05,58.410000,59.460000,57.030000,58.730000,58.730000,959991,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-06,58.030000,59.150000,53.900000,55.550000,55.550000,1323388,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-09,55.300000,59.420000,55.300000,57.810000,57.810000,820764,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-10,58.270000,58.405000,55.630000,57.440000,57.440000,873314,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-11,57.050000,57.360000,53.650000,53.820000,53.820000,594207,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-12,54.020000,54.130000,49.960000,52.370000,52.370000,1206842,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-13,52.380000,54.030000,52.080000,52.550000,52.550000,583128,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-16,54.010000,55.630000,53.215000,54.540000,54.540000,785434,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-17,54.080000,55.760000,53.950000,54.280000,54.280000,886224,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-18,53.650000,55.460000,53.200000,54.340000,54.340000,761265,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-19,54.020000,55.922000,52.430000,53.670000,53.670000,627106,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-20,53.940000,55.500000,53.030000,55.110000,55.110000,682271,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-23,55.120000,56.900000,54.530000,56.070000,56.070000,612309,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-24,56.860000,57.920000,55.720000,57.810000,57.810000,580235,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-25,58.230000,64.640000,58.230000,63.550000,63.550000,2010631,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-26,66.150000,72.160000,66.110000,70.570000,70.570000,3118851,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-27,69.960000,70.890000,67.180000,67.570000,67.570000,1238242,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-05-31,68.280000,73.680000,68.205000,71.720000,71.720000,1344771,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-01,71.020000,71.560000,69.010000,70.540000,70.540000,760023,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-02,70.560000,74.200000,70.500000,74.120000,74.120000,711230,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-03,73.480000,73.480000,69.971000,70.200000,70.200000,869762,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-06,70.500000,72.830000,68.440000,72.600000,72.600000,604391,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-07,71.400000,72.640000,69.680100,71.050000,71.050000,853358,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-08,71.160000,71.790000,68.380000,69.880000,69.880000,636136,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-09,69.260000,70.200000,65.380000,65.410000,65.410000,1003592,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-10,64.460000,64.980000,62.280000,63.170000,63.170000,1017320,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-13,62.540000,63.190000,60.390000,60.650000,60.650000,1182457,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-14,60.840000,62.173700,59.550000,60.580000,60.580000,787569,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-15,60.940000,61.688900,58.820000,59.140000,59.140000,812954,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-16,58.720000,59.840000,57.680000,58.380000,58.380000,837979,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-17,58.300000,58.340000,55.810000,55.970000,55.970000,907412,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-20,56.980000,58.690000,56.410000,56.640000,56.640000,863961,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-21,56.930000,56.950000,54.630000,55.780000,55.780000,2087463,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-22,55.790000,57.960000,54.440000,56.140000,56.140000,996117,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-23,57.110000,57.110000,55.150000,56.950000,56.950000,789183,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-24,54.000000,55.540000,53.000000,54.310000,54.310000,1812647,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-27,53.530000,54.250000,50.130000,52.500000,52.500000,1416572,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-28,53.420000,56.080000,53.080000,55.300000,55.300000,957964,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-29,56.220000,56.993000,53.630000,55.600000,55.600000,831766,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-06-30,55.630000,56.230000,54.670000,55.490000,55.490000,781598,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-01,55.000000,61.640000,53.560000,61.440000,61.440000,1453262,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-05,60.600000,60.989900,58.245000,59.420000,59.420000,1021130,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-06,59.110000,60.709900,57.700000,60.430000,60.430000,680203,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-07,60.940000,62.180000,60.000000,61.520000,61.520000,634134,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-08,61.520000,62.700000,60.570000,62.180000,62.180000,629803,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-11,62.660000,64.640000,62.290000,63.460000,63.460000,715383,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-12,64.000000,64.780000,62.940000,64.000000,64.000000,793205,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-13,64.360000,65.260000,61.880000,62.820000,62.820000,983571,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-14,63.430000,63.430000,61.572500,63.010000,63.010000,562543,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-15,63.160000,65.060000,62.720000,64.480000,64.480000,875118,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-18,64.320000,65.310000,63.850000,64.830000,64.830000,661777,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-19,64.730000,65.110000,63.240000,64.030000,64.030000,906201,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-20,64.280000,66.230000,63.205500,65.740000,65.740000,666890,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-21,66.320000,67.100000,64.480000,64.970000,64.970000,774176,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-22,65.240000,65.850000,64.580000,65.490000,65.490000,770778,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-25,65.640000,66.470000,60.470000,66.200000,66.200000,3493118,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-26,66.300000,68.870000,65.660000,66.810000,66.810000,810429,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-27,66.980000,68.690000,66.980000,68.410000,68.410000,699030,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-28,68.480000,69.220000,66.610000,68.290000,68.290000,696647,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-07-29,68.010000,68.300000,66.500000,68.080000,68.080000,622464,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-01,68.470000,72.480000,68.160000,71.800000,71.800000,986250,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-02,72.070000,72.930000,68.020000,70.560000,70.560000,958283,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-03,70.460000,71.480000,69.800000,71.360000,71.360000,444189,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-04,71.360000,74.540000,70.680000,71.030000,71.030000,747472,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-05,72.120000,79.020000,71.611000,78.420000,78.420000,1094242,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-08,76.860000,79.789000,75.320000,76.330000,76.330000,727785,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-09,76.730000,77.340000,75.720000,76.400000,76.400000,330264,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-10,76.170000,76.880000,73.020000,73.270000,73.270000,513398,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-11,73.720000,74.430000,72.320000,74.270000,74.270000,450104,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-12,73.950000,74.400000,72.570000,74.080000,74.080000,375870,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-15,74.320000,76.430000,74.320000,75.680000,75.680000,387813,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-16,75.380000,75.670000,73.530000,73.580000,73.580000,378661,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-17,73.450000,73.530000,72.000000,73.100000,73.100000,339536,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-18,73.100000,74.170000,71.710000,73.440000,73.440000,368427,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-19,72.860000,73.340000,72.320000,72.780000,72.780000,346697,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-22,72.890000,76.330000,72.750000,76.180000,76.180000,747169,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-23,76.600000,77.000000,75.567600,75.790000,75.790000,307428,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-24,75.800000,77.620000,70.600000,70.830000,70.830000,808598,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-25,70.830000,73.135000,67.490000,69.350000,69.350000,682292,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-26,69.430000,71.150000,69.120000,70.800000,70.800000,414638,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-29,71.100000,71.840000,70.220000,71.560000,71.560000,402068,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-30,71.320000,73.280000,70.280000,70.750000,70.750000,512896,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-08-31,70.450000,72.760000,69.215000,69.850000,69.850000,369628,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-01,69.800000,70.699900,67.810000,69.020000,69.020000,359276,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-02,69.290000,69.970000,67.850000,69.170000,69.170000,292599,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-06,69.540000,71.820000,69.170000,71.390000,71.390000,484477,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-07,71.730000,73.900000,71.720000,72.530000,72.530000,459800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-08,72.470000,73.890000,70.960000,73.520000,73.520000,307278,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-09,72.440000,72.950000,69.750000,69.790000,69.790000,501100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-12,69.080000,74.350000,68.000000,73.990000,73.990000,497025,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-13,73.310000,73.400000,70.410000,71.390000,71.390000,493253,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-14,71.840000,74.530000,71.540000,73.600000,73.600000,598178,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-15,73.530000,75.020000,72.180000,74.330000,74.330000,388897,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-16,73.670000,76.170000,73.350000,75.670000,75.670000,728566,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-19,75.960000,79.230000,74.830000,77.100000,77.100000,594125,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-20,77.830000,80.110000,77.110000,78.090000,78.090000,666820,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-21,78.130000,79.480000,75.210000,77.790000,77.790000,545969,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-22,78.570000,78.872600,76.800000,77.090000,77.090000,494381,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-23,77.040000,77.780000,75.560000,75.570000,75.570000,484655,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-26,77.250000,77.250000,75.250000,76.000000,76.000000,382362,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-27,75.790000,78.230000,75.490000,78.090000,78.090000,367557,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-28,78.220000,78.870000,75.590000,76.670000,76.670000,422727,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-29,75.000000,75.350000,69.770000,69.940000,69.940000,1378031,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-09-30,70.260000,70.380000,67.060000,67.780000,67.780000,857140,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-03,67.650000,68.400000,65.760000,68.230000,68.230000,727095,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-04,68.220000,69.690000,66.860000,68.570000,68.570000,560922,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-05,68.770000,71.668000,68.660000,70.300000,70.300000,1957855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-06,38.630000,38.920000,35.315000,36.210000,36.210000,16731379,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-07,36.100000,36.240000,33.160000,34.270000,34.270000,5197185,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-10,35.100000,36.429900,34.760000,35.520000,35.520000,2680946,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-11,34.980000,35.680000,34.080000,34.830000,34.830000,2199461,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-12,35.000000,36.040000,34.560000,35.760000,35.760000,2361371,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-13,35.360000,37.240000,35.120000,36.170000,36.170000,2264457,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-14,36.300000,36.490000,35.240000,35.320000,35.320000,2010809,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-17,35.750000,36.780000,35.210000,36.580000,36.580000,1475061,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-18,37.090000,39.240000,36.960000,38.070000,38.070000,2065120,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-19,38.110000,38.149500,36.250000,36.840000,36.840000,1624295,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-20,36.890000,38.240000,36.230000,37.600000,37.600000,1184354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-21,37.330000,37.550000,36.200000,36.675000,36.675000,1484184,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-24,36.850000,37.720000,36.100000,37.200000,37.200000,1108385,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-25,37.350000,37.870000,36.400000,36.670000,36.670000,1083698,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-26,36.710000,38.120000,36.360000,37.090000,37.090000,922253,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-27,37.450000,38.600000,35.990000,36.210000,36.210000,1160133,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-28,36.030000,37.620000,35.250000,36.340000,36.340000,1714329,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-10-31,36.550000,36.639900,35.383300,35.600000,35.600000,1788541,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-01,35.760000,37.050000,35.350000,37.000000,37.000000,1272248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-02,36.660000,36.970000,35.820000,35.950000,35.950000,1553567,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-03,36.220000,36.220000,31.380000,31.410000,31.410000,3369509,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-04,31.580000,33.780000,31.420000,33.750000,33.750000,2157424,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-07,34.600000,36.500000,33.850000,36.260000,36.260000,1555482,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-08,36.200000,38.330000,35.800000,37.560000,37.560000,1230875,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-09,39.390000,44.420000,39.020000,43.470000,43.470000,2615946,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-10,44.130000,46.380000,43.340000,45.760000,45.760000,2145440,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-11,45.360000,46.850000,44.480000,46.540000,46.540000,1212998,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-14,47.690000,50.050000,46.732000,50.040000,50.040000,1567455,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-15,49.710000,52.850000,46.290000,48.230000,48.230000,3062601,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-16,47.540000,49.570000,45.560000,45.670000,45.670000,1413876,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-17,45.750000,46.580000,44.420000,46.360000,46.360000,1091305,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-18,46.500000,46.940000,44.890000,45.975000,45.975000,872160,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-21,46.030000,47.380000,45.630000,47.150000,47.150000,868299,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-22,46.720000,47.390000,45.280000,45.650000,45.650000,1415554,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-23,44.600000,47.780000,43.344000,47.690000,47.690000,1100061,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-25,47.630000,48.250000,46.890000,47.880000,47.880000,524185,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-28,47.710000,48.440000,45.030000,45.310000,45.310000,1255541,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-29,45.530000,47.060000,45.280000,46.030000,46.030000,1029078,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-11-30,46.800000,46.870000,43.780000,43.870000,43.870000,5176621,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-01,44.130000,44.750000,41.320000,41.580000,41.580000,1990320,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-02,41.600000,42.820000,40.620000,41.570000,41.570000,1591746,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-05,41.750000,42.690000,39.180000,41.240000,41.240000,2344190,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-06,41.450000,42.380000,40.370000,41.810000,41.810000,1483499,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-07,40.770000,41.246200,39.550000,40.280000,40.280000,1611174,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-08,40.280000,40.990000,39.275000,40.805000,40.805000,1592148,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-09,41.290000,43.580000,41.110000,42.250000,42.250000,1401075,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-12,42.280000,42.860000,41.500000,42.610000,42.610000,1019049,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-13,42.900000,44.320000,42.609200,43.910000,43.910000,1184636,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-14,43.690000,44.620000,42.700000,43.210000,43.210000,626530,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-15,43.500000,43.600000,42.415000,43.130000,43.130000,1014016,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-16,43.170000,44.450000,42.720000,44.390000,44.390000,4464488,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-19,43.990000,45.070000,42.960000,43.420000,43.420000,850499,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-20,43.550000,44.148800,41.900000,42.220000,42.220000,708330,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-21,42.390000,42.420000,40.430000,40.480000,40.480000,804339,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-22,40.570000,40.870000,38.940000,39.390000,39.390000,834317,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-23,39.540000,41.685000,39.355000,41.290000,41.290000,777395,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-27,41.340000,42.040000,40.810000,41.040000,41.040000,600466,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-28,41.500000,41.700000,39.930000,40.010000,40.010000,580488,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-29,39.850000,40.450000,37.460000,38.060000,38.060000,1220006,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2016-12-30,38.310000,39.150000,37.050000,37.440000,37.440000,846768,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-03,38.640000,39.130000,37.200000,38.640000,38.640000,819306,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-04,38.590000,41.750000,38.340000,41.290000,41.290000,1089360,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-05,41.550000,41.730000,40.375000,41.350000,41.350000,573196,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-06,41.630000,43.220000,41.630000,42.230000,42.230000,685739,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-09,42.890000,43.750000,41.650000,43.500000,43.500000,1849318,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-10,43.230000,44.950000,42.560000,44.710000,44.710000,775546,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-11,44.510000,45.640000,40.330000,41.250000,41.250000,1504301,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-12,41.030000,42.200000,40.285000,41.840000,41.840000,660122,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-13,41.810000,43.390000,41.320000,41.600000,41.600000,1030720,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-17,41.050000,41.100000,37.980000,38.220000,38.220000,1398902,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-18,39.040000,39.040000,37.020000,38.510000,38.510000,1187252,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-19,38.500000,39.740000,38.060000,39.080000,39.080000,1579572,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-20,39.120000,39.220000,38.020000,38.960000,38.960000,817805,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-23,38.990000,39.650000,37.710000,38.160000,38.160000,821817,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-24,38.190000,38.870000,36.650000,37.620000,37.620000,774336,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-25,37.930000,38.250000,37.270000,37.830000,37.830000,521521,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-26,37.900000,38.330000,36.990000,37.110000,37.110000,538324,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-27,37.170000,38.285000,36.579900,38.090000,38.090000,629426,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-30,38.010000,38.200000,36.530000,36.880000,36.880000,662187,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-01-31,36.480000,40.110000,35.980000,39.990000,39.990000,1023177,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-01,40.070000,40.500000,39.010000,40.450000,40.450000,795014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-02,40.760000,41.690000,39.730000,41.460000,41.460000,1032594,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-03,42.000000,42.980000,39.980000,42.760000,42.760000,1291964,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-06,42.610000,43.150000,42.320000,43.010000,43.010000,702139,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-07,43.190000,43.330000,40.120000,40.460000,40.460000,976106,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-08,40.170000,40.920000,39.660000,40.630000,40.630000,1188887,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-09,45.770000,46.540000,40.930000,44.960000,44.960000,2262859,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-10,45.000000,46.200000,44.560000,45.570000,45.570000,646289,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-13,45.980000,46.450000,45.050000,45.610000,45.610000,832970,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-14,45.110000,46.300000,44.500000,46.110000,46.110000,479910,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-15,45.940000,47.480000,45.660000,47.090000,47.090000,561283,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-16,46.970000,48.330000,46.410000,47.020000,47.020000,870124,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-17,46.860000,48.450000,45.970000,48.280000,48.280000,799181,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-21,48.590000,48.590000,46.370000,46.860000,46.860000,728226,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-22,46.790000,47.320000,45.680000,45.950000,45.950000,632121,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-23,46.120000,46.940000,45.670000,46.250000,46.250000,607000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-24,45.900000,47.150000,45.000000,46.620000,46.620000,642690,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-27,46.730000,51.550000,46.600000,51.310000,51.310000,1305395,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-02-28,51.500000,53.940000,50.740000,51.640000,51.640000,1341667,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-01,52.790000,53.930000,51.150000,51.300000,51.300000,994645,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-02,51.000000,52.970000,50.010000,50.520000,50.520000,997525,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-03,50.510000,51.600000,49.880000,51.440000,51.440000,682233,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-06,51.160000,51.330000,49.580000,50.360000,50.360000,679951,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-07,49.920000,51.140000,49.000000,49.940000,49.940000,656454,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-08,50.040000,52.320000,49.640000,52.240000,52.240000,932253,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-09,52.180000,52.860000,50.710000,51.480000,51.480000,811667,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-10,51.660000,51.950000,49.910000,50.730000,50.730000,1066570,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-13,51.090000,51.090000,49.890000,50.480000,50.480000,637093,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-14,50.420000,51.780000,49.500000,51.530000,51.530000,1080713,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-15,51.770000,55.150000,51.350000,54.270000,54.270000,1296204,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-16,54.210000,55.690000,53.250000,54.480000,54.480000,1248818,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-17,50.700000,56.270000,50.310000,55.250000,55.250000,4863078,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-20,55.410000,59.800000,55.410000,59.710000,59.710000,1846964,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-21,60.000000,60.410000,53.420000,54.210000,54.210000,1663840,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-22,54.290000,54.600000,52.010000,53.250000,53.250000,1138811,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-23,53.210000,53.940000,52.180000,53.180000,53.180000,845099,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-24,53.380000,53.580000,51.680000,52.470000,52.470000,936232,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-27,51.350000,53.630000,50.770000,52.320000,52.320000,986456,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-28,52.300000,53.200000,51.460000,52.080000,52.080000,574912,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-29,52.000000,53.580000,51.380000,52.830000,52.830000,926735,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-30,52.810000,52.810000,50.700000,51.250000,51.250000,582672,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-03-31,51.310000,51.800000,50.500000,51.250000,51.250000,806771,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-03,51.290000,52.100000,50.190000,50.440000,50.440000,620261,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-04,50.310000,51.320000,49.700000,50.160000,50.160000,486719,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-05,50.350000,51.000000,47.660000,47.750000,47.750000,863386,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-06,47.870000,48.470000,46.900000,47.810000,47.810000,666781,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-07,47.650000,48.610000,47.160000,48.510000,48.510000,621709,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-10,48.600000,49.650000,47.700000,49.250000,49.250000,498330,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-11,49.010000,49.770000,48.190000,48.850000,48.850000,706856,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-12,49.060000,50.100000,48.540000,49.180000,49.180000,738836,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-13,48.990000,50.720000,48.790000,49.850000,49.850000,987860,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-17,50.060000,51.060000,49.120000,50.950000,50.950000,766634,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-18,50.760000,50.860000,49.140000,49.730000,49.730000,762478,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-19,49.910000,50.660000,49.330000,49.560000,49.560000,653086,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-20,49.940000,50.710000,49.440000,50.460000,50.460000,692287,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-21,50.570000,51.220000,49.190000,49.510000,49.510000,664849,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-24,50.360000,50.720000,49.400000,50.300000,50.300000,447465,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-25,50.640000,51.910000,50.390000,51.350000,51.350000,473787,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-26,51.550000,54.310000,51.540000,54.020000,54.020000,792136,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-27,54.160000,54.220000,52.570000,52.770000,52.770000,453742,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-04-28,52.800000,53.660000,51.330000,53.600000,53.600000,487797,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-01,53.700000,55.650000,53.000000,55.360000,55.360000,415832,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-02,55.380000,55.380000,52.720000,53.070000,53.070000,818663,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-03,52.840000,55.080000,52.310000,55.000000,55.000000,680226,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-04,55.010000,55.340000,53.980000,54.870000,54.870000,720108,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-05,53.450000,57.390000,52.170000,55.070000,55.070000,1026191,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-08,54.680000,54.680000,52.030000,52.610000,52.610000,829911,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-09,53.020000,54.770000,52.520000,54.020000,54.020000,598648,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-10,54.010000,57.500000,53.130000,55.700000,55.700000,965512,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-11,55.460000,56.460000,53.810000,55.360000,55.360000,501444,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-12,55.150000,57.250000,54.780000,56.770000,56.770000,656385,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-15,65.000000,68.000000,62.600000,66.000000,66.000000,6372899,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-16,66.930000,72.230000,65.580000,72.010000,72.010000,2491263,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-17,70.840000,72.930000,68.640000,70.130000,70.130000,2154960,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-18,70.460000,72.210000,69.780000,71.090000,71.090000,930871,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-19,71.540000,72.330000,70.000000,71.670000,71.670000,833038,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-22,71.890000,74.020000,70.790000,73.930000,73.930000,989166,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-23,74.500000,75.830000,74.070000,74.870000,74.870000,946324,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-24,71.440000,71.480000,67.340000,69.970000,69.970000,4653348,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-25,70.290000,70.980000,69.290000,69.500000,69.500000,1009413,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-26,69.270000,70.490000,65.500000,65.800000,65.800000,1355285,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-30,65.590000,66.000000,63.560000,64.090000,64.090000,1047172,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-05-31,65.520000,65.720000,62.960000,65.460000,65.460000,1171176,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-01,66.150000,70.840000,66.150000,69.700000,69.700000,1377534,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-02,69.810000,72.030000,69.600000,71.990000,71.990000,1268851,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-05,72.170000,72.390000,69.140000,69.930000,69.930000,825753,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-06,69.900000,72.800000,69.900000,71.280000,71.280000,1228180,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-07,71.450000,72.280000,70.720000,71.600000,71.600000,1218655,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-08,71.630000,74.160000,70.870000,73.460000,73.460000,672643,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-09,73.170000,75.050000,71.570000,72.830000,72.830000,801222,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-12,72.930000,73.450000,70.630000,72.820000,72.820000,684361,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-13,73.030000,75.070000,72.200000,74.310000,74.310000,751386,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-14,74.360000,76.960000,73.250000,74.800000,74.800000,644602,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-15,74.370000,75.730000,73.450000,75.350000,75.350000,832864,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-16,75.820000,76.240000,74.490000,76.070000,76.070000,1240731,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-19,76.800000,82.310000,76.450000,79.050000,79.050000,1304292,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-20,78.960000,84.180000,78.330000,81.380000,81.380000,1030421,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-21,81.670000,84.690000,81.280000,84.520000,84.520000,1488778,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-22,85.520000,86.920000,83.500000,83.960000,83.960000,955692,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-23,83.960000,85.330000,82.130000,85.210000,85.210000,724345,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-26,85.760000,85.760000,80.580000,82.920000,82.920000,974667,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-27,83.610000,83.860000,79.670000,79.830000,79.830000,1397767,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-28,80.500000,80.880000,78.690000,79.970000,79.970000,1081166,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-29,79.900000,80.300000,77.060000,79.030000,79.030000,997699,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-06-30,79.040000,80.160000,77.780000,79.760000,79.760000,677498,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-03,80.930000,83.190000,79.960000,81.700000,81.700000,376028,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-05,81.760000,86.110000,81.760000,85.710000,85.710000,1059579,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-06,85.000000,85.620000,82.540000,82.970000,82.970000,1293757,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-07,83.070000,85.500000,83.070000,84.080000,84.080000,602273,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-10,83.950000,86.730000,76.020000,79.410000,79.410000,1955231,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-11,79.240000,80.670000,78.250000,79.000000,79.000000,996642,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-12,79.620000,79.960000,78.290000,78.900000,78.900000,664849,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-13,78.920000,80.500000,76.500000,79.970000,79.970000,909964,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-14,80.060000,80.630000,78.270000,78.740000,78.740000,692196,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-17,79.520000,81.330000,77.140000,77.750000,77.750000,726374,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-18,77.500000,78.855000,77.000000,78.120000,78.120000,504120,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-19,78.500000,79.540000,77.530000,78.460000,78.460000,487495,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-20,78.500000,80.610000,77.810000,80.510000,80.510000,718669,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-21,81.590000,82.290000,79.970000,82.020000,82.020000,878073,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-24,82.040000,83.730000,80.670000,83.540000,83.540000,720118,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-25,83.090000,83.460000,80.380000,81.010000,81.010000,716756,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-26,80.840000,81.800000,80.490000,81.570000,81.570000,472278,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-27,82.390000,83.230000,79.030000,79.700000,79.700000,1009514,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-28,79.250000,83.050000,78.760000,82.630000,82.630000,528371,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-07-31,82.620000,83.620000,81.510000,82.740000,82.740000,615936,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-01,83.390000,83.430000,81.070000,81.150000,81.150000,520651,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-02,81.290000,83.900000,79.690000,83.550000,83.550000,486348,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-03,83.370000,83.470000,81.370000,81.500000,81.500000,399224,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-04,82.030000,82.460000,80.840000,82.440000,82.440000,450066,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-07,82.530000,83.650000,82.070000,82.930000,82.930000,444347,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-08,82.870000,83.220000,81.000000,81.440000,81.440000,541794,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-09,80.960000,82.020000,79.240000,80.520000,80.520000,731676,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-10,78.160000,78.990000,74.140000,75.940000,75.940000,2078084,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-11,76.030000,78.620000,75.580000,78.220000,78.220000,829688,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-14,79.220000,79.990000,78.200000,79.640000,79.640000,609509,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-15,80.020000,80.610000,79.250000,80.370000,80.370000,498685,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-16,80.800000,82.330000,80.300000,81.350000,81.350000,585775,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-17,81.120000,82.020000,79.720000,80.280000,80.280000,494441,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-18,80.290000,81.990000,79.790000,81.420000,81.420000,574164,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-21,81.280000,85.100000,81.280000,84.680000,84.680000,664385,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-22,84.830000,86.010000,83.510000,85.800000,85.800000,537320,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-23,85.210000,87.100000,84.750000,84.810000,84.810000,443029,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-24,85.040000,85.770000,83.600000,83.990000,83.990000,812473,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-25,84.490000,84.490000,82.410000,83.320000,83.320000,423841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-28,84.780000,84.980000,82.580000,83.200000,83.200000,778828,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-29,82.160000,82.990000,81.140000,82.520000,82.520000,665285,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-30,82.670000,83.960000,81.500000,83.140000,83.140000,677836,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-08-31,83.320000,86.180000,82.840000,85.730000,85.730000,834121,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-01,85.950000,89.450000,85.580000,88.910000,88.910000,807053,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-05,88.280000,88.570000,85.320000,86.800000,86.800000,646728,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-06,88.070000,88.070000,84.620000,86.020000,86.020000,570554,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-07,76.380000,79.500000,72.320000,72.530000,72.530000,5985755,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-08,72.500000,73.920000,70.760000,73.690000,73.690000,1276709,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-11,75.000000,79.090000,74.970000,78.680000,78.680000,1170112,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-12,79.410000,81.110000,78.000000,79.490000,79.490000,840924,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-13,79.030000,80.930000,78.220000,80.570000,80.570000,777986,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-14,80.660000,80.660000,78.000000,78.150000,78.150000,722160,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-15,77.360000,77.622500,75.580000,76.210000,76.210000,1243741,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-18,76.400000,76.610000,74.610000,76.000000,76.000000,1129697,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-19,75.620000,76.130000,74.500000,75.040000,75.040000,641353,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-20,97.360000,116.930000,96.340000,113.840000,113.840000,18316828,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-21,112.920000,117.440000,108.120000,112.920000,112.920000,4523853,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-22,111.140000,118.400000,110.600000,113.800000,113.800000,2322718,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-25,112.400000,118.300000,112.130000,117.040000,117.040000,2081827,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-26,117.400000,117.400000,111.110000,112.060000,112.060000,1557056,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-27,113.480000,115.480000,112.490000,113.460000,113.460000,1095354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-28,114.310000,118.970000,111.910000,118.270000,118.270000,1642826,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-09-29,117.320000,119.020000,115.360000,117.490000,117.490000,805868,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-02,122.310000,125.960000,121.020000,122.310000,122.310000,2321143,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-03,122.010000,122.660000,119.570000,119.900000,119.900000,1214841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-04,119.000000,121.990000,118.390000,120.160000,120.160000,576553,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-05,120.170000,123.000000,119.580000,121.390000,121.390000,756940,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-06,121.500000,124.730000,121.180000,122.650000,122.650000,793294,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-09,122.500000,123.990000,121.390000,121.500000,121.500000,687214,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-10,122.040000,123.770000,119.040000,122.290000,122.290000,985948,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-11,122.800000,125.130000,120.600000,124.860000,124.860000,793295,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-12,123.510000,126.160000,123.240000,124.200000,124.200000,874088,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-13,124.910000,125.150000,122.790000,123.000000,123.000000,838628,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-16,123.010000,125.500000,120.600000,121.890000,121.890000,1034561,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-17,122.360000,122.500000,118.420000,118.700000,118.700000,1031390,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-18,119.640000,120.460000,115.680000,117.550000,117.550000,1020295,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-19,116.000000,118.340000,114.270000,115.630000,115.630000,1199739,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-20,115.610000,115.740000,111.250000,114.700000,114.700000,1307070,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-23,114.660000,116.460000,112.950000,115.570000,115.570000,805790,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-24,116.220000,119.750000,115.500000,117.070000,117.070000,977043,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-25,117.000000,118.250000,114.820000,117.400000,117.400000,776279,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-26,116.440000,118.430000,113.250000,114.490000,114.490000,867049,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-27,114.630000,122.580000,114.630000,119.920000,119.920000,1357617,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-30,120.230000,123.560000,118.800000,122.960000,122.960000,1096725,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-10-31,123.440000,124.530000,121.720000,121.840000,121.840000,861688,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-01,123.440000,124.500000,120.080000,121.090000,121.090000,867021,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-02,121.340000,147.630000,120.870000,133.590000,133.590000,3967503,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-03,133.340000,137.840000,132.200000,132.360000,132.360000,1460580,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-06,131.450000,132.500000,129.160000,130.500000,130.500000,1085799,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-07,129.200000,131.410000,128.170000,129.500000,129.500000,836690,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-08,131.140000,137.000000,127.200000,132.330000,132.330000,1649047,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-09,134.980000,138.030000,131.100000,137.680000,137.680000,1366601,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-10,137.600000,140.790000,134.900000,139.980000,139.980000,1381071,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-13,138.140000,138.140000,128.780000,129.110000,129.110000,1449153,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-14,130.060000,134.790000,128.000000,130.320000,130.320000,3296837,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-15,128.390000,130.570000,124.960000,125.950000,125.950000,1883262,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-16,127.110000,129.330000,124.610000,126.380000,126.380000,1234408,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-17,126.170000,128.590000,125.570000,127.510000,127.510000,894411,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-20,127.360000,129.540000,126.590000,128.150000,128.150000,914506,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-21,129.580000,132.980000,129.120000,132.010000,132.010000,991991,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-22,131.450000,133.470000,129.350000,132.330000,132.330000,771704,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-24,132.330000,134.890000,131.000000,132.850000,132.850000,783126,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-27,133.820000,133.820000,129.535000,131.440000,131.440000,1089830,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-28,132.930000,132.930000,128.550000,129.740000,129.740000,940979,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-29,129.670000,131.110000,125.670000,128.140000,128.140000,1403953,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-11-30,129.420000,135.270000,128.155000,134.540000,134.540000,5318223,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-01,134.530000,138.000000,132.785000,137.310000,137.310000,1235158,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-04,137.190000,139.900000,126.560000,128.010000,128.010000,1306130,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-05,128.290000,132.610000,126.150000,127.000000,127.000000,862231,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-06,127.660000,128.220000,121.240000,124.570000,124.570000,930082,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-07,125.150000,130.870000,124.665000,128.730000,128.730000,873312,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-08,129.170000,132.570000,129.170000,130.890000,130.890000,730965,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-11,131.720000,132.240000,126.400000,128.200000,128.200000,914067,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-12,126.980000,131.565000,125.850000,127.290000,127.290000,809982,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-13,126.750000,127.615000,123.300000,124.860000,124.860000,1466281,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-14,125.880000,126.770000,121.315000,123.660000,123.660000,1268394,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-15,130.160000,131.990000,123.900000,125.590000,125.590000,2532071,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-18,126.510000,126.510000,122.050000,122.760000,122.760000,1029799,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-19,122.760000,123.580000,119.550000,122.850000,122.850000,1113944,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-20,123.810000,123.810000,120.279400,121.970000,121.970000,715307,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-21,121.720000,124.150000,120.865000,122.830000,122.830000,474473,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-22,121.920000,124.960000,121.240000,123.960000,123.960000,1029296,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-26,123.480000,125.250000,122.745000,124.680000,124.680000,407209,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-27,123.070000,128.749900,123.010000,128.560000,128.560000,378789,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-28,129.340000,129.950000,128.270000,129.880000,129.880000,435129,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2017-12-29,130.200000,130.430000,126.770000,127.050000,127.050000,515713,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-02,128.320000,132.000000,125.870000,131.850000,131.850000,439373,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-03,131.380000,136.710000,130.270100,134.650000,134.650000,709044,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-04,134.940000,135.890000,129.570000,131.960000,131.960000,773686,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-05,131.960000,131.960000,127.350000,127.730000,127.730000,716805,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-08,130.330000,131.330000,126.564700,129.180000,129.180000,1127897,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-09,129.800000,132.210000,128.250000,130.740000,130.740000,682387,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-10,129.000000,130.880000,128.320000,128.600000,128.600000,691693,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-11,129.320000,129.910000,127.768800,128.050000,128.050000,565113,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-12,127.950000,132.470000,127.550000,129.070000,129.070000,795764,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-16,130.000000,131.025000,122.968800,124.640000,124.640000,910939,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-17,126.130000,127.900000,123.450000,125.250000,125.250000,1142674,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-18,125.930000,126.730000,123.850000,123.990000,123.990000,533057,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-19,124.750000,125.500000,122.630000,124.830000,124.830000,840670,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-22,126.070000,132.375000,126.070000,131.000000,131.000000,1993329,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-23,131.000000,139.630000,130.081000,137.030000,137.030000,2721830,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-24,136.760000,138.080000,131.902800,133.890000,133.890000,965032,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-25,135.350000,135.649800,133.000000,134.290000,134.290000,1050889,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-26,136.290000,136.290000,133.225000,134.390000,134.390000,522115,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-29,133.440000,134.959000,132.010000,133.560000,133.560000,901807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-30,131.920000,132.680000,128.895000,131.230000,131.230000,664491,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-01-31,132.430000,132.910000,128.390000,129.980000,129.980000,538950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-01,129.040000,131.470000,127.290000,129.430000,129.430000,795684,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-02,127.770000,129.660000,124.030000,124.500000,124.500000,777821,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-05,123.630000,126.740000,118.930000,119.920000,119.920000,918774,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-06,117.370000,122.610000,115.790000,122.170000,122.170000,1167695,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-07,121.670000,123.930000,121.155000,122.090000,122.090000,712118,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-08,123.010000,123.590000,116.280000,116.320000,116.320000,929025,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-09,116.920000,118.130500,108.130000,115.920000,115.920000,1205468,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-12,117.500000,119.590000,116.240000,117.300000,117.300000,565200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-13,116.430000,119.440000,115.220000,119.260000,119.260000,507984,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-14,117.840000,120.430000,115.670000,119.980000,119.980000,496727,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-15,120.480000,121.820000,118.170000,121.740000,121.740000,707054,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-16,121.890000,124.030000,121.270000,122.880000,122.880000,645522,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-20,121.620000,123.765000,120.130000,120.830000,120.830000,394956,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-21,121.000000,122.150000,119.070000,119.180000,119.180000,321060,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-22,119.450000,121.970000,119.410000,119.860000,119.860000,416425,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-23,120.300000,121.470000,118.888000,121.420000,121.420000,391354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-26,122.250000,123.670000,121.160000,123.000000,123.000000,564003,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-27,123.540000,123.930000,122.500000,123.290000,123.290000,425007,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-02-28,123.400000,124.590000,120.130000,120.160000,120.160000,674456,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-01,120.000000,122.800000,118.010000,119.130000,119.130000,620193,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-02,118.050000,121.830000,117.400000,121.160000,121.160000,464855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-05,120.830000,127.990000,120.820000,126.580000,126.580000,747211,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-06,127.640000,127.850000,121.370000,123.250000,123.250000,681887,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-07,122.060000,124.320000,121.500000,123.990000,123.990000,788238,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-08,124.110000,127.700000,123.610000,126.740000,126.740000,429735,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-09,128.260000,134.910000,128.120000,133.020000,133.020000,891309,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-12,133.430000,143.830000,131.494000,142.040000,142.040000,1334341,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-13,142.040000,152.747400,142.030000,144.160000,144.160000,1908563,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-14,140.080000,145.920000,139.910000,141.830000,141.830000,1001332,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-15,142.690000,146.590000,141.070000,141.380000,141.380000,657732,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-16,141.360000,146.060000,137.820000,145.060000,145.060000,1444004,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-19,143.780000,149.190000,142.527300,146.560000,146.560000,1044852,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-20,147.200000,153.985000,146.050000,148.540000,148.540000,1009783,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-21,147.890000,149.729000,146.100000,146.260000,146.260000,481387,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-22,144.760000,146.790000,142.000000,142.500000,142.500000,396616,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-23,141.500000,143.590000,137.750000,138.060000,138.060000,736647,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-26,141.580000,141.660000,135.310000,138.510000,138.510000,906807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-27,139.500000,139.690000,130.610000,131.180000,131.180000,836926,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-28,130.650000,132.325000,126.080000,129.870000,129.870000,863854,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-03-29,130.860000,131.460000,117.710000,119.100000,119.100000,3171092,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-02,118.410000,118.710000,96.840000,101.180000,101.180000,5781600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-03,101.410000,104.950000,98.520000,99.410000,99.410000,2497428,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-04,98.000000,105.700000,96.020000,102.290000,102.290000,1945998,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-05,103.000000,103.540000,95.830000,96.440000,96.440000,1468095,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-06,95.210000,97.225000,93.010000,95.080000,95.080000,1958468,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-09,96.160000,99.150000,96.160000,97.330000,97.330000,1094322,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-10,99.260000,101.560000,97.960000,98.080000,98.080000,1352856,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-11,96.830000,99.380000,96.330000,97.630000,97.630000,875952,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-12,98.920000,102.355000,97.900000,100.750000,100.750000,627511,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-13,101.490000,102.160000,98.770000,100.760000,100.760000,577735,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-16,102.170000,103.850000,95.780000,95.840000,95.840000,1065756,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-17,96.180000,99.000000,95.550000,98.350000,98.350000,992039,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-18,98.500000,99.329900,96.030000,97.700000,97.700000,695875,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-19,95.668000,98.680000,95.668000,96.190000,96.190000,681516,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-20,96.400000,99.157500,95.240000,97.480000,97.480000,1285479,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-23,98.500000,99.300000,94.770000,95.860000,95.860000,677155,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-24,96.190000,97.150000,94.480000,94.730000,94.730000,948933,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-25,94.730000,95.870000,93.110000,94.330000,94.330000,707161,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-26,95.340000,97.280000,94.150000,95.300000,95.300000,607010,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-27,95.810000,98.320000,95.750000,96.630000,96.630000,516140,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-04-30,97.000000,97.524100,94.490000,94.530000,94.530000,680436,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-01,94.250000,94.710000,90.550000,92.180000,92.180000,1270402,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-02,91.660000,92.810000,89.560000,90.020000,90.020000,1297702,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-03,90.260000,91.340000,88.310000,88.310000,88.310000,922791,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-04,89.000000,95.590000,87.350000,92.350000,92.350000,2877574,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-07,92.410000,98.700000,91.540000,97.420000,97.420000,1099354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-08,97.700000,104.620000,94.710000,96.140000,96.140000,1698209,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-09,96.190000,98.020000,95.610000,97.090000,97.090000,593608,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-10,97.000000,100.850000,96.150000,98.280000,98.280000,909614,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-11,98.300000,101.910000,98.300000,100.910000,100.910000,856762,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-14,101.550000,106.830000,101.550000,103.130000,103.130000,1297222,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-15,101.740000,103.650000,100.510000,101.990000,101.990000,792270,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-16,102.090000,102.535000,100.940000,101.590000,101.590000,972468,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-17,101.330000,102.420000,100.020000,101.640000,101.640000,865688,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-18,101.310000,103.140000,100.905000,102.810000,102.810000,731510,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-21,103.170000,103.750000,99.825000,100.800000,100.800000,616742,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-22,101.250000,101.565000,98.690000,98.960000,98.960000,544270,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-23,98.210000,98.690000,96.720000,98.100000,98.100000,617642,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-24,98.230000,99.580000,97.950000,98.970000,98.970000,448342,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-25,98.820000,100.540000,98.820000,99.980000,99.980000,530992,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-29,99.330000,101.340000,98.300000,100.060000,100.060000,661134,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-30,100.760000,101.270000,99.150000,100.460000,100.460000,591209,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-05-31,100.570000,102.100000,98.890000,99.470000,99.470000,744228,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-01,99.810000,100.780000,99.050000,100.650000,100.650000,945015,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-04,101.510000,101.620000,97.465000,101.000000,101.000000,688533,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-05,100.910000,103.220000,100.600000,101.020000,101.020000,575161,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-06,101.580000,102.680000,100.920000,101.660000,101.660000,594152,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-07,102.170000,102.550000,99.115000,99.910000,99.910000,618819,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-08,100.270000,101.845000,99.540000,100.240000,100.240000,435093,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-11,100.470000,100.770000,99.700000,100.050000,100.050000,383149,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-12,100.450000,106.300000,100.450000,105.910000,105.910000,869557,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-13,105.600000,106.940000,102.670000,102.860000,102.860000,738636,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-14,102.890000,108.290000,102.800000,107.060000,107.060000,645577,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-15,106.700000,108.000000,105.850000,107.800000,107.800000,1116608,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-18,106.190000,109.410000,105.700000,106.230000,106.230000,806950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-19,104.640000,105.780200,103.745000,104.620000,104.620000,664481,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-20,105.510000,106.300000,104.490000,105.260000,105.260000,515069,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-21,105.060000,106.080000,102.270000,102.690000,102.690000,348051,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-22,103.020000,104.310000,101.678000,104.200000,104.200000,711365,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-25,103.480000,103.750000,99.340000,100.040000,100.040000,520204,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-26,100.140000,101.389000,94.060000,98.510000,98.510000,790315,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-27,99.880000,101.289900,95.940000,96.070000,96.070000,494195,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-28,96.070000,98.255000,94.980000,97.170000,97.170000,601990,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-06-29,97.990000,101.000000,96.310000,98.490000,98.490000,730516,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-02,98.190000,99.800000,97.150000,98.080000,98.080000,547184,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-03,99.060000,101.300000,98.250000,98.620000,98.620000,310067,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-05,100.000000,100.630000,96.450000,98.050000,98.050000,730755,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-06,98.200000,101.920000,98.200000,101.030000,101.030000,519928,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-09,101.230000,103.100000,100.510500,102.780000,102.780000,562502,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-10,103.570000,105.690000,102.550000,104.730000,104.730000,741258,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-11,103.740000,106.100000,102.640000,105.880000,105.880000,440506,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-12,106.940000,108.685000,106.130000,108.050000,108.050000,489907,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-13,108.260000,108.980000,106.240000,107.470000,107.470000,425217,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-16,107.710000,108.390000,101.990000,102.760000,102.760000,896374,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-17,102.100000,103.200000,100.450000,102.270000,102.270000,506831,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-18,103.000000,105.690000,102.100000,105.370000,105.370000,555397,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-19,104.680000,107.440000,104.459500,106.260000,106.260000,426652,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-20,106.330000,108.070000,105.750000,105.930000,105.930000,418391,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-23,105.470000,107.640000,104.090000,105.710000,105.710000,489505,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-24,106.180000,107.330000,101.735000,102.660000,102.660000,565290,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-25,102.940000,106.505000,101.990000,105.740000,105.740000,647340,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-26,105.560000,108.130000,102.680000,106.550000,106.550000,754680,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-27,107.500000,107.500000,103.570000,104.510000,104.510000,654585,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-30,103.970000,104.570000,95.170000,96.810000,96.810000,1328531,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-07-31,97.210000,98.900000,94.980000,95.000000,95.000000,886899,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-01,94.870000,96.156400,94.010000,94.490000,94.490000,809319,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-02,98.000000,98.000000,92.040000,95.220000,95.220000,1091624,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-03,96.320000,96.320000,91.410000,91.650000,91.650000,1056114,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-06,91.190000,93.390000,89.240000,93.070000,93.070000,1303833,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-07,96.000000,96.140000,92.750000,93.880000,93.880000,986175,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-08,93.900000,94.670000,92.750000,92.970000,92.970000,832180,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-09,94.090000,96.745000,92.660000,94.250000,94.250000,1400707,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-10,94.000000,97.485700,94.000000,97.380000,97.380000,662971,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-13,92.000000,93.250000,88.160000,90.950000,90.950000,4006893,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-14,90.700000,93.340000,90.600000,93.180000,93.180000,1041425,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-15,91.730000,92.391600,90.175000,91.220000,91.220000,1051166,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-16,91.650000,93.345000,90.430000,92.950000,92.950000,619665,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-17,93.180000,95.230000,91.860000,94.580000,94.580000,635880,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-20,94.810000,97.170000,94.110000,96.370000,96.370000,986159,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-21,96.620000,97.900000,95.510100,97.500000,97.500000,660841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-22,97.400000,98.980000,96.610000,97.880000,97.880000,648699,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-23,97.250000,98.845000,96.870000,96.990000,96.990000,874412,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-24,96.900000,98.840000,95.226700,96.870000,96.870000,936059,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-27,100.440000,117.629900,100.010000,112.590000,112.590000,3340110,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-28,114.280000,118.310000,113.800000,117.550000,117.550000,1393895,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-29,117.090000,119.844000,116.090000,119.100000,119.100000,883786,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-30,119.850000,122.865000,118.955000,121.880000,121.880000,780908,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-08-31,122.350000,124.215000,120.810000,122.670000,122.670000,604671,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-04,121.260000,122.615000,118.270000,119.120000,119.120000,887609,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-05,118.970000,119.990000,116.841000,118.080000,118.080000,584781,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-06,117.440000,118.310000,111.940000,112.130000,112.130000,574549,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-07,112.000000,113.550000,108.740000,109.000000,109.000000,773059,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-10,109.610000,110.000000,102.660000,104.250000,104.250000,1049658,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-11,102.770000,103.500000,99.380000,100.350000,100.350000,1137302,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-12,99.110000,99.400000,91.120000,94.750000,94.750000,2614328,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-13,94.100000,99.729000,92.500000,94.960000,94.960000,1191712,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-14,95.430000,99.070000,95.390400,97.140000,97.140000,820156,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-17,96.780000,97.840000,92.790000,93.350000,93.350000,706051,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-18,93.480000,95.400000,92.225000,93.750000,93.750000,552675,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-19,93.750000,95.050000,92.320000,94.820000,94.820000,518150,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-20,95.090000,96.140000,94.510000,95.210000,95.210000,523139,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-21,95.290000,95.570000,93.360000,94.570000,94.570000,798745,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-24,94.240000,94.850000,91.550000,93.260000,93.260000,563668,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-25,93.760000,94.750000,92.050000,93.890000,93.890000,577883,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-26,94.000000,94.950000,91.260000,91.330000,91.330000,651192,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-27,88.000000,91.240000,86.953200,90.090000,90.090000,1908672,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-09-28,90.090000,91.500000,87.430000,87.520000,87.520000,1169988,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-01,89.500000,89.600000,88.040000,88.330000,88.330000,640474,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-02,88.640000,88.640000,86.090000,87.200000,87.200000,722902,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-03,87.310000,88.630000,84.480000,88.180000,88.180000,513968,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-04,87.910000,88.124700,85.060000,86.220000,86.220000,647003,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-05,86.400000,89.500000,84.670000,86.750000,86.750000,865439,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-08,86.450000,86.610000,82.449900,83.240000,83.240000,809857,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-09,82.580000,83.640000,80.950000,81.680000,81.680000,791503,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-10,81.210000,83.970000,80.000000,80.990000,80.990000,1200071,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-11,80.770000,82.679900,78.850000,79.300000,79.300000,847724,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-12,80.730000,82.190000,79.770000,81.950000,81.950000,750817,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-15,81.270000,82.400000,79.360000,80.010000,80.010000,513963,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-16,80.590000,83.010000,80.040000,82.910000,82.910000,591660,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-17,82.740000,82.740000,79.630000,81.260000,81.260000,451235,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-18,80.950000,81.700000,78.290000,78.590000,78.590000,715548,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-19,78.850000,79.790000,76.295000,76.650000,76.650000,974223,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-22,76.450000,76.450000,72.340000,74.950000,74.950000,775304,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-23,73.720000,78.345000,73.530000,76.600000,76.600000,1033945,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-24,76.610000,78.110000,71.850000,73.000000,73.000000,1164970,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-25,73.280000,78.800000,73.280000,77.920000,77.920000,870846,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-26,76.770000,78.140000,75.317500,76.750000,76.750000,799949,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-29,78.240000,78.780000,72.805000,73.900000,73.900000,944936,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-30,73.690000,78.170000,73.100000,78.010000,78.010000,659578,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-10-31,79.190000,81.730000,79.015000,80.430000,80.430000,723155,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-01,80.740000,88.400000,80.690000,88.130000,88.130000,946827,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-02,88.100000,90.000000,84.010000,88.260000,88.260000,810910,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-05,88.170000,89.200000,85.710000,88.160000,88.160000,753560,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-06,87.380000,88.340000,85.410000,86.280000,86.280000,1184238,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-07,79.550000,81.000000,71.950000,76.050000,76.050000,3040483,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-08,75.670000,77.000000,72.580000,73.040000,73.040000,1417232,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-09,72.680000,73.670000,70.430000,72.410000,72.410000,800661,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-12,71.690000,72.250000,67.690000,67.920000,67.920000,937814,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-13,68.100000,70.450000,66.830000,67.310000,67.310000,900396,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-14,68.320000,69.510000,63.610000,65.070000,65.070000,1361717,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-15,64.900000,70.530000,63.570000,69.370000,69.370000,969287,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-16,69.180000,73.690000,68.030000,73.160000,73.160000,883246,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-19,72.720000,74.410000,70.220000,71.480000,71.480000,972134,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-20,69.560000,73.280000,68.000000,72.660000,72.660000,847318,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-21,73.390000,74.920000,71.550000,72.680000,72.680000,575578,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-23,72.050000,75.700000,72.030000,73.340000,73.340000,251909,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-26,74.650000,78.760000,74.591800,78.350000,78.350000,688014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-27,77.580000,79.030000,75.600000,77.910000,77.910000,551882,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-28,78.520000,79.820000,76.330000,78.020000,78.020000,628993,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-29,77.900000,81.980000,77.730000,80.610000,80.610000,843747,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-11-30,80.600000,82.480000,80.600000,81.160000,81.160000,775613,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-03,82.380000,84.890000,82.200000,84.290000,84.290000,874939,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-04,83.740000,85.550000,78.140000,78.350000,78.350000,821992,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-06,77.390000,80.480000,74.300000,79.730000,79.730000,1056333,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-07,80.000000,81.597500,74.040000,74.380000,74.380000,1100041,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-10,74.750000,78.030000,74.430000,76.690000,76.690000,800886,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-11,77.650000,77.990000,75.630000,76.790000,76.790000,691679,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-12,77.880000,81.035000,77.710000,79.500000,79.500000,499309,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-13,79.700000,80.720000,74.880000,75.660000,75.660000,779008,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-14,74.700000,77.790000,73.680000,77.130000,77.130000,688874,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-17,76.360000,79.360000,74.170000,74.300000,74.300000,900129,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-18,75.490000,77.100000,70.930000,72.540000,72.540000,1016223,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-19,72.390000,75.975000,67.720000,68.380000,68.380000,872885,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-20,68.240000,70.720000,64.790000,65.810000,65.810000,1040475,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-21,66.180000,67.560000,61.780000,63.300000,63.300000,1452848,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-24,62.380000,65.620000,60.270000,62.670000,62.670000,537443,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-26,63.030000,68.260000,63.030000,68.100000,68.100000,1966753,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-27,66.820000,69.820000,65.500000,68.590000,68.590000,690755,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-28,68.950000,72.490000,68.270000,70.400000,70.400000,794133,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2018-12-31,71.040000,73.940000,71.040000,72.910000,72.910000,794653,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-02,71.300000,73.760000,70.290000,72.760000,72.760000,773376,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-03,73.150000,74.970000,71.200000,73.210000,73.210000,645412,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-04,74.000000,75.890000,72.355000,75.200000,75.200000,855794,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-07,77.000000,83.710000,77.000000,81.780000,81.780000,1156928,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-08,82.890000,85.500000,81.880000,85.340000,85.340000,996114,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-09,85.600000,86.875000,84.244700,84.780000,84.780000,534088,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-10,84.220000,89.520000,83.360000,89.160000,89.160000,645321,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-11,88.360000,90.700000,86.862300,89.120000,89.120000,552359,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-14,87.940000,87.940000,83.960000,84.020000,84.020000,736166,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-15,78.250000,82.490000,78.120000,80.450000,80.450000,3311546,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-16,80.540000,84.660000,80.520000,80.880000,80.880000,935351,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-17,80.330000,82.050000,79.750000,80.680000,80.680000,680095,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-18,81.450000,83.180000,79.000000,83.120000,83.120000,1062959,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-22,82.500000,83.210000,78.890000,80.660000,80.660000,1019913,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-23,81.250000,82.420000,78.520000,80.010000,80.010000,821743,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-24,79.840000,81.210000,79.030000,80.790000,80.790000,792551,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-25,81.340000,83.720000,80.420000,83.050000,83.050000,943701,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-28,81.860000,82.455000,75.145000,76.660000,76.660000,1768905,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-29,76.680000,79.520000,75.310000,79.120000,79.120000,597734,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-30,79.430000,81.980000,77.700000,81.700000,81.700000,463099,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-01-31,81.440000,84.130000,80.900000,83.530000,83.530000,763013,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-01,83.120000,85.160000,82.530000,84.580000,84.580000,975804,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-04,85.000000,85.330000,84.180000,85.230000,85.230000,354602,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-05,85.320000,86.450000,81.510000,82.300000,82.300000,749465,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-06,81.920000,83.070000,80.770000,81.760000,81.760000,955706,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-07,81.570000,82.650000,80.110000,80.800000,80.800000,1003222,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-08,82.340000,82.340000,74.290000,77.690000,77.690000,1637853,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-11,78.000000,80.860000,76.880000,80.810000,80.810000,746781,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-12,81.140000,83.960000,79.950000,83.830000,83.830000,592482,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-13,84.550000,85.690000,83.655000,84.390000,84.390000,694342,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-14,84.310000,84.739600,82.850000,83.030000,83.030000,397986,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-15,83.340000,83.759900,82.020000,83.530000,83.530000,542209,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-19,83.570000,85.330000,80.230000,80.380000,80.380000,788957,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-20,80.600000,81.300000,77.350000,77.750000,77.750000,744637,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-21,77.360000,78.370000,75.250000,76.210000,76.210000,816655,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-22,76.320000,78.420000,76.210000,78.180000,78.180000,610512,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-25,78.790000,81.710000,78.550000,81.620000,81.620000,513791,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-26,81.200000,82.575000,80.500000,81.700000,81.700000,634374,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-27,81.400000,85.200000,81.042500,85.000000,85.000000,689034,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-02-28,84.890000,86.210000,83.040000,85.000000,85.000000,679185,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-01,85.710000,85.990000,84.900000,85.370000,85.370000,537870,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-04,86.050000,86.400000,82.660000,85.000000,85.000000,717821,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-05,88.160000,90.330000,87.350000,88.310000,88.310000,849886,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-06,85.460000,87.120000,83.030000,84.750000,84.750000,2301307,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-07,85.150000,85.440000,82.850000,83.370000,83.370000,589402,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-08,82.770000,83.740000,81.295000,83.270000,83.270000,553997,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-11,83.500000,88.180000,83.465000,87.850000,87.850000,703320,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-12,88.050000,89.600000,86.590000,87.970000,87.970000,601903,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-13,88.200000,92.050000,87.970000,91.760000,91.760000,625643,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-14,91.410000,92.730000,88.230000,88.340000,88.340000,457323,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-15,88.410000,91.660000,88.030000,91.430000,91.430000,1096509,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-18,91.680000,92.430000,88.750000,90.240000,90.240000,622206,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-19,90.400000,90.920000,87.985000,88.630000,88.630000,428421,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-20,88.620000,90.000000,86.690000,88.680000,88.680000,520085,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-21,88.130000,91.330000,87.910000,90.740000,90.740000,511218,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-22,90.070000,90.450000,84.290000,84.520000,84.520000,764495,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-25,84.270000,85.922900,82.519600,84.170000,84.170000,506354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-26,84.980000,87.410000,84.280000,87.140000,87.140000,528344,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-27,87.460000,88.200000,84.670000,86.350000,86.350000,625388,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-28,86.530000,91.085000,86.330000,90.610000,90.610000,717710,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-03-29,90.190000,93.950000,90.190000,93.450000,93.450000,1275020,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-01,94.360000,96.080000,91.290000,91.830000,91.830000,699417,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-02,92.000000,93.310000,91.350000,92.570000,92.570000,415153,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-03,93.310000,93.410000,91.410000,92.060000,92.060000,732709,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-04,92.130000,93.000000,90.675000,91.450000,91.450000,417745,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-05,91.670000,93.000000,91.270000,92.790000,92.790000,752221,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-08,93.000000,93.890000,88.590000,90.170000,90.170000,1025209,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-09,90.990000,91.600000,88.595000,88.910000,88.910000,900744,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-10,89.810000,92.470000,89.590000,90.890000,90.890000,650539,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-11,91.250000,91.920000,87.020000,88.100000,88.100000,854440,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-12,89.360000,90.250000,88.120000,89.810000,89.810000,787295,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-15,91.230000,92.900000,87.385000,88.530000,88.530000,720635,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-16,88.960000,90.740000,88.430000,88.560000,88.560000,450172,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-17,89.080000,89.740000,83.583500,84.890000,84.890000,867241,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-18,85.060000,86.230000,79.790000,82.070000,82.070000,1376402,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-22,81.450000,83.830000,80.485000,83.160000,83.160000,712807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-23,83.240000,88.270000,82.890000,87.410000,87.410000,609798,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-24,87.330000,87.330000,84.670000,85.370000,85.370000,346836,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-25,84.900000,88.010000,83.500000,87.880000,87.880000,650464,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-26,87.950000,88.450000,84.950000,87.060000,87.060000,845615,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-29,86.980000,90.155000,86.640000,88.530000,88.530000,527217,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-04-30,88.500000,89.670000,86.460000,89.340000,89.340000,812800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-01,91.890000,92.850000,82.500000,83.030000,83.030000,1660539,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-02,84.250000,86.480000,82.470000,82.540000,82.540000,935628,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-03,79.800000,79.960000,76.855000,77.290000,77.290000,4643888,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-06,75.050000,76.000000,72.350000,74.080000,74.080000,3708799,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-07,73.440000,73.980000,70.370000,70.820000,70.820000,2810451,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-08,70.570000,71.080000,69.820000,70.150000,70.150000,1532600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-09,69.400000,72.490000,67.732400,72.140000,72.140000,2042284,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-10,71.570000,74.180000,70.710000,71.460000,71.460000,1434605,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-13,69.390000,70.460000,67.600000,68.770000,68.770000,1439611,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-14,69.120000,69.455000,67.250000,67.600000,67.600000,1511387,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-15,67.010000,70.630000,66.010000,68.070000,68.070000,927102,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-16,68.210000,70.420000,67.520000,68.730000,68.730000,894788,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-17,67.910000,69.250000,67.330000,67.540000,67.540000,815480,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-20,67.250000,67.720000,65.810000,65.860000,65.860000,1144338,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-21,66.640000,68.210000,66.080000,67.870000,67.870000,1232030,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-22,67.580000,68.720000,66.120000,67.810000,67.810000,501392,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-23,66.750000,68.125000,65.890000,67.910000,67.910000,722783,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-24,68.090000,69.630000,68.050000,68.930000,68.930000,1247517,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-28,69.010000,69.820000,67.880000,68.130000,68.130000,1097261,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-29,67.110000,68.700000,66.790000,67.630000,67.630000,738643,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-30,68.070000,69.210000,67.615000,68.710000,68.710000,572016,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-05-31,68.040000,68.910000,67.090000,67.520000,67.520000,612590,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-03,67.680000,68.810000,66.170000,66.870000,66.870000,1289928,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-04,67.580000,68.830000,65.950000,68.800000,68.800000,781891,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-05,69.250000,71.080000,68.000000,70.550000,70.550000,1095645,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-06,69.880000,71.650000,69.430000,70.800000,70.800000,585061,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-07,71.180000,71.570000,69.910000,70.400000,70.400000,915836,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-10,71.030000,72.780000,70.710000,70.720000,70.720000,709129,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-11,71.780000,72.050000,68.970000,69.920000,69.920000,612485,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-12,69.430000,70.170000,68.060000,70.000000,70.000000,362004,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-13,70.360000,71.755000,69.350000,71.240000,71.240000,471785,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-14,71.570000,71.570000,69.770000,70.030000,70.030000,413454,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-17,70.310000,72.250000,69.840000,71.500000,71.500000,720790,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-18,72.540000,74.340000,71.940000,73.020000,73.020000,870328,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-19,73.070000,73.985000,71.580000,71.970000,71.970000,809342,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-20,73.280000,74.270000,72.570000,73.440000,73.440000,388194,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-21,73.480000,74.850000,72.240000,74.370000,74.370000,688721,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-24,74.070000,74.070000,71.410000,71.800000,71.800000,479817,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-25,72.000000,72.980000,70.625000,71.140000,71.140000,331878,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-26,71.400000,72.100000,69.340000,69.490000,69.490000,548094,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-27,69.970000,72.390000,69.740000,71.080000,71.080000,787248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-06-28,71.430000,72.640000,70.870000,72.560000,72.560000,1112912,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-01,73.690000,74.500000,70.970000,72.010000,72.010000,646560,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-02,71.860000,73.800000,71.420000,72.970000,72.970000,398316,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-03,72.960000,73.750000,71.370000,72.640000,72.640000,340565,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-05,72.310000,72.860000,71.230000,72.190000,72.190000,623524,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-08,71.720000,71.880000,69.520000,70.900000,70.900000,537679,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-09,70.460000,73.980000,69.790000,73.240000,73.240000,668338,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-10,73.470000,74.390000,72.510000,74.110000,74.110000,733915,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-11,74.550000,74.850000,72.550000,73.410000,73.410000,653367,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-12,73.100000,73.210000,71.110000,71.540000,71.540000,774690,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-15,71.530000,73.588300,71.150000,72.790000,72.790000,592799,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-16,72.790000,74.450000,71.900000,74.240000,74.240000,507787,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-17,74.240000,74.950000,72.020000,72.680000,72.680000,966311,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-18,72.900000,76.310000,72.730000,75.890000,75.890000,826782,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-19,75.950000,75.950000,74.750000,75.370000,75.370000,1334910,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-22,75.820000,76.870000,75.120000,76.390000,76.390000,939614,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-23,76.580000,77.940000,75.700000,76.900000,76.900000,656923,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-24,76.900000,77.195000,75.000000,76.480000,76.480000,695731,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-25,76.080000,76.320000,73.415000,74.140000,74.140000,708562,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-26,74.460000,76.500000,73.875000,76.360000,76.360000,346719,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-29,76.500000,77.040000,75.220000,75.630000,75.630000,518045,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-30,75.910000,78.015000,75.605000,77.980000,77.980000,479902,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-07-31,77.430000,79.090000,77.430000,77.590000,77.590000,707827,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-01,77.450000,77.810000,74.310000,75.360000,75.360000,581895,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-02,74.950000,75.190000,72.520000,73.980000,73.980000,547939,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-05,72.750000,73.500000,70.900000,71.410000,71.410000,956248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-06,70.000000,75.890000,69.110000,74.380000,74.380000,954968,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-07,75.320000,81.690000,72.670000,80.500000,80.500000,1452038,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-08,80.790000,83.340000,80.790000,82.970000,82.970000,1088888,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-09,82.830000,84.480000,79.490000,80.780000,80.780000,779014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-12,80.000000,81.145000,78.590000,78.880000,78.880000,644441,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-13,79.100000,81.480000,78.600000,80.000000,80.000000,849514,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-14,78.940000,80.400000,78.730000,79.050000,79.050000,965273,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-15,79.080000,79.730000,77.680000,78.370000,78.370000,394433,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-16,78.770000,81.010000,78.770000,80.690000,80.690000,504297,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-19,81.980000,82.500000,80.460000,82.200000,82.200000,771566,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-20,81.940000,84.300000,81.510000,82.140000,82.140000,619019,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-21,83.430000,84.225700,81.970000,83.370000,83.370000,552138,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-22,83.990000,84.250000,81.030000,82.160000,82.160000,706155,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-23,81.720000,83.980000,81.303100,81.890000,81.890000,796300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-26,83.560000,83.920000,81.580000,82.240000,82.240000,700122,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-27,82.960000,83.950000,81.500000,82.210000,82.210000,1558886,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-28,81.990000,82.830000,81.280000,82.320000,82.320000,357525,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-29,83.000000,83.430000,80.110000,82.390000,82.390000,593201,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-08-30,82.610000,83.090000,80.410000,80.690000,80.690000,422758,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-03,82.500000,84.950000,80.172500,81.760000,81.760000,1026032,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-04,82.260000,83.460000,80.695000,82.330000,82.330000,746140,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-05,82.970000,83.730000,81.670000,83.140000,83.140000,470726,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-06,83.140000,83.440000,79.740000,79.820000,79.820000,648439,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-09,79.410000,83.130000,78.520000,82.690000,82.690000,780200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-10,82.220000,84.480000,81.580000,84.270000,84.270000,754404,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-11,84.700000,86.980000,84.350000,86.170000,86.170000,642073,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-12,86.660000,86.980000,83.080000,83.170000,83.170000,613878,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-13,83.140000,85.690000,83.040000,83.690000,83.690000,862244,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-16,83.470000,86.540000,83.300000,84.770000,84.770000,554019,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-17,85.030000,88.000000,84.990000,87.820000,87.820000,958210,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-18,87.950000,87.970000,84.540000,85.490000,85.490000,746135,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-19,85.840000,86.380000,84.300000,84.600000,84.600000,659722,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-20,84.900000,87.190000,84.770000,86.500000,86.500000,1279705,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-23,86.690000,87.100000,84.500000,84.740000,84.740000,591390,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-24,85.180000,85.510000,83.020000,83.480000,83.480000,634732,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-25,83.040000,84.520000,81.800000,83.690000,83.690000,340758,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-26,83.630000,84.610000,79.970000,80.060000,80.060000,738436,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-27,80.130000,82.100000,79.500000,81.100000,81.100000,603398,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-09-30,81.100000,81.720000,78.020000,80.420000,80.420000,828572,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-01,80.070000,80.420000,74.300000,74.510000,74.510000,907596,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-02,74.150000,78.090000,73.320000,75.760000,75.760000,1048925,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-03,75.580000,76.990000,74.260000,76.700000,76.700000,525743,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-04,76.540000,78.710000,75.010000,77.020000,77.020000,517628,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-07,76.980000,78.440000,76.215000,76.980000,76.980000,464689,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-08,76.410000,77.310000,74.190000,75.490000,75.490000,634110,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-09,76.520000,77.550000,75.870000,77.000000,77.000000,445545,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-10,76.740000,78.535000,76.730000,77.640000,77.640000,312431,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-11,78.800000,79.570000,77.510000,78.970000,78.970000,413906,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-14,78.530000,80.500000,78.265000,79.140000,79.140000,332574,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-15,79.530000,81.430000,79.490000,80.850000,80.850000,537503,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-16,80.960000,82.660000,80.390000,81.670000,81.670000,793170,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-17,81.990000,83.000000,80.940000,81.880000,81.880000,495147,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-18,81.910000,85.110000,81.340000,84.780000,84.780000,853945,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-21,85.000000,86.910000,84.665000,86.760000,86.760000,639115,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-22,87.380000,90.550000,87.380000,89.160000,89.160000,879150,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-23,88.810000,91.590000,88.810000,89.760000,89.760000,682321,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-24,90.100000,90.100000,88.060000,88.900000,88.900000,464173,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-25,88.030000,89.930000,88.030000,89.250000,89.250000,316742,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-28,89.190000,90.770000,89.190000,90.140000,90.140000,497841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-29,89.500000,90.300000,87.790000,88.200000,88.200000,764238,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-30,88.010000,89.580000,87.020000,87.270000,87.270000,716154,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-10-31,85.390000,87.305000,83.060000,86.740000,86.740000,1078167,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-01,87.040000,92.350000,86.500000,91.010000,91.010000,755704,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-04,90.140000,92.250000,90.140000,91.740000,91.740000,546727,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-05,91.980000,92.865000,90.890000,92.050000,92.050000,419429,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-06,92.290000,92.290000,90.080000,90.530000,90.530000,447562,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-07,91.140000,92.435000,90.570000,91.540000,91.540000,541519,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-08,91.500000,93.980000,90.850000,93.030000,93.030000,536578,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-11,93.100000,93.530000,91.570000,92.450000,92.450000,285501,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-12,92.200000,93.090000,90.550000,90.850000,90.850000,429822,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-13,90.550000,91.950000,89.750000,90.580000,90.580000,669834,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-14,90.730000,90.830000,88.930000,90.460000,90.460000,647507,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-15,90.570000,92.390000,90.273600,92.050000,92.050000,365687,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-18,92.000000,93.020000,90.470000,92.730000,92.730000,736814,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-19,93.920000,99.920000,93.890000,97.930000,97.930000,1251992,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-20,97.980000,109.710000,97.980000,108.210000,108.210000,2263399,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-21,107.000000,111.320000,104.540000,111.200000,111.200000,1735538,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-22,111.200000,112.430000,105.685000,106.910000,106.910000,1490010,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-25,116.010000,116.500000,110.735000,112.420000,112.420000,1718387,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-26,112.710000,119.185000,112.710000,119.060000,119.060000,1237607,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-27,119.000000,120.000000,116.200000,117.560000,117.560000,591776,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-11-29,117.310000,119.500000,116.463800,117.140000,117.140000,332436,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-02,118.010000,119.930000,117.500000,118.580000,118.580000,784721,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-03,117.730000,122.870000,116.230000,122.370000,122.370000,815122,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-04,122.000000,123.905000,119.753300,121.980000,121.980000,763175,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-05,121.660000,125.590000,121.640000,124.230000,124.230000,980080,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-06,124.340000,125.720000,123.170000,123.760000,123.760000,888878,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-09,124.550000,124.550000,120.050000,120.710000,120.710000,533403,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-10,120.110000,123.490000,118.910000,121.840000,121.840000,696861,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-11,120.980000,122.330000,117.790000,118.790000,118.790000,522843,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-12,118.170000,121.245000,117.340000,120.610000,120.610000,471831,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-13,120.500000,121.530000,117.053800,117.740000,117.740000,469555,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-16,118.640000,122.610000,118.410000,120.120000,120.120000,786132,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-17,123.700000,125.000000,115.450000,116.550000,116.550000,1368636,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-18,117.270000,117.885000,114.770000,115.340000,115.340000,987251,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-19,116.100000,118.000000,113.630000,117.850000,117.850000,1085294,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-20,117.880000,117.880000,115.000000,115.930000,115.930000,946076,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-23,115.740000,118.100000,115.000000,117.330000,117.330000,507794,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-24,117.080000,117.810000,115.960000,117.690000,117.690000,190801,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-26,118.000000,118.370000,117.060000,117.770000,117.770000,185083,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-27,118.300000,118.300000,116.110000,117.540000,117.540000,326635,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-30,116.830000,117.820000,114.050000,114.690000,114.690000,339771,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2019-12-31,114.000000,116.800800,113.500000,115.170000,115.170000,368671,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-02,115.570000,117.600000,114.010000,115.620000,115.620000,592943,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-03,114.230000,116.930000,113.845000,115.680000,115.680000,425998,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-06,115.150000,116.959300,114.100000,115.970000,115.970000,668629,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-07,115.970000,117.015000,114.560000,115.290000,115.290000,392517,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-08,115.410000,116.380000,114.650000,115.470000,115.470000,554417,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-09,116.000000,120.970000,116.000000,118.060000,118.060000,604108,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-10,118.350000,120.570000,117.660000,119.250000,119.250000,647072,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-13,118.000000,118.490000,112.480000,114.650000,114.650000,822176,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-14,113.400000,118.530000,111.530000,118.440000,118.440000,836903,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-15,119.230000,122.420000,117.350000,118.090000,118.090000,694195,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-16,118.970000,119.960000,117.480000,119.340000,119.340000,522766,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-17,119.010000,119.460000,116.160000,118.820000,118.820000,860384,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-21,118.410000,121.470000,117.100000,117.980000,117.980000,654283,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-22,118.440000,120.574000,114.680000,115.630000,115.630000,663492,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-23,115.240000,118.790000,112.730000,117.960000,117.960000,704571,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-24,118.110000,120.780000,118.010000,120.000000,120.000000,894612,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-27,117.510000,120.366000,114.905000,117.030000,117.030000,884182,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-28,117.970000,118.480000,113.840000,114.720000,114.720000,644701,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-29,114.710000,119.250000,114.320000,117.930000,117.930000,517168,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-30,116.720000,118.000000,114.560000,115.450000,115.450000,392796,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-01-31,114.740000,116.030000,113.510000,114.790000,114.790000,484580,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-03,115.920000,117.560000,114.240000,114.660000,114.660000,520268,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-04,116.620000,120.620000,115.960000,119.960000,119.960000,734148,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-05,120.990000,123.640000,120.670000,121.590000,121.590000,806354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-06,115.690000,125.730000,115.690000,121.960000,121.960000,1090288,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-07,122.000000,128.225000,120.260000,125.480000,125.480000,852262,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-10,124.750000,133.000000,124.270000,131.500000,131.500000,1496829,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-11,130.460000,133.110000,128.630000,129.540000,129.540000,873040,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-12,129.510000,134.510000,128.700000,133.990000,133.990000,897084,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-13,133.980000,134.330000,129.850000,130.100000,130.100000,416507,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-14,130.050000,130.830000,127.410000,128.700000,128.700000,398981,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-18,129.100000,130.030000,125.170000,128.680000,128.680000,750083,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-19,128.830000,131.650000,128.650000,129.000000,129.000000,326262,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-20,129.190000,133.610000,128.000000,133.120000,133.120000,714910,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-21,133.120000,133.480000,129.750000,131.030000,131.030000,429216,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-24,125.500000,125.500000,121.560000,122.290000,122.290000,747078,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-25,123.220000,124.257600,118.140000,119.290000,119.290000,550850,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-26,119.930000,120.510000,115.570000,118.050000,118.050000,537857,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-27,114.830000,117.720000,110.530000,112.490000,112.490000,949161,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-02-28,106.280000,118.560000,106.280000,117.660000,117.660000,1106989,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-02,118.890000,119.420000,111.010000,114.780000,114.780000,1032570,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-03,115.820000,116.080000,108.960100,111.420000,111.420000,569770,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-04,114.090000,118.000000,113.440000,117.240000,117.240000,699859,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-05,114.580000,118.740000,114.580000,116.910000,116.910000,582764,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-06,114.140000,115.475000,110.350000,113.390000,113.390000,613749,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-09,106.720000,111.400000,106.080000,109.960000,109.960000,914519,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-10,112.800000,114.160000,103.950000,109.390000,109.390000,970523,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-11,106.960000,107.615000,99.920800,101.890000,101.890000,766365,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-12,94.870000,100.700000,90.000000,93.120000,93.120000,912528,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-13,97.020000,102.460000,84.970000,101.570000,101.570000,1077077,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-16,118.810000,134.260000,90.549300,98.300000,98.300000,2229206,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-17,100.020000,108.930000,99.030000,103.000000,103.000000,1498355,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-18,97.950000,104.940000,92.600000,103.740000,103.740000,1062766,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-19,104.690000,115.000000,103.050000,105.970000,105.970000,917354,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-20,105.730000,112.730000,100.160000,103.850000,103.850000,1279286,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-23,106.490000,106.490000,94.750000,99.060000,99.060000,804538,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-24,103.080000,104.625000,97.140000,99.940000,99.940000,827201,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-25,101.370000,102.990000,95.500000,98.780000,98.780000,855369,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-26,98.020000,108.000000,98.020000,107.210000,107.210000,894104,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-27,105.020000,106.830000,98.620000,104.200000,104.200000,719926,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-30,105.300000,109.335000,104.490000,108.830000,108.830000,612190,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-03-31,108.560000,111.870000,105.900000,108.850000,108.850000,1156557,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-01,105.140000,109.410000,103.690000,104.540000,104.540000,742676,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-02,103.570000,108.410000,98.010000,104.210000,104.210000,805093,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-03,101.450000,105.980000,100.020000,105.820000,105.820000,501447,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-06,108.240000,112.250000,107.670600,112.140000,112.140000,774242,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-07,114.960000,116.490000,108.990000,109.520000,109.520000,773494,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-08,104.750000,114.340000,103.650000,111.390000,111.390000,737375,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-09,110.740000,117.100000,110.740000,116.380000,116.380000,572169,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-13,120.000000,120.050000,114.300000,119.010000,119.010000,1215357,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-14,121.140000,124.200000,119.665000,120.720000,120.720000,822765,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-15,117.730000,124.480000,116.936300,121.500000,121.500000,450995,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-16,123.320000,128.970000,120.246000,127.720000,127.720000,894865,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-17,131.740000,138.700000,130.250000,138.480000,138.480000,1386307,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-20,136.620000,146.080000,135.490000,144.870000,144.870000,1469644,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-21,144.500000,146.560000,135.170000,137.850000,137.850000,1203432,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-22,140.000000,141.740000,137.718800,140.110000,140.110000,383334,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-23,139.820000,144.410000,139.820000,141.640000,141.640000,1092022,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-24,143.750000,147.000000,141.795000,145.630000,145.630000,696386,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-27,147.280000,147.410000,142.265000,142.700000,142.700000,487329,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-28,142.430000,142.890000,136.640000,137.500000,137.500000,626613,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-29,140.010000,141.755200,132.910000,135.810000,135.810000,651230,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-04-30,136.270000,138.330000,131.570000,131.700000,131.700000,679350,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-01,130.450000,131.369700,124.950000,128.970000,128.970000,525665,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-04,130.540000,136.770000,129.020000,136.630000,136.630000,923186,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-05,137.530000,143.180000,137.050000,141.230000,141.230000,735555,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-06,141.240000,151.840000,137.490000,145.270000,145.270000,2229320,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-07,144.140000,145.709700,139.775000,141.450000,141.450000,1048200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-08,142.580000,143.120000,135.860000,136.130000,136.130000,708527,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-11,136.710000,144.200000,135.420000,142.430000,142.430000,899284,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-12,143.180000,149.240000,140.040000,144.190000,144.190000,835278,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-13,144.960000,146.540000,137.940000,139.460000,139.460000,857827,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-14,134.630000,138.000000,133.420000,136.200000,136.200000,935058,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-15,136.520000,139.600000,135.310000,139.280000,139.280000,762595,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-18,143.640000,145.820000,141.290000,144.870000,144.870000,617291,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-19,145.240000,146.770000,142.180000,142.410000,142.410000,484768,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-20,143.780000,145.080000,141.265000,143.450000,143.450000,737469,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-21,142.780000,144.219900,140.440000,141.860000,141.860000,669113,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-22,141.610000,142.350000,138.210000,140.520000,140.520000,775950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-26,141.060000,144.500000,135.800000,136.430000,136.430000,806127,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-27,134.140000,134.140000,126.240000,133.350000,133.350000,856891,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-28,135.260000,136.140000,132.470000,133.100000,133.100000,579386,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-05-29,134.590000,135.320000,129.560000,135.270000,135.270000,869807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-01,135.120000,136.630000,131.330000,133.570000,133.570000,560356,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-02,130.677000,139.190000,130.677000,138.820000,138.820000,705226,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-03,138.810000,138.810000,134.020000,137.250000,137.250000,563743,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-04,137.060000,139.034900,131.110000,131.900000,131.900000,623494,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-05,131.010000,132.595000,127.340000,127.590000,127.590000,610916,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-08,128.500000,131.140000,123.977900,130.440000,130.440000,612809,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-09,130.170000,132.270000,128.320000,129.790000,129.790000,535807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-10,130.550000,132.570000,127.670000,129.710000,129.710000,608136,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-11,128.160000,130.920000,125.000000,125.910000,125.910000,865944,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-12,127.410000,127.985000,120.050000,125.390000,125.390000,838331,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-15,123.170000,130.035000,120.820000,128.380000,128.380000,600534,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-16,130.150000,132.519600,128.320000,132.260000,132.260000,414569,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-17,132.880000,138.259900,132.880000,136.670000,136.670000,1654839,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-18,136.940000,142.290000,136.940000,141.990000,141.990000,922756,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-19,143.700000,150.710000,143.100000,150.710000,150.710000,2540535,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-22,149.960000,153.680000,147.570000,153.000000,153.000000,1292202,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-23,153.510000,156.980000,151.255000,151.830000,151.830000,1280036,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-24,151.990000,153.810000,148.580000,151.760000,151.760000,757406,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-25,151.250000,156.440000,150.385000,156.440000,156.440000,806527,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-26,156.260000,158.370000,150.027500,151.900000,151.900000,2866011,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-29,152.270000,152.270000,145.360000,147.910000,147.910000,499200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-06-30,148.140000,151.740000,146.090000,148.110000,148.110000,903200,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-01,148.530000,151.390000,147.560000,148.770000,148.770000,480100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-02,148.870000,151.080000,146.480000,149.870000,149.870000,419300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-06,149.960000,154.680000,149.370000,152.430000,152.430000,923600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-07,153.520000,164.090000,153.520000,160.000000,160.000000,1616400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-08,159.620000,162.570000,156.990000,160.420000,160.420000,851800,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-09,161.000000,161.000000,155.690000,158.740000,158.740000,480100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-10,157.500000,162.330000,157.300000,162.250000,162.250000,748700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-13,162.660000,162.890000,152.010000,152.740000,152.740000,667900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-14,152.740000,157.600000,149.850000,157.230000,157.230000,769300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-15,157.490000,159.270000,155.730000,158.020000,158.020000,472100,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-16,157.540000,157.830000,153.990000,156.030000,156.030000,362600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-17,157.360000,161.070000,155.940000,158.360000,158.360000,333400,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-20,164.670000,167.330000,160.170000,165.490000,165.490000,906133,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-21,165.020000,166.480000,157.340000,158.030000,158.030000,684760,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-22,158.420000,159.150000,155.550000,157.980000,157.980000,363353,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-23,159.070000,161.480000,154.130000,154.610000,154.610000,636105,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-24,152.410000,153.470000,148.590000,153.100000,153.100000,281289,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-27,155.680000,158.050000,151.540000,157.510000,157.510000,951793,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-28,157.060000,158.065000,153.540000,154.330000,154.330000,517452,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-29,155.670000,156.538300,150.370000,150.560000,150.560000,426409,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-30,148.520000,152.950000,148.520000,151.110000,151.110000,295573,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-07-31,151.340000,151.420000,143.610000,145.760000,145.760000,507286,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-03,146.790000,153.010000,145.580000,152.300000,152.300000,415576,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-04,152.320000,154.155000,150.560000,152.760000,152.760000,318856,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-05,153.130000,153.940000,146.770000,150.440000,150.440000,573897,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-06,148.640000,149.210000,141.500000,144.120000,144.120000,705527,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-07,145.260000,147.075000,142.180000,143.530000,143.530000,400552,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-10,143.500000,143.740000,137.215000,138.570000,138.570000,536457,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-11,136.660000,139.960000,133.400000,136.610000,136.610000,469949,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-12,136.320000,139.400000,135.020000,136.690000,136.690000,391563,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-13,138.110000,141.400000,136.780000,137.430000,137.430000,313872,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-14,137.050000,137.830000,134.480000,136.140000,136.140000,213265,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-17,137.790000,143.600000,137.000000,140.700000,140.700000,470494,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-18,140.350000,140.940000,138.830000,139.920000,139.920000,298883,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-19,140.260000,140.900000,136.610000,137.220000,137.220000,299029,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-20,136.170000,137.370000,134.370000,136.360000,136.360000,486802,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-21,137.420000,137.670000,134.280000,136.600000,136.600000,355446,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-24,136.620000,138.580000,131.040000,131.750000,131.750000,449382,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-25,130.650000,135.065000,128.270000,134.090000,134.090000,423103,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-26,133.730000,134.450000,132.050000,133.050000,133.050000,363229,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-27,134.430000,137.190000,132.550000,133.050000,133.050000,410627,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-28,132.420000,133.530000,130.600000,131.410000,131.410000,200647,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-08-31,131.920000,134.865000,131.920000,132.640000,132.640000,804395,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-01,133.310000,133.310000,129.040000,130.410000,130.410000,475401,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-02,131.460000,131.460000,128.420000,130.660000,130.660000,428604,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-03,129.750000,131.630000,124.665000,125.190000,125.190000,310861,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-04,126.180000,126.180000,119.670000,122.830000,122.830000,459373,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-08,122.030000,125.170000,120.810000,122.990000,122.990000,753594,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-09,124.100000,124.900000,121.810000,123.060000,123.060000,535611,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-10,122.290000,124.960000,121.190000,121.190000,121.190000,385672,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-11,122.620000,123.500000,120.240000,122.440000,122.440000,448973,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-14,125.000000,131.180000,124.060000,131.000000,131.000000,693492,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-15,131.880000,132.640000,130.090000,130.510000,130.510000,448458,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-16,130.410000,132.850000,129.695000,131.280000,131.280000,506774,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-17,130.410000,132.960000,129.515000,131.020000,131.020000,408471,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-18,131.670000,133.300000,128.180000,132.260000,132.260000,1476807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-21,131.820000,137.150000,129.600000,130.920000,130.920000,560855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-22,130.730000,134.180000,129.110000,133.640000,133.640000,465395,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-23,133.910000,136.070000,132.210000,134.500000,134.500000,458152,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-24,132.870000,134.200000,130.800000,133.340000,133.340000,428034,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-25,134.130000,138.800000,132.370000,138.310000,138.310000,635462,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-28,139.160000,140.000000,137.170000,139.810000,139.810000,352945,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-29,140.000000,145.250000,138.660000,145.010000,145.010000,501709,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-09-30,144.170000,147.000000,142.370000,145.600000,145.600000,548027,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-01,146.700000,148.760000,143.300000,143.740000,143.740000,558802,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-02,141.840000,143.720000,135.240000,135.680000,135.680000,614415,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-05,136.290000,142.270000,136.290000,142.000000,142.000000,494865,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-06,142.010000,146.765000,142.010000,143.260000,143.260000,366495,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-07,144.030000,146.500000,142.580000,145.400000,145.400000,386076,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-08,146.800000,147.760000,144.805000,146.040000,146.040000,247281,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-09,145.860000,147.975000,145.190000,147.000000,147.000000,275481,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-12,148.000000,148.050000,145.090000,147.000000,147.000000,313612,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-13,147.000000,148.740000,144.760000,146.660000,146.660000,267376,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-14,147.360000,147.990000,143.860000,143.910000,143.910000,251950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-15,142.520000,145.720000,141.300000,143.940000,143.940000,302824,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-16,144.120000,148.070000,144.120000,145.400000,145.400000,338564,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-19,144.940000,145.400000,139.530000,140.640000,140.640000,535527,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-20,141.920000,143.510000,140.410000,141.450000,141.450000,348978,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-21,141.360000,143.410000,135.930000,136.480000,136.480000,359797,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-22,136.490000,140.660000,133.767500,134.300000,134.300000,481958,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-23,134.750000,134.750000,130.720000,131.840000,131.840000,528914,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-26,130.080000,132.000000,126.710000,128.670000,128.670000,473261,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-27,128.520000,130.880000,126.070000,126.820000,126.820000,521974,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-28,125.590000,126.850000,123.235000,124.880000,124.880000,447468,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-29,124.930000,125.380000,121.560000,123.320000,123.320000,547506,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-10-30,122.800000,124.600000,119.290000,122.970000,122.970000,733508,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-02,124.360000,126.225000,122.000000,124.910000,124.910000,479820,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-03,125.000000,130.430000,125.000000,129.050000,129.050000,360182,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-04,133.420000,140.840000,132.465000,139.490000,139.490000,891934,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-05,143.560000,144.630000,136.330000,137.860000,137.860000,742696,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-06,136.030000,137.840000,126.230000,130.730000,130.730000,956971,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-09,133.620000,134.670000,126.660000,127.480000,127.480000,605058,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-10,127.200000,127.635000,124.580000,125.050000,125.050000,844767,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-11,126.620000,130.690000,123.150000,129.090000,129.090000,740426,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-12,129.740000,133.800000,129.740000,132.440000,132.440000,472221,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-13,133.350000,136.670000,132.620100,135.510000,135.510000,725862,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-16,136.010000,136.010000,128.510000,131.050000,131.050000,463384,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-17,130.920000,131.040000,127.722500,129.300000,129.300000,391355,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-18,130.000000,130.230000,125.040000,125.450000,125.450000,678009,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-19,126.620000,126.620000,122.660000,123.810000,123.810000,689843,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-20,123.820000,125.305000,122.923800,124.700000,124.700000,425632,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-23,125.000000,125.500000,120.830000,123.020000,123.020000,493691,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-24,125.690000,128.000000,123.030000,125.660000,125.660000,872388,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-25,127.430000,128.000000,123.675000,125.450000,125.450000,512765,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-27,125.880000,130.210000,125.640000,129.860000,129.860000,265015,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-11-30,130.310000,132.260000,129.040000,129.910000,129.910000,824970,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-01,130.780000,134.450000,130.650000,132.270000,132.270000,434773,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-02,131.920000,131.920000,127.695000,129.470000,129.470000,356191,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-03,130.000000,132.870000,129.680000,131.170000,131.170000,299566,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-04,130.620000,132.070000,127.254600,129.560000,129.560000,320585,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-07,129.740000,130.670000,126.000000,126.810000,126.810000,312574,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-08,127.070000,128.210000,125.350000,128.050000,128.050000,346394,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-09,127.510000,127.590000,121.975000,124.040000,124.040000,530700,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-10,124.040000,127.300000,123.470000,126.050000,126.050000,349811,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-11,126.420000,130.400000,126.260000,129.650000,129.650000,493440,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-14,131.630000,135.370000,131.005000,132.690000,132.690000,529806,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-15,134.070000,136.640000,133.080000,135.700000,135.700000,425227,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-16,136.050000,139.490000,134.710000,138.320000,138.320000,584826,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-17,139.930000,139.930000,136.420000,138.650000,138.650000,601322,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-18,140.000000,142.610000,136.880000,142.390000,142.390000,1235425,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-21,137.120000,140.790000,136.831000,139.430000,139.430000,486526,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-22,139.440000,142.350000,137.570000,138.310000,138.310000,572348,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-23,138.300000,140.010000,135.470000,138.620000,138.620000,590043,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-24,138.620000,140.110000,136.800000,137.560000,137.560000,150982,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-28,138.600000,140.000000,133.670000,134.080000,134.080000,337788,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-29,134.560000,136.910000,130.000000,130.560000,130.560000,368145,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-30,131.900000,134.155000,129.170000,131.040000,131.040000,256897,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2020-12-31,131.330000,132.420000,127.690000,129.970000,129.970000,338669,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-04,130.690000,132.780000,126.940000,128.100000,128.100000,527642,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-05,125.560000,127.700000,124.000000,127.450000,127.450000,499762,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-06,126.330000,128.125000,125.380000,126.830000,126.830000,758599,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-07,133.620000,140.000000,132.030000,139.400000,139.400000,1072701,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-08,138.730000,147.000000,137.723900,146.660000,146.660000,829857,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-11,148.560000,157.390000,146.420000,156.630000,156.630000,1316695,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-12,156.030000,165.910000,156.030000,165.650000,165.650000,1550933,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-13,165.650000,175.410000,163.950000,170.930000,170.930000,2440830,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-14,169.780000,169.780000,164.015800,165.070000,165.070000,1279970,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-15,165.350000,171.010000,165.350000,166.360000,166.360000,711647,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-19,167.880000,171.000000,167.020000,168.410000,168.410000,637880,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-20,169.650000,173.000000,167.010000,170.970000,170.970000,1028018,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-21,172.540000,172.610000,166.350000,166.750000,166.750000,543691,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-22,165.780000,173.200000,163.900000,172.380000,172.380000,534971,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-25,170.430000,176.780000,168.145000,175.690000,175.690000,1158044,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-26,174.150000,178.410000,169.160000,170.020000,170.020000,539596,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-27,168.580000,168.890000,152.510000,155.390000,155.390000,1249540,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-28,157.504300,157.504300,149.626100,154.740000,154.740000,829775,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-01-29,154.630000,156.670000,148.305000,150.480000,150.480000,931950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-01,154.650000,156.620000,146.900000,149.250000,149.250000,854656,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-02,149.920000,154.150000,148.320000,154.050000,154.050000,998563,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-03,154.090000,157.270000,149.985000,151.250000,151.250000,812466,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-04,152.800000,162.000000,152.355000,157.910000,157.910000,878985,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-05,158.420000,167.700000,158.420000,165.110000,165.110000,616426,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-08,165.460000,169.930000,162.250000,165.150000,165.150000,636082,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-09,165.000000,169.840000,163.870000,167.650000,167.650000,510059,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-10,169.810000,172.815000,162.140000,164.160000,164.160000,891841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-11,166.980000,168.880000,160.230000,165.380000,165.380000,617507,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-12,156.000000,162.970000,148.570000,157.920000,157.920000,924755,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-16,160.919700,160.919700,150.510000,153.810000,153.810000,803036,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-17,152.440000,157.000000,150.070000,156.530000,156.530000,507950,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-18,154.600000,156.440000,150.170000,150.230000,150.230000,711646,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-19,152.140000,155.530000,151.334000,155.060000,155.060000,682875,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-22,150.910000,153.610000,148.000000,148.070000,148.070000,469508,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-23,147.000000,154.310000,143.340000,153.210000,153.210000,602153,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-24,152.750000,155.570000,150.830000,151.590000,151.590000,368998,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-25,151.920000,154.800000,143.425000,146.590000,146.590000,461453,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-02-26,147.010000,149.000000,143.910000,148.100000,148.100000,500633,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-01,149.360000,151.350000,147.950000,148.750000,148.750000,443294,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-02,149.290000,153.250000,148.070000,152.410000,152.410000,572014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-03,151.910000,152.000000,143.540000,144.320000,144.320000,500703,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-04,143.350000,144.720000,136.885000,137.370000,137.370000,791027,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-05,136.948100,143.420000,133.087300,143.390000,143.390000,491344,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-08,142.140000,144.500000,138.290000,138.620000,138.620000,583844,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-09,141.880000,143.414300,137.600000,137.680000,137.680000,881251,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-10,139.630000,139.850000,134.120000,134.680000,134.680000,517001,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-11,138.210000,143.700000,136.485000,142.980000,142.980000,704280,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-12,140.690000,142.490000,137.070000,142.200000,142.200000,466042,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-15,142.000000,146.250000,141.150000,146.120000,146.120000,535883,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-16,147.340000,148.535000,142.070000,143.780000,143.780000,650660,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-17,142.340000,146.605000,141.510000,145.150000,145.150000,459437,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-18,143.150000,144.860000,139.790000,140.040000,140.040000,345298,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-19,141.430000,144.620000,138.880000,144.160000,144.160000,1046714,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-22,143.570000,146.870000,140.700000,144.150000,144.150000,643056,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-23,143.380000,143.640000,137.800000,138.660000,138.660000,405089,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-24,139.330000,140.540000,134.010000,134.630000,134.630000,464388,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-25,133.370000,135.740000,130.280000,135.240000,135.240000,637405,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-26,134.480000,136.390000,133.020000,136.250000,136.250000,252907,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-29,135.950000,136.730000,133.610000,133.800000,133.800000,320181,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-30,132.660000,137.560000,130.526300,135.130000,135.130000,359685,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-03-31,137.300000,142.280000,136.560000,141.190000,141.190000,539679,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-01,143.170000,145.160000,140.490000,141.810000,141.810000,324981,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-05,143.200000,144.930000,141.171000,142.650000,142.650000,399407,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-06,141.150000,143.910000,141.020000,142.010000,142.010000,411652,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-07,141.360000,143.040000,140.020000,140.670000,140.670000,336668,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-08,143.210000,144.540000,141.100000,142.500000,142.500000,346971,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-09,141.940000,142.310000,137.100000,138.230000,138.230000,419935,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-12,137.080000,137.865000,134.090000,135.030000,135.030000,522762,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-13,136.010000,137.000000,133.115000,136.230000,136.230000,477023,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-14,137.400000,140.365000,136.180000,138.310000,138.310000,566029,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-15,139.760000,142.710000,138.730000,139.020000,139.020000,428329,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-16,139.590000,140.060000,137.385000,138.880000,138.880000,768381,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-19,138.340000,140.815000,136.090000,137.400000,137.400000,492633,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-20,131.750000,136.910000,131.750000,136.030000,136.030000,508156,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-21,136.940000,138.480000,134.115000,137.530000,137.530000,241926,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-22,136.450000,140.410000,134.665000,137.770000,137.770000,370121,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-23,138.590000,140.470000,135.620000,136.720000,136.720000,328130,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-26,137.780000,143.350000,135.970000,142.900000,142.900000,683224,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-27,142.140000,144.060000,140.745000,141.300000,141.300000,541942,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-28,140.990000,144.990000,139.070000,143.530000,143.530000,454047,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-29,145.000000,147.980000,137.520000,139.690000,139.690000,731446,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-04-30,139.110000,144.450000,139.110000,140.640000,140.640000,430915,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-03,140.480000,140.610000,134.230000,135.340000,135.340000,554770,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-04,134.640000,135.690000,130.455000,131.570000,131.570000,644695,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-05,131.640000,133.290000,129.140000,132.670000,132.670000,613514,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-06,132.000000,134.000000,128.705000,132.100000,132.100000,630229,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-07,133.440000,135.490000,130.760000,131.300000,131.300000,325838,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-10,131.280000,131.280000,127.220000,128.630000,128.630000,397783,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-11,126.450000,133.355000,125.080000,132.410000,132.410000,496997,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-12,131.270000,135.240000,131.070000,133.360000,133.360000,440709,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-13,134.290000,134.920000,127.720000,132.920000,132.920000,608959,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-14,133.680000,137.650000,131.580000,135.700000,135.700000,457714,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-17,135.210000,136.685000,134.060000,135.890000,135.890000,262687,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-18,135.390000,138.443100,134.230000,135.150000,135.150000,241376,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-19,133.240000,137.240000,133.020000,134.930000,134.930000,442478,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-20,135.250000,140.675000,132.460000,140.100000,140.100000,512248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-21,140.630000,142.050000,138.980000,140.060000,140.060000,470952,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-24,141.340000,141.560000,138.140000,138.280000,138.280000,343273,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-25,139.350000,140.385000,138.050000,139.400000,139.400000,504254,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-26,140.740000,141.540000,138.280000,138.800000,138.800000,569155,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-27,139.590000,142.250000,136.850000,140.230000,140.230000,553167,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-05-28,140.950000,144.720000,139.850000,141.990000,141.990000,500181,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-01,142.230000,145.150000,141.110000,144.280000,144.280000,591169,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-02,143.860000,145.240000,142.155000,142.850000,142.850000,761142,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-03,141.820000,148.589600,140.385000,147.290000,147.290000,556853,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-04,147.430000,148.000000,144.020000,145.600000,145.600000,413260,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-07,145.880000,150.850000,144.450000,150.460000,150.460000,847124,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-08,152.000000,153.250000,149.980000,151.080000,151.080000,470538,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-09,152.250000,157.500000,151.310000,157.410000,157.410000,653503,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-10,158.010000,163.290000,156.850000,163.260000,163.260000,655329,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-11,161.760000,165.330000,161.760000,165.020000,165.020000,712585,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-14,165.420000,167.370000,164.050000,166.660000,166.660000,821336,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-15,166.500000,168.780000,165.490000,166.500000,166.500000,981841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-16,166.450000,168.370000,164.940000,168.300000,168.300000,707264,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-17,167.920000,172.530000,167.920000,172.250000,172.250000,629588,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-18,171.080000,177.530000,169.970000,176.890000,176.890000,1522882,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-21,175.860000,175.860000,169.700000,171.260000,171.260000,1060094,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-22,171.400000,173.130000,168.510000,172.950000,172.950000,721099,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-23,171.820000,175.760000,171.820000,174.630000,174.630000,530097,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-24,176.310000,176.970000,172.860000,173.680000,173.680000,790224,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-25,174.130000,176.750000,172.650000,175.390000,175.390000,914794,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-28,155.140000,168.340000,154.015500,166.200000,166.200000,2069677,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-29,166.900000,167.155000,164.510000,165.870000,165.870000,756188,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-06-30,165.410000,173.910000,163.290000,169.520000,169.520000,652014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-01,169.700000,170.060000,166.155000,169.750000,169.750000,522436,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-02,169.490000,172.140000,167.010000,171.430000,171.430000,338946,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-06,172.260000,175.410000,168.680000,174.380000,174.380000,669515,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-07,175.820000,176.000000,170.220000,172.590000,172.590000,358074,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-08,170.160000,172.750000,169.000100,172.500000,172.500000,364077,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-09,173.430000,177.600000,171.650000,176.740000,176.740000,655909,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-12,177.000000,180.240000,176.360000,177.030000,177.030000,908095,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-13,176.030000,178.680000,174.670000,175.630000,175.630000,450616,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-14,175.630000,176.945000,169.100000,170.340000,170.340000,609250,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-15,170.070000,172.360000,168.060000,171.950000,171.950000,474890,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-16,173.020000,177.970000,171.780000,177.540000,177.540000,544252,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-19,177.520000,177.530000,172.275000,175.310000,175.310000,517886,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-20,176.290000,184.830000,174.730000,183.170000,183.170000,1395865,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-21,184.000000,184.000000,178.310000,180.090000,180.090000,718897,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-22,180.090000,182.530000,178.220000,181.810000,181.810000,768966,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-23,182.000000,183.465000,180.090400,182.410000,182.410000,514417,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-26,182.130000,182.930000,178.090000,178.110000,178.110000,270680,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-27,176.870000,177.910000,172.810000,176.590000,176.590000,350552,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-28,176.720000,182.439900,174.550000,182.100000,182.100000,354290,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-29,182.080000,184.450000,180.500000,181.830000,181.830000,345036,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-07-30,180.420000,181.620000,178.200000,178.940000,178.940000,409176,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-02,178.300000,179.970000,175.860000,177.960000,177.960000,448427,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-03,179.140000,180.000000,174.150000,178.810000,178.810000,986016,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-04,177.240000,186.480000,175.700000,183.440000,183.440000,800530,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-05,183.800000,194.280000,183.320000,193.900000,193.900000,972857,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-06,192.880000,199.910000,191.300000,195.230000,195.230000,815770,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-09,193.550000,201.650000,192.991000,200.250000,200.250000,1291875,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-10,201.960000,208.950000,198.960000,207.730000,207.730000,979266,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-11,206.900000,209.725000,200.865000,202.850000,202.850000,1169255,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-12,203.500000,204.910000,195.000000,200.920000,200.920000,450871,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-13,199.510000,202.260000,195.530000,196.540000,196.540000,865810,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-16,196.300000,198.710000,193.350000,196.780000,196.780000,663416,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-17,195.710000,202.335000,193.850000,200.250000,200.250000,586925,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-18,201.770000,201.770000,197.510000,197.530000,197.530000,475202,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-19,196.440000,201.000000,195.000000,196.990000,196.990000,379568,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-20,198.430000,201.320000,196.120000,197.780000,197.780000,973664,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-23,198.720000,201.490000,196.600000,198.400000,198.400000,911054,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-24,199.010000,202.579900,196.080000,201.900000,201.900000,298951,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-25,201.180000,205.390000,198.701100,204.920000,204.920000,365213,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-26,205.070000,207.245000,202.380000,202.390000,202.390000,335782,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-27,202.090000,208.550000,201.960000,203.930000,203.930000,376820,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-30,204.800000,208.320000,203.110000,203.510000,203.510000,467308,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-08-31,204.450000,205.685000,200.325000,201.430000,201.430000,806868,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-01,200.720000,201.680000,196.560000,197.040000,197.040000,587855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-02,198.990000,202.770000,197.030000,200.180000,200.180000,540806,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-03,199.670000,200.420000,197.360000,197.460000,197.460000,321033,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-07,197.680000,197.680000,188.010000,188.270000,188.270000,656091,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-08,186.650000,188.880000,184.210000,186.310000,186.310000,324814,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-09,187.000000,190.160000,186.910000,189.600000,189.600000,349580,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-10,190.420000,192.440000,188.425000,189.550000,189.550000,374553,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-13,190.550000,190.550000,183.000000,185.790000,185.790000,496121,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-14,185.320000,189.870000,184.710000,187.970000,187.970000,401741,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-15,187.470000,190.000000,186.240000,187.480000,187.480000,417524,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-16,189.100000,191.860000,185.965000,190.200000,190.200000,323891,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-17,190.430000,191.850000,185.410000,190.340000,190.340000,1187034,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-20,187.970000,188.160000,181.960000,183.460000,183.460000,575014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-21,184.540000,187.095000,183.690000,184.150000,184.150000,761808,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-22,185.210000,185.420000,181.260000,182.210000,182.210000,1042299,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-23,183.490000,187.750000,180.650000,186.950000,186.950000,292592,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-24,185.900000,189.079900,185.400000,187.400000,187.400000,228286,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-27,187.130000,194.470000,181.395000,193.850000,193.850000,799551,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-28,180.270000,184.270000,174.390000,177.080000,177.080000,1247487,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-29,178.530000,182.660000,177.000000,177.450000,177.450000,388331,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-09-30,177.840000,191.410000,177.840000,188.810000,188.810000,774412,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-01,188.420000,193.890000,186.550000,192.680000,192.680000,400316,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-04,195.000000,198.050000,193.010000,195.020000,195.020000,606934,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-05,195.340000,199.690000,195.250000,198.350000,198.350000,394777,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-06,196.040000,201.490000,196.040000,201.080000,201.080000,555562,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-07,201.830000,204.940000,198.850000,202.910000,202.910000,307382,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-08,203.450000,206.840000,202.070000,203.700000,203.700000,313556,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-11,203.870000,206.227300,202.480000,204.530000,204.530000,222186,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-12,206.380000,206.505000,202.490000,203.440000,203.440000,402312,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-13,204.000000,206.280000,200.800000,203.890000,203.890000,317425,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-14,207.000000,212.000000,205.280000,209.290000,209.290000,455160,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-15,210.000000,210.190000,207.370000,208.560000,208.560000,404871,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-18,208.860000,208.860000,202.300000,203.900000,203.900000,332464,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-19,203.580000,207.150000,201.280000,206.590000,206.590000,259702,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-20,208.310000,208.805600,203.170000,203.820000,203.820000,279715,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-21,204.460000,205.290000,201.860000,204.330000,204.330000,237502,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-22,205.170000,205.170000,198.360000,198.610000,198.610000,481274,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-25,198.000000,202.750000,195.985700,199.670000,199.670000,398412,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-26,199.680000,200.000000,196.570000,197.710000,197.710000,376254,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-27,197.470000,197.940000,190.190000,191.160000,191.160000,769248,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-28,169.070000,172.460000,156.010000,162.140000,162.140000,2766395,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-10-29,161.120000,164.360000,154.820400,159.560000,159.560000,1466194,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-01,160.940000,168.700000,160.130100,166.360000,166.360000,804207,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-02,167.530000,169.590000,163.880000,167.650000,167.650000,596873,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-03,167.010000,173.350000,165.410000,172.870000,172.870000,947596,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-04,172.460000,185.720000,172.460000,185.550000,185.550000,1039407,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-05,185.880000,188.220000,181.460000,187.250000,187.250000,709955,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-08,188.470000,189.860000,183.280000,187.970000,187.970000,592840,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-09,189.000000,189.000000,181.990000,183.920000,183.920000,471548,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-10,183.100000,186.340000,176.010000,176.250000,176.250000,424829,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-11,177.240000,181.880000,172.680000,173.050000,173.050000,532312,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-12,174.050000,174.740000,169.900000,170.870000,170.870000,600807,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-15,169.740000,174.600000,169.270000,173.310000,173.310000,571323,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-16,172.790000,174.650000,169.780000,172.940000,172.940000,305683,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-17,171.700000,173.640000,167.435000,172.730000,172.730000,483780,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-18,182.290000,189.690000,178.510000,178.980000,178.980000,1717499,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-19,174.720000,182.315000,172.570000,181.000000,181.000000,645359,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-22,188.990000,195.000000,186.020000,187.010000,187.010000,1366964,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-23,188.000000,189.360000,180.960000,187.150000,187.150000,565040,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-24,187.590000,189.035200,184.010000,188.800000,188.800000,273187,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-26,188.800000,192.980000,185.650000,188.530000,188.530000,341317,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-29,189.750000,190.240000,180.380000,180.740000,180.740000,417930,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-11-30,181.530000,185.370000,179.075000,183.800000,183.800000,844545,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-01,183.190000,186.270000,179.640000,179.930000,179.930000,371358,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-02,179.430000,184.440000,178.500000,182.850000,182.850000,430748,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-03,183.570000,185.540000,170.250000,171.360000,171.360000,640153,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-06,170.000000,177.620000,169.220000,177.000000,177.000000,581665,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-07,180.110000,183.350000,176.560000,180.280000,180.280000,1107432,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-08,181.230000,183.950000,176.470000,176.920000,176.920000,731929,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-09,177.440000,177.990000,169.900000,172.470000,172.470000,1133827,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-10,172.970000,179.249900,172.300000,173.650000,173.650000,394416,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-13,175.540000,187.680000,174.260000,186.420000,186.420000,891063,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-14,186.270000,190.060000,183.111700,185.730000,185.730000,658494,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-15,185.730000,194.100000,184.750000,191.060000,191.060000,760079,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-16,186.570000,190.540000,180.883000,184.880000,184.880000,560511,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-17,183.895000,195.800000,180.000000,194.570000,194.570000,959204,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-20,195.190000,199.498500,190.520000,198.290000,198.290000,1526165,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-21,199.000000,199.880000,196.290000,199.590000,199.590000,1174858,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-22,189.130000,193.745000,184.020000,187.380000,187.380000,1240197,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-23,189.180000,196.300000,185.940000,194.350000,194.350000,390372,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-27,190.000000,190.000000,159.110000,161.110000,161.110000,4534195,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-28,161.430000,171.990000,161.110000,168.700000,168.700000,1207179,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-29,169.900000,170.360000,165.270000,170.080000,170.080000,582885,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-30,169.740000,174.500000,168.965000,171.030000,171.030000,676928,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2021-12-31,171.620000,175.320000,169.580000,169.580000,169.580000,381809,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-03,171.060000,173.997000,165.580000,173.910000,173.910000,993152,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-04,172.050000,174.660000,161.580000,165.230000,165.230000,833121,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-05,161.570000,163.282500,154.590000,155.090000,155.090000,886775,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-06,156.190000,156.190000,146.310000,151.000000,151.000000,1122350,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-07,151.000000,153.300000,147.410000,148.130000,148.130000,594186,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-10,146.160000,150.170000,142.510000,150.160000,150.160000,841198,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-11,151.110000,152.120000,146.330000,148.030000,148.030000,673526,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-12,146.890000,149.469900,144.010000,147.540000,147.540000,750426,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-13,147.470000,150.819900,144.965000,148.000000,148.000000,606300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-14,147.780000,152.415000,142.690000,148.500000,148.500000,457129,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-18,145.650000,147.010000,138.610000,139.190000,139.190000,647486,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-19,141.270000,144.180000,137.690000,138.620000,138.620000,474976,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-20,146.160000,146.440000,137.900000,138.310000,138.310000,576251,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-21,130.200000,137.920000,129.850000,136.410000,136.410000,1164719,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-24,132.890000,136.980000,128.130000,136.530000,136.530000,986617,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-25,135.540000,136.440000,130.460000,130.940000,130.940000,806325,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-26,133.580000,136.760000,129.870000,130.120000,130.120000,774089,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-27,130.530000,131.990000,126.890000,127.180000,127.180000,904491,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-28,129.060000,132.555000,125.000000,132.090000,132.090000,929752,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-01-31,132.580000,137.780000,132.580000,137.600000,137.600000,1183697,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-01,138.140000,146.260000,138.090000,144.930000,144.930000,1137525,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-02,144.670000,145.980000,143.380100,145.260000,145.260000,670613,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-03,145.040000,147.289900,141.280000,142.510000,142.510000,469357,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-04,141.590000,146.390000,140.660000,145.420000,145.420000,670018,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-07,145.660000,149.770000,145.195000,148.650000,148.650000,489553,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-08,147.410000,149.400000,144.260000,147.640000,147.640000,695521,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-09,149.140000,151.570000,146.550000,151.400000,151.400000,779751,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-10,148.150000,157.090000,147.570000,150.860000,150.860000,896337,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-11,149.280000,154.450000,148.070000,150.760000,150.760000,972660,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-14,150.760000,151.150000,147.665000,148.660000,148.660000,944752,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-15,150.020000,153.770000,149.660000,153.300000,153.300000,580050,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-16,153.290000,153.650000,149.740000,153.280000,153.280000,333496,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-17,152.710000,152.970000,149.660000,149.950000,149.950000,722726,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-18,150.490000,151.430000,145.685000,147.500000,147.500000,739096,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-22,146.790000,149.060000,145.310000,146.810000,146.810000,926057,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-23,148.430000,149.310000,145.925000,147.470000,147.470000,991284,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-24,144.910000,152.970000,143.300000,152.890000,152.890000,1245315,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-25,152.115000,155.105000,150.210000,155.000000,155.000000,928882,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-02-28,154.180000,158.300000,150.580000,157.850000,157.850000,786568,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-01,158.880000,164.400000,157.320000,162.510000,162.510000,922470,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-02,162.140000,163.980000,159.530000,163.200000,163.200000,427142,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-03,164.510000,167.675000,163.740000,165.070000,165.070000,1189187,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-04,164.220000,166.840000,160.630000,164.440000,164.440000,1516187,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-07,163.750000,165.210000,161.870000,163.000000,163.000000,755990,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-08,160.220000,166.070000,160.220000,162.000000,162.000000,1007316,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-09,162.590000,165.330000,160.980000,162.230000,162.230000,926651,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-10,161.510000,163.960000,156.600000,160.560000,160.560000,773019,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-11,161.240000,161.990000,153.865000,154.960000,154.960000,602254,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-14,154.820000,156.400000,150.153900,151.800000,151.800000,726704,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-15,152.020000,153.090000,149.000000,152.920000,152.920000,593433,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-16,154.560000,158.985000,153.020000,158.970000,158.970000,539717,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-17,162.000000,164.230000,160.150000,163.080000,163.080000,816659,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-18,164.730000,166.430000,163.350000,165.250000,165.250000,1015885,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-21,164.170000,166.000000,161.750000,162.430000,162.430000,673854,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-22,163.570000,164.140000,161.220000,163.830000,163.830000,716479,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-23,162.870000,164.500000,161.905000,162.350000,162.350000,612600,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-24,164.260000,164.260000,160.590000,163.700000,163.700000,865294,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-25,165.000000,165.000000,161.360000,163.810000,163.810000,539581,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-28,163.460000,164.132000,158.850000,161.650000,161.650000,664696,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-29,163.630000,166.740000,163.570000,166.740000,166.740000,744314,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-30,167.410000,169.869900,165.020000,165.240000,165.240000,553418,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-03-31,166.560000,168.570000,163.050000,163.290000,163.290000,646067,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-01,166.410000,180.350000,164.010000,169.290000,169.290000,1789117,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-04,167.260000,167.690000,160.460000,161.770000,161.770000,1507762,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-05,161.250000,165.980000,159.470000,159.910000,159.910000,656877,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-06,158.020000,160.400000,157.202800,158.470000,158.470000,736219,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-07,157.950000,168.040000,157.660000,162.250000,162.250000,1047516,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-08,163.000000,168.480000,162.990000,163.420000,163.420000,686277,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-11,163.800000,165.275000,157.180000,157.430000,157.430000,610107,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-12,158.460000,165.150000,157.790000,159.580000,159.580000,956142,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-13,160.790000,168.590000,158.810000,168.460000,168.460000,578967,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-14,168.430000,170.040000,167.300000,167.340000,167.340000,458718,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-18,166.160000,166.739700,155.845000,156.680000,156.680000,655017,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-19,157.480000,161.640000,156.990000,161.200000,161.200000,638331,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-20,164.280000,168.320000,160.475000,167.950000,167.950000,525357,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-21,168.730000,171.840000,168.300000,168.750000,168.750000,878121,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-22,168.340000,169.060000,166.430000,167.000000,167.000000,784088,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-25,161.110000,164.330000,157.350000,162.070000,162.070000,900250,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-26,160.150000,161.110000,154.580000,155.000000,155.000000,968304,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-27,155.740000,157.666700,153.890000,154.920000,154.920000,1047733,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-28,150.360000,151.310000,138.520000,143.160000,143.160000,1893889,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-04-29,142.040000,143.750000,132.450000,133.430000,133.430000,1428607,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-02,131.590000,139.150000,131.590000,139.050000,139.050000,843908,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-03,140.170000,143.280000,139.445000,142.890000,142.890000,691520,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-04,143.720000,144.980000,138.730000,143.430000,143.430000,940900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-05,142.740000,142.740000,134.510000,136.740000,136.740000,791844,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-06,135.160000,136.500000,132.130000,134.750000,134.750000,596459,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-09,132.110000,132.210000,120.160000,122.520000,122.520000,1416206,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-10,126.210000,131.060000,124.340000,128.180000,128.180000,1013188,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-11,126.470000,129.160000,119.580000,120.420000,120.420000,944318,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-12,119.300000,123.135000,117.580000,121.330000,121.330000,1047476,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-13,124.010000,128.770000,124.000000,126.470000,126.470000,740287,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-16,125.740000,127.910000,123.270000,124.870000,124.870000,939591,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-17,127.410000,130.100000,125.660000,129.310000,129.310000,724151,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-18,126.440000,130.900000,125.520000,128.310000,128.310000,660865,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-19,128.470000,131.350000,127.340000,129.360000,129.360000,744136,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-20,129.820000,133.130000,129.220000,132.270000,132.270000,1168848,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-23,132.070000,133.290000,128.310000,129.580000,129.580000,910311,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-24,128.590000,128.590000,124.795000,127.050000,127.050000,536433,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-25,126.670000,127.830000,124.830000,126.750000,126.750000,916561,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-26,127.190000,129.060000,125.020000,125.600000,125.600000,330301,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-27,125.370000,127.920000,121.360000,127.770000,127.770000,557786,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-05-31,127.560000,127.700000,122.500000,125.800000,125.800000,1006135,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-01,126.010000,129.290000,122.900000,123.050000,123.050000,489080,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-02,122.560000,125.590000,120.430000,125.500000,125.500000,522566,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-03,124.990000,131.800000,124.790000,131.520000,131.520000,648056,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-06,133.110000,134.070000,130.230000,131.630000,131.630000,1348118,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-07,131.450000,134.290000,130.270000,134.010000,134.010000,737877,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-08,133.850000,141.540000,132.950000,139.400000,139.400000,842791,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-09,138.400000,139.340000,134.550000,135.000000,135.000000,1076936,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-10,133.110000,134.100000,130.290000,132.110000,132.110000,834145,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-13,127.400000,129.920000,122.570000,127.700000,127.700000,1080350,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-14,128.740000,137.080000,128.620000,133.520000,133.520000,1303507,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-15,133.460000,137.312900,133.145000,135.450000,135.450000,1002452,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-16,131.190000,135.080000,128.800000,134.820000,134.820000,876809,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-17,135.830000,139.370000,134.770000,137.090000,137.090000,1308641,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-21,138.720000,141.250000,138.350000,139.020000,139.020000,1059837,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-22,137.360000,142.600000,135.210000,141.560000,141.560000,876972,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-23,142.510000,146.430000,137.820000,146.300000,146.300000,825730,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-24,147.680000,148.250000,144.340000,147.500000,147.500000,1629326,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-27,144.470000,146.650000,141.550000,146.490000,146.490000,1198014,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-28,146.140000,147.480000,139.510000,142.200000,142.200000,1716752,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-29,142.230000,146.010000,140.010000,145.430000,145.430000,441019,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-06-30,144.270000,147.528100,143.090000,145.850000,145.850000,837703,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-01,145.000000,148.510000,144.180000,148.250000,148.250000,568298,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-05,146.960000,151.220000,145.060000,150.730000,150.730000,800217,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-06,149.870000,153.010000,149.530000,150.000000,150.000000,711487,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-07,149.610000,154.000000,149.330000,153.420000,153.420000,492503,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-08,151.710000,153.020000,150.100000,152.490000,152.490000,577616,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-11,152.370000,153.290000,150.230000,150.910000,150.910000,585808,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-12,149.750000,149.900000,143.550000,145.850000,145.850000,781768,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-13,143.440000,147.575000,140.940000,142.700000,142.700000,708072,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-14,141.040000,142.600000,138.290000,138.540000,138.540000,739303,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-15,138.160000,146.400000,138.042500,145.390000,145.390000,994221,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-18,145.530000,147.740000,140.000000,140.640000,140.640000,556585,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-19,143.020000,145.860000,141.590000,145.720000,145.720000,442885,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-20,146.630000,149.720000,144.900000,146.560000,146.560000,436595,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-21,146.560000,149.140000,146.419800,147.200000,147.200000,425727,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-22,148.510000,148.510000,143.010000,143.210000,143.210000,550589,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-25,143.000000,143.150000,139.590000,141.200000,141.200000,474067,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-26,141.960000,142.890000,137.016500,140.000000,140.000000,674474,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-27,140.050000,143.660000,137.000000,141.970000,141.970000,779013,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-28,137.000000,145.280000,135.460000,143.520000,143.520000,542416,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-07-29,143.000000,143.930000,139.420000,142.040000,142.040000,609488,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-01,141.820000,143.910000,138.660000,139.950000,139.950000,438196,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-02,140.290000,142.860000,138.175000,141.970000,141.970000,317168,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-03,210.000000,220.920000,198.000100,212.010000,212.010000,8541970,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-04,189.425000,226.000000,188.880000,224.050000,224.050000,3393077,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-05,224.010000,226.000000,213.480000,218.580000,218.580000,1356668,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-08,216.070000,231.530000,216.070000,230.740000,230.740000,2286775,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-09,230.350000,231.500000,222.560000,223.370000,223.370000,1117944,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-10,225.330000,233.880000,224.400000,232.000000,232.000000,969763,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-11,231.900000,234.510000,228.000000,229.390000,229.390000,736959,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-12,229.390000,236.800000,228.030000,233.850000,233.850000,619833,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-15,226.160000,233.220000,225.000000,231.010000,231.010000,731907,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-16,232.550000,234.980000,227.780000,228.150000,228.150000,700538,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-17,226.090000,226.960000,222.240000,223.130000,223.130000,518331,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-18,223.970000,224.850000,221.000000,223.450000,223.450000,466900,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-19,222.250000,222.250000,212.430000,215.970000,215.970000,881795,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-22,216.020000,221.270000,216.020000,217.910000,217.910000,892139,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-23,216.580000,220.430000,213.150000,216.890000,216.890000,749884,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-24,217.840000,224.150000,216.325000,221.000000,221.000000,664683,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-25,222.060000,222.060000,213.220000,213.920000,213.920000,795739,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-26,217.670000,218.690000,209.530000,210.940000,210.940000,1589300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-29,209.750000,212.700000,206.120000,209.030000,209.030000,744176,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-30,209.560000,211.000000,207.540000,209.970000,209.970000,791520,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-08-31,209.940000,212.000000,205.970000,206.670000,206.670000,705745,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-01,206.730000,211.820000,204.140000,211.250000,211.250000,757063,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-02,210.970000,213.650000,204.231000,205.450000,205.450000,644431,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-06,204.400000,204.850000,199.390000,201.260000,201.260000,980509,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-07,201.490000,209.140000,200.250000,208.860000,208.860000,1262561,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-08,205.370000,227.155000,203.860000,226.300000,226.300000,2017797,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-09,219.040000,228.045000,218.715000,223.270000,223.270000,712725,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-12,214.890000,216.000000,210.190000,212.000000,212.000000,2778564,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-13,208.250000,209.375000,205.020000,206.590000,206.590000,2288773,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-14,207.280000,209.150000,203.010000,208.280000,208.280000,1232338,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-15,206.400000,210.860000,202.600000,208.480000,208.480000,778817,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-16,207.590000,213.060000,205.850000,213.000000,213.000000,1559304,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-19,210.920000,216.060000,208.090000,216.000000,216.000000,952300,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-20,216.000000,219.630000,210.840000,212.010000,212.010000,625624,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-21,212.880000,214.340000,206.140000,206.390000,206.390000,472677,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-22,205.290000,205.290000,200.000000,202.710000,202.710000,633836,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-23,202.440000,203.910000,198.410000,200.780000,200.780000,544881,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-26,200.420000,204.520000,197.200000,197.390000,197.390000,715059,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-27,201.330000,204.950000,200.650000,202.610000,202.610000,806753,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-28,205.580000,211.500000,205.580000,210.760000,210.760000,1016284,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-29,210.820000,211.100000,206.210000,209.390000,209.390000,1073880,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-09-30,208.160000,216.890000,199.110000,200.160000,200.160000,1684601,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-03,205.100000,206.930000,194.010000,196.790000,196.790000,1414229,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-04,199.270000,201.270000,192.420000,201.240000,201.240000,1813000,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-05,199.810000,202.720000,195.190000,201.020000,201.020000,1116855,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-06,199.900000,202.570000,198.595000,202.370000,202.370000,814977,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-07,201.000000,202.530000,194.960000,195.810000,195.810000,844420,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-10,194.460000,195.180000,186.560000,186.820000,186.820000,1341218,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-11,187.160000,189.625700,182.805000,186.680000,186.680000,1072774,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-12,186.330000,187.030000,183.960000,185.110000,185.110000,583137,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-13,182.280000,191.980000,181.650000,191.760000,191.760000,2252063,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-14,193.140000,195.770000,185.260000,185.530000,185.530000,706049,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-17,186.560000,195.670000,186.560000,195.090000,195.090000,604321,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-18,195.020000,197.360000,192.710000,194.050000,194.050000,654915,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-19,192.880000,194.490000,190.700000,192.000000,192.000000,769185,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-20,191.400000,197.990000,190.400000,192.980000,192.980000,670339,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-21,194.010000,199.830000,193.100000,198.880000,198.880000,968672,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-24,198.330000,199.130000,191.490000,195.850000,195.850000,1425536,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-25,196.090000,201.070000,195.800000,198.560000,198.560000,698831,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-26,199.580000,203.240000,197.830000,201.020000,201.020000,723529,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-27,197.500000,199.990000,190.430000,194.000000,194.000000,2286189,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-28,195.470000,204.970000,194.985000,204.510000,204.510000,979455,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-10-31,203.380000,209.970000,202.965400,207.260000,207.260000,771367,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-01,209.460000,214.762000,206.990000,213.120000,213.120000,646952,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-02,213.310000,219.770000,210.202600,214.350000,214.350000,663034,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-03,210.630000,220.330000,210.630000,215.720000,215.720000,1338440,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-04,215.410000,215.410000,203.190000,208.340000,208.340000,749453,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-07,208.740000,210.370000,204.310000,204.930000,204.930000,487401,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-08,205.110000,206.950000,203.090000,204.760000,204.760000,1081335,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-09,205.000000,205.000000,197.220000,197.940000,197.940000,622830,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-10,202.790000,214.570000,202.210000,212.450000,212.450000,861251,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-11,212.450000,216.520000,209.570000,216.370000,216.370000,819424,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-14,217.060000,219.170000,213.470000,213.480000,213.480000,516793,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-15,217.430000,218.950000,212.390000,214.290000,214.290000,513664,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-16,214.540000,215.680000,210.665000,211.990000,211.990000,460468,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-17,212.840000,212.840000,206.505000,209.120000,209.120000,419531,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-18,212.010000,219.030000,210.745000,217.360000,217.360000,670181,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-21,217.830000,222.590000,204.380000,206.650000,206.650000,991502,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-22,206.310000,212.685000,205.000000,209.410000,209.410000,523850,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-23,209.990000,214.670000,207.460000,208.490000,208.490000,377444,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-25,207.890000,214.260000,206.360000,212.720000,212.720000,356464,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-28,213.080000,217.340000,208.090000,209.200000,209.200000,807989,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-29,209.500000,212.700000,203.530000,204.790000,204.790000,516440,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-11-30,207.210000,221.150000,205.190000,220.590000,220.590000,2478264,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-01,220.350000,223.400000,218.590000,220.250000,220.250000,603783,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-02,217.520000,235.475700,216.770000,234.400000,234.400000,922229,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-05,231.480000,233.800000,224.730000,226.200000,226.200000,757841,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-06,224.840000,226.270000,215.280000,219.640000,219.640000,425412,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-07,219.390000,231.510000,219.390000,231.330000,231.330000,926240,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-08,232.330000,239.680000,230.965000,238.010000,238.010000,1139156,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-09,235.000000,242.315000,230.710000,231.330000,231.330000,1075414,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-12,230.870000,236.750000,228.800000,235.860000,235.860000,1178913,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-13,239.310000,241.680000,234.300000,236.980000,236.980000,618789,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-14,234.890000,237.950000,232.050000,233.910000,233.910000,674977,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-15,233.000000,233.000000,226.325000,229.370000,229.370000,823193,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-16,229.000000,238.790000,228.690000,236.920000,236.920000,1308346,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-19,236.920000,236.920000,231.120100,234.070000,234.070000,377507,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-20,234.000000,239.520000,233.535000,237.550000,237.550000,1181016,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-21,237.420000,242.970000,236.330000,241.310000,241.310000,590176,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-22,239.610000,241.070000,237.360000,239.490000,239.490000,427073,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-23,237.450000,239.280000,233.810100,237.900000,237.900000,417093,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-27,238.030000,238.590000,231.685000,232.310000,232.310000,631037,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-28,232.300000,235.599900,230.030000,231.620000,231.620000,453810,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-29,232.000000,238.480000,230.280000,238.050000,238.050000,466371,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
2022-12-30,237.070000,239.050000,233.490000,237.650000,237.650000,518002,0.000000,1.000000,ALNY,Common Stock,Alnylam Pharmaceuticals Inc,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",1178670,NASDAQ,USD,USA,LIFE SCIENCES,PHARMACEUTICAL PREPARATIONS,"675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",https://www.alnylam.com,December,2025-03-31,43277083000,-57815000,None,-0.49,0.886,None,None,-2.09,18.27,-0.115,0.0304,-0.0179,-15.01,2348099000,2019664000,-2.09,0,0.202,325.06,11,12,7,1,1,-,2000,18.43,374.91,17.86,204.85,0.211,333.7,205.87,290.98,267.0,130388000,125464000,3.802,97.497,None,None
